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ABSTRACT OF THE DISSERTATION
Development of an in vitro Culture System for Cryptosporidium parvum
by
Georgia Wilke
Doctor of Philosophy in Biology and Biomedical Sciences
Molecular Microbiology and Microbial Pathogenesis
Washington University in St. Louis, 2020
Professor L. David Sibley, Chair

Cryptosporidium is a genus of protozoan parasites that causes diarrheal disease in
humans and other animals. There are two major species that cause disease in humans: C. parvum,
which infects both humans and animals, and C. hominis, which primarily infects humans. A
recent study investigating the etiologies of pediatric diarrheal illness in Africa and South Asia
found that Cryptosporidium is the 2nd most prevalent cause of diarrhea in infants and may be a
contributing factor to chronic malnutrition. This discovery has led to renewed interest in studying
this parasite and a reexamination of the barriers to studying Cryptosporidium. The main obstacle
hindering research on this parasite is that it cannot be propagated in vitro and instead must be
passaged through large animals such as calves to generate infectious oocysts. The cell culture
models that are available rely on adenocarcinoma cells and only support a few days of growth
and do not enable complete life cycle development in vitro. These limitations have stalled the
development of research tools for investigating Cryptosporidium biology and have also slowed
developmental progress of new therapies.

x

Recent developments in stem cell culture have allowed for the isolation of human and
mouse intestinal stem cells, which can be propagated indefinitely and differentiated into primary
intestinal epithelial cells (IECs). We found that mouse IEC monolayers supported robust C.
parvum growth. We utilized this system to create a hybridoma bank of novel antibodies targeting
the intracellular stages of C. parvum, something that had not been attempted previously due to
the lack of a mouse cell line that supported Cryptosporidium growth. These antibodies have
unique staining patterns for many life cycle stages, enabling unambiguous identification of
different stages and facilitating life cycle description in diverse culture platforms.
The mouse IEC monolayers supported superior parasite growth to adenocarcinoma cell lines, but
they had a short lifespan and did not support complete life cycle development in vitro. In order to
improve the longevity of the IEC monolayers, we introduced several components to the system:
the use of stem cell culture medium to grow the monolayers, the inclusion of a feeder cell layer
to create a robust extracellular matrix, and an air-liquid interface at the surface of the monolayer.
These modifications led to long-lasting monolayers with improved differentiation status; the
monolayers contained proliferating cells and all of the differentiated lineages of the intestinal
epithelium. These monolayers supported long-term C. parvum growth as well as the
development of infectious oocysts, indicating complete life cycle development in vitro. This
improved IEC system will be a valuable tool for selecting transgenic parasites in vitro, as well as
investigating drug mechanism and target identification. Since the monolayers are great models of
the intestinal epithelium, this system will be vital to studying host-pathogen interactions in a
platform that resembles the parasite’s natural niche.

xi

Chapter 1
Introduction

The first draft of this work was written by GW. Comments from LDS were incorporated into the
final chapter here.
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Cryptosporidium and cryptosporidiosis
Cryptosporidium is an obligate intracellular parasite that belongs to the phylum
Apicomplexa, which includes other disease-causing parasites such as Toxoplasma, Plasmodium,
and Eimeria. Over 20 different species of Cryptosporidium are recognized, many of which are
specific to a single vertebrate host (1). The majority of human infections are caused by C.
hominis, which is limited to humans, and C. parvum, which can be spread from ruminants (2-4).
Cryptosporidiosis is characterized by profuse watery diarrhea and abdominal pain that is selflimiting in healthy individuals (5).
Cryptosporidium was first identified as a gastrointestinal parasite in mice by Edward
Tyzzer early in the 20th century (6-8). It was named Cryptosporidium due to the lack of
sporocysts within the oocyst, a characteristic of other coccidia (a subclass of the Apicomplexans
that includes Toxoplasma and Cyclospora). It was not recognized as a human pathogen until the
late 1970s when it was found in a rectal biopsy from a 3-year-old child suffering from
enterocolitis (9). In the 1980s, Cryptosporidium was identified as an opportunistic pathogen in
patients immunocompromised from HIV/AIDS (10). During this time, the parasite became
strongly associated with the disease and cryptosporidiosis was one of the first recognized AIDSdefining illnesses. Cryptosporidiosis in immunocompromised patients is a protracted, deadly
illness (11), with potential for extra-gastrointestinal infection by the parasite in either the
hepatobiliary (12) or respiratory tracts (13). Fortunately, with the introduction of anti-retroviral
therapy, morbidity and mortality from Cryptosporidium in HIV/AIDS patients has declined
significantly over the ensuing years.
At the same time cryptosporidiosis became recognized as a severe illness in
immunocompromised patients, it was also identified as a cause of short-term diarrhea in
2

immunocompetent individuals (14). This latter scenario became well-appreciated with two major
waterborne outbreaks of cryptosporidiosis: in 1989 in Swindon and Oxfordshire, affecting 5,000
people (15), and in 1993 in Milwaukee, affecting 400,000 people (16). The magnitude of these
outbreaks helped emphasize the role of contaminated drinking water in spreading
Cryptosporidium and led to research on the identification and treatment of oocyst contamination
of water supplies (17). Cryptosporidium continues to be a cause of sporadic outbreaks associated
with public water and swimming facilities (18).
In recent years, Cryptosporidium has been identified as a major cause of diarrhea in
children in developing regions. This finding can be attributed to two important studies: GEMS
(Global Enteric Multicenter Study, (19)) and the MAL-ED (Malnutrition and Enteric Disease)
study (20, 21). GEMS was a 3-year prospective study with over 20,000 child participants (aged
0-59 months) from seven sites in Africa and Asia. Children with moderate-to-severe diarrhea
were enrolled along with age-matched controls. Fecal samples were collected at enrollment to
identify potential enteropathogens. MAL-ED was a birth cohort study with eight sites in Africa,
Asia, and South America. Children were enrolled at birth and diarrheal episodes were identified
through frequent home visits and fecal sample collection up till the child became two years of
age. GEMS found Cryptosporidium to be the second and third leading pathogen identified in
diarrhea in infants (0-11 months) and toddlers (12-23 months), respectively, behind Rotavirus
and Shigella spp. Surprisingly, Cryptosporidium was a major pathogen at all sites visited
independent of HIV prevalence. MAL-ED found Cryptosporidium to be the fifth and seventh
leading cause of diarrhea in infants and toddlers, respectively. Both studies used the same
commercial immunoassay to identify Cryptosporidium in the fecal samples. The difference in
their findings could be due to the different sites of the studies as well as the fact that GEMS
3

enrolled patients with moderate to severe diarrhea only, while MAL-ED captured all cases of
diarrhea, including mild disease that did not require hospitalization or administration of
intravenous fluids.
The GEMS and MAL-ED studies have drawn attention to the global burden of
Cryptosporidium. Other studies have directly linked Cryptosporidium to childhood malnutrition
(22, 23), growth faltering (24), and mortality (25), and it is generally known that diarrhea is a
major cause of child mortality worldwide (26) and malnutrition and diarrhea have a reciprocal
relationship (27). As a widespread gastrointestinal pathogen, Cryptosporidium therefore plays a
significant role in childhood malnutrition and mortality. Based on the GEMS data, the number of
pediatric diarrhea cases annually attributable to Cryptosporidium in sub-Saharan Africa and Asia
is estimated to be ~7.6 million with ~200,000 deaths (2). These numbers have caused a renewed
research interest in Cryptosporidium biology and a reexamination of the lack of treatment
options for the disease (28). The one drug approved for Cryptosporidium infection by the FDA is
nitazoxanide and while this drug shortens disease duration in healthy patients (29), it has limited
effectiveness in malnourished children (30) and no effectiveness in immunosuppressed patients
(31), the two patient populations that most need treatment. Recently, multiple new candidates
have emerged for cryptosporidiosis therapy, notably bumped kinase inhibitors of C. parvum
calcium-dependent protein kinase 1 (32), a PI(4) kinase inhibitor (33), and a repurposed leprosy
drug, clofazimine (34). These drugs have shown promise in animal studies and will hopefully
prove to be effective in humans in upcoming clinical trials.
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Life cycle of Cryptosporidium
Cryptosporidium has a complex life cycle consisting of asexual and sexual stages that
culminate in oocyst formation (see figure 1.1). Unlike related parasites Toxoplasma and
Plasmodium, Cryptosporidium’s life cycle is completed within a single host. Humans and other
animals become infected when they ingest oocysts, which excyst as they travel through the
stomach and small intestine. Excystation occurs in response to a variety of factors, including
temperature change and bile salt exposure (35). In the duodenum and ileum, each oocyst releases
4 sporozoites, which infect intestinal epithelial cells and transform into trophozoites, initiating
the asexual phase of the life cycle (merogony). Trophozoites develop into type 1 meronts, which
contain 8 merozoites. These merozoites are released and go on to infect more epithelial cells,
where they can initiate another round of merogony, or become type II meronts, which are
thought to initiate the sexual phase of the life cycle (gametogony). Type II meronts contain 4
merozoites; when these merozoites are released, they invade epithelial cells and are hypothesized
to become either micro- or macrogamonts. There is no concrete proof of this, but it is clear by
electron microscopy that there is a distinct life cycle stage with 4 merozoites (36). Microgamonts
contain 16 parasites, which are released to fertilize macrogamonts, initiating oocyst
development. Sporulation (sporozoite formation) occurs within the host cell, after which the
oocyst is released into the intestinal lumen. Endogenous sporulation is unusual for a coccidian
parasite; other coccidians like Toxoplasma, sporulate outside of the host in the environment.
Amazingly, Tyzzer’s original publication on the discovery of C. parvum defined many
basic features of the parasite life cycle that still hold true today (8) with some modifications.
Tyzzer proposed a single round of schizogony (asexual merogony), and it was later discovered
that type I meronts undergo multiple rounds of asexual replication, and there is also a separate
5

type II meront stage (36) that precedes sexual development. Additionally, while Tyzzer only
identified one type of oocyst, there have been several reports of both “thick-” and “thin-walled”
oocysts forming in vivo (36, 37). By transmission electron microscopy, thick-walled oocysts
have an inner and outer wall that surround the sporozoites; these walls enable the oocyst to travel
through the intestine unaltered and be excreted in the feces. Thin-walled oocysts have only one
membrane, in addition to the host-derived parasitophorous vacuole membrane, surrounding the
sporozoites and are hypothesized to rupture easily within the host intestine, starting another
round of infection. Unlike thick-walled oocysts, thin-walled oocysts are not found in the feces.
Thin-walled oocysts have been proposed to be the source of autoinfection that enables
Cryptosporidium to grow for weeks and months in immunocompromised patients (36).
When Cryptosporidium infects a host cell, it does not invade the host cytoplasm like
other apicomplexans; instead the parasite establishes itself in a “intracellular but extracytosolic”
location in the apical region of the cell. After the parasite attaches itself to a cell, it actively
invades (38) and becomes encapsulated by the host cell membrane, forming a parasitophorous
vacuole or “sac” in the microvillous region of the enteric epithelial cell (39). The parasite
membrane and host-derived vacuole membrane fuse at the base of the parasite (40) at the “zone
of attachment”, the region that separates the parasite from the host cell cytoplasm. This region
contains a membranous structure with extensive folds that is the feeder organelle of the parasite
(36, 41). It has been hypothesized that the feeder organelle membrane regulates nutrient uptake
from the host cell cytoplasm (42) and is likely the location for the numerous nutrient transporters
found in the Cryptosporidium genome (43, 44).
This unusual relationship with the host cell has caused discussion about
Cryptosporidium’s grouping with the coccidia, a subclass of apicomplexans that includes other
6

pathogens like Toxoplasma and Sarcocystis (45). The “epicellular” location of Cryptosporidium
is like that of gregarines, another group of apicomplexans distantly related to Toxoplasma and
Plasmodium. Gregarines are intestinal parasites of invertebrates; they attach to the apical side of
the host cell and take up the host’s cytoplasm through a specialized feeding organelle. This
process appears superficially similar to how Cryptosporidium gains its nutrients from the host,
however, Cryptosporidium, unlike the gregarines, becomes overlaid by the host cell membrane
during the infection process. There is genetic evidence from 18S small subunit ribosomal RNA
sequencing that Cryptosporidium arose from a common alveolate ancestor shared with
gregarines, forming a separate clade from the other major apicomplexan clade containing the
coccidia (46). In addition to its unusual relationship with the host cell, Cryptosporidium is also
atypical for a coccidian due to its autoinfective, thin-walled oocyst, lack of sporocyst within the
oocyst, and its resistance to anticoccidial drugs (47). Cryptosporidium was originally grouped
with the coccidia due to its similar life cycle, however, it is possible that Cryptosporidium is
more distantly related to the coccidia then what was initially thought. It is important to keep this
in mind when attempting to make inferences about Cryptosporidium’s biology from what we
know about coccidian parasites in general.

Animal models of cryptosporidiosis
In general, there is no “simple” animal model for studying Cryptosporidium infection.
The most clinically significant Cryptosporidium species are C. parvum and C. hominis, which do
not cause productive oocyst shedding in adult immunocompetent mice (48, 49). There are two
mouse-specific Cryptosporidium species, C. muris and C. tyzzeri, but there has been no
significant interest in using one of these species as a model pathogen in mouse infections. C.
7

muris was identified by Tyzzer in the early 1900s and it infects the stomach (6) and not the small
intestine. C. tyzzeri was more recently identified and appears to have a similar life cycle to C.
parvum (50); it is possible that in future studies this parasite could be used as an animal model of
disease, similar to mouse-specific Plasmodium species such as P. berghei.
Unlike adult mice, neonatal mice are susceptible to C. parvum (51-53). Specifically
nursing mice are susceptible; mice that are 7-8 days old are the most consistent in terms of
infection outcome (53). Weaned mice can become susceptible if they are given a proteindeficient diet in a model of malnutrition (54, 55), modeling the increased susceptibility to
infection seen in malnourished children (56, 57). While both immunocompetent and genetically
immunocompromised neonatal mice are susceptible, only immunocompromised mice develop
prolonged infections (58-60). The neonatal mouse model has been used to assess the efficacy of
anticryptosporidial agents in vivo (32, 61) and also to study the parasite life cycle (36, 62).
Adult mice are only susceptible to C. parvum if they are immunocompromised. SCID
mice develop chronic infections with prolonged oocyst shedding and extraintestinal involvement,
mimicking what is seen in AIDS patients (63, 64). Interferon-γ knockout mice are another model
used to study cryptosporidiosis (65) and were recently used to develop a genetic system for C.
parvum (66) and also evaluate new treatment candidates, such as a PI(4)K inhibitor (33) and
bumped-kinase inhibitors (32). Immunocompromised mice are probably the most “accessible” of
the different animal models available to study C. parvum, however, these models do not
recapitulate one major aspect of human cryptosporidiosis: diarrhea. Therefore, it is difficult to
study symptom alleviation in drug treatment studies using mice. Piglet and neonatal calf models
develop the watery diarrhea and dehydration seen in human cases (67-69) and can be used to
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study the efficacy of different treatment candidates (33, 67, 70); however, these large animal
models are only routinely used by a few specialized labs.
C. parvum has all the above animal model options available; the options for C. hominis,
the Cryptosporidium species that most commonly infects humans (2-4), are much more limited.
C. hominis cannot infect mice but can infect guinea pigs, piglets and calves (71-73). Guinea pigs
are not used frequently but have been used to test the efficacy of different drugs (74, 75).
Gnotobiotic piglets are used by the Tzipori lab to passage the C. hominis TU502 strain,
originally isolated from a child with diarrhea in sub-Saharan Africa (71); C. hominis oocysts can
be obtained from piglets and used for challenge studies (76). The piglet model can also be used
to evaluate drug efficacy against C. hominis (70, 77). Since a calf model has not been created,
the piglet model is currently the only in vivo model for C. hominis; like the large animal models
for C. parvum, it is only routinely used in very specialized labs and is not easily available to all
researchers.

Cell culture models for Cryptosporidium
To date, no systems claiming continuous cultivation or complete life cycle development
of Cryptosporidium have been independently verified. Therefore, most in vitro studies rely on
cell culture platforms that support 2-3 days of growth, which rapidly declines as the parasite
enters the sexual part of its life cycle. These cell culture platforms are mainly cancer cell lines of
different origins. Most in vitro studies are done with C. parvum instead of C. hominis due to the
limited availability of C. hominis oocysts. A brief overview of some of these in vitro systems is
below.
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C. parvum growth has been described in undifferentiated and differentiated HT-29 cells
(human colorectal adenocarcinoma line), with growth being 5 to 6-fold better in differentiated
cells, but still declining by day 5 post-infection (78). MDCK cells have been reported to be
support asexual and sexual development of C. parvum, but not oocyst development (79). The
MDCK model has been adapted by Arrowood and colleagues to investigate potential
anticryptosporidial treatments (80-82). Upton and colleagues have developed a model using
HCT-8 cells (human ileocecal adenocarcinoma line) (83-85). One group improved upon this
model by finding that C. parvum infection lasted longer in “starved” cells in which the cell
growth medium was not renewed for 7-14 days (86). HCT-8 cells have been used to investigate
the interaction between C. parvum and host cells (87, 88), as well as define the C. parvum
transcriptome during infection (89). Caco-2 cells (human adenocarcinoma cell line) have also
been used to study C. parvum infection (44, 90, 91).
Complete development of Cryptosporidium in a cell-free culture system has been
reported (92), but the results have not been replicated (93). It has been suggested the original
images of developing C. parvum in axenic culture were misinterpreted and were likely budding
yeast or another contaminant (94). At this time, axenic culture has not been used to evaluate drug
efficacy against Cryptosporidium or any other investigation into parasite biology.
Recently, there have been three new models published claiming to support complete life
cycle development of C. parvum in vitro (95-97); these models use adenocarcinoma lines but
modify the cell culture platform to potentially support better C. parvum growth. For example,
one system utilizes a hollow fiber cartridge with circulating medium to support HCT-8 cell
growth (95). Within the cartridge, HCT-8 cells form monolayers around “lumens” and the
composition of the medium inside and outside the lumen can be controlled separately. The
10

authors found that C. parvum grew optimally when the apical side of the HCT-8 cells was in a
low redox environment, mimicking the low oxygen environment of the gut. The medium was
also altered to include lipids that may be required for Cryptosporidium growth (98, 99). The
authors found that this system sustained parasite growth for weeks, potentially months, and
produced oocysts that were infectious to HCT-8 cells and immunocompromised mice. While this
system is promising, it is unclear how reliable it is because it has not yet been replicated in
another lab. The authors also claim to observe oocyst development in 24 hours in normal HCT-8
culture, something that is biologically improbable, considering the typical length of the complete
C. parvum life cycle (3-6 days). Additionally, all perturbations to the system were done serially,
instead of in parallel, to determine the optimal medium composition for C. parvum growth; for
example, if two lipid mixes were tested, one mix was tested in the hollow fiber for 2 weeks, and
then washed out, and the new mix was added after that. Oocyst development was then compared
from the two time periods. This experimental design is likely out of necessity because the hollow
fiber system is expensive and it is not practical to have multiple systems running to test each
variable individually. However, this means that the final medium composition and recirculation
settings the authors arrived at are not thoroughly tested. If the system can be replicated in another
lab, it would be a great system for producing oocysts in vitro and possibly long-term drug
experiments, but not necessarily a good system for any kind of biological investigation into the
parasite. The monolayers on the hollow fibers cannot be accessed easily; to do any kind of
microscopy or collect samples for RNA/DNA, the cartridge needs to be opened, which
permanently ends the experiment. So, while this system has potential, its future role in
Cryptosporidium investigation is unclear.
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Another recently developed cell platform also utilizes a 3D scaffold to recreate the
intestinal environment. This system relies on silk scaffolds with a hollow lumen; the lumen is
populated with Caco-2 and HT29-MTX cells and the porous bulk space of the scaffold contains
primary human intestinal myofibroblasts (H-InMyoFibs) (96, 100). Each cell type has a role:
Caco-2 cells are “enterocyte-like”; HT29-MTX cells secrete mucus, replicating an important
aspect of the intestinal environment; H-InMyoFibs secrete various growth factors and cytokines
that help support cell viability. The 3D scaffold also enables the creation of an oxygen gradient
across the cells in the lumen, mimicking the low oxygen environment of the intestine (100). This
system, like the hollow fiber system, supported C. parvum growth and oocyst development.
Additionally, infectious material from one scaffold could be propagated to another scaffold for at
least three passages, potentially enabling continuous culture. This study did have some caveats;
for example, parasite growth was measured by 18S RNA levels, which remained stable over a
15-day period but did not show any amplification from the day 1 values, making it unclear how
much parasite growth was happening. Also, the evidence for passaged infection was only
presented as microscopy, there was no quantitative data showing the level of infection for each
passage. If the system can support continuous passage, it would greatly facilitate genetic
modification of C. parvum, which is currently possible but requires the use of animal to generate
infectious transgenic oocysts (66). However, the system does rely on specialized equipment to
create the porous silk scaffolds, so it is unclear how easily the system can be set up in a new lab.
Like the hollow fiber system, this platform has promise if the results can be replicated by other
researchers.
The most recently published system is simpler than the other two systems; it only relies
on the COLO-680N cell line, which is a human squamous cell carcinoma line derived from the
12

esophagus (97). This line has not previously been tested for its ability to support C. parvum
growth. The authors found that COLO cells supported C. parvum oocyst development, and that
oocysts purified from cell culture could be used to infect fresh cell cultures, thereby propagating
the infection (97). Additionally, infected COLO cells could be frozen by traditional
cryopreservation methods, thawed at a later date, and oocyst production would begin again
within three days. This development is especially interesting because currently there is no way to
preserve Cryptosporidium oocysts, requiring researchers to continually purify oocysts from
animal sources in order to maintain viable stocks. This system, if replicable, would be the easiest
for other labs to adopt, since it requires no special equipment or growth medium. However, the
study has several caveats: like the hollow fiber study, the authors report oocyst development by
HCT-8 cells, something that has not been seen by other researchers; also, the evidence for
propagation is the presence of C. parvum 18S RNA, shown as a cDNA band in a gel – there is no
quantitative PCR. There are also no low magnification images of infected cell cultures to
demonstrate the density of infection, only small images showing individual parasites. This
system could be a great boon to the Cryptosporidium research community if it can be reproduced
by other labs; it is an inexpensive and accessible system that would facilitate many kinds of
studies.
Since Cryptosporidium was first recognized as a public health threat in the 1980s (101,
102), there have been claims of complete life cycle development and continuous propagation in
vitro and ex vivo (37, 103, 104), but no system has proven to be reproducible. The three new
systems described here have unique advantages and disadvantages and could all have a role in
enabling new lines of investigation into Cryptosporidium. However, their true utility cannot be
determined until their results are replicated by other hands. The lack of an in vitro culture system
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has hindered Cryptosporidium for the past several decades but hopefully the renewed interest in
cryptosporidiosis (28) will instigate a reexamination of the approach to developing a cell culture
platform for this parasite.

Anti-Cryptosporidium antibodies
The various obstacles stalling Cryptosporidium research (difficult animal models, lack of
culture system) has led to a general absence of tools for investigators. For example, there are
very few anti-Cryptosporidium antibodies publicly available, making microscopy-based studies
difficult. For a lab beginning to investigate Cryptosporidium, it can take a significant amount of
time to understand the progression of the parasite life cycle in vitro without markers designating
specific life cycle stages. Currently, the only published “visual maps” of the parasite life cycle
are based on electron microscopy (36) or bright field images (105), or, most commonly, authors
enumerate different life cycle stages without providing any images (86).
There are two commercially available antibodies that many researchers rely on: SporoGloTM and Crypt-a-GloTM (Waterborne, Inc); the former is a rat polyclonal antibody raised
against sporozoites that broadly recognizes all life cycle stages, the latter is a mouse monoclonal
antibody raised against oocyst wall proteins that recognizes oocysts. Sporo-gloTM is very useful
due to its broad reactivity and is used in many microscopy-based inhibitor studies (88, 106, 107).
However, it has limited usefulness in enabling the researcher to detect specific life cycle stages
without familiarity of other stage markers, such as size, nuclei number, and timing of
appearance. Crypt-a-gloTM is primarily intended as a tool to detect oocyst contamination of water
supplies, but it has also been used to evaluate the ability of different cell culture systems to
produce oocysts (96, 97).
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Antibodies that have been made against Cryptosporidium have been raised against
extracellular stages (sporozoites, oocysts) or specific recombinant proteins. The former approach
has aided in the discovery of proteins that likely have a role in parasite motility and invasion. For
example, 4E9 is a monoclonal antibody raised against fixed whole sporozoites that can block C.
parvum sporozoite attachment and invasion (108). It also shows reactivity against material shed
by sporozoites during gliding motility (108). By western blot, 4E9 recognizes two glycoproteins,
gp40 and GP900. After the identification of gp40 by 4E9, researchers cloned and sequenced the
gene encoding gp40 (109) and discovered the gene also encoded a previously-identified protein,
gp15 (110, 111), that is also hypothesized to be involved in parasite motility. Without an
accessible genetics system, it is difficult to investigate the role of gp40 and gp15 in C. parvum
further, but these antibody-based studies have been successful in identifying the two proteins as
important targets. 4E9 has also been useful in assessing C. parvum life cycle progression in a
novel cell culture platform (96).
Antibodies against specific recombinant proteins have been made to investigate the
function of various proteins during the parasite life cycle. Usually these studies follow one of
two approaches: identifying a gene of interest, then creating the recombinant protein and specific
antibody (44), or identifying a protein of interest first by affinity chromatography (112). CpABC,
a putative transporter of large organic anions, was identified using the first approach (44);
antisera to recombinant CpABC localized it to the host-parasite interface, providing additional
evidence that this interface is the location of the parasite “feeder organelle” (44). Gal-affinity
chromatography has been used to identify lectins on the sporozoite surface; purification of one of
these lectins led to the identification of the p30 gene and protein (112). Antisera to p30 revealed
that it can associate with the previously mentioned gp40 and GP900 proteins (112), suggesting it
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has a role in parasite motility. Both of these approaches to gene/protein function discovery have
led to important findings about C. parvum biology, but as said above, it is difficult to pursue
further studies without an accessible genetics system.
Antibodies raised against whole parasites and recombinant proteins have been very useful
to the Cryptosporidium field, but there is room for improvement in terms of identifying life cycle
markers. This gap in knowledge may be due in part to the fact that it has been impossible to
make antibodies against intracellular stages specifically; the adenocarcinoma cell lines that
support C. parvum growth are all human-derived, so immunization of mice with infected cellular
material would lead to the creation of host-specific antibodies. In order to create novel antibodies
against intracellular parasite stages, it will be necessary to identify a murine cell line that
supports robust parasite growth.

Advancements in intestinal stem cell culture
The epithelial lining of the small intestine is organized into crypts and villi; the lining
turns over every 3-5 days in the mouse, a process driven by cell proliferation in the crypts and
balanced by apoptosis at the villi (113). Self-renewing stem cells, identified by expression of
LGR5 (114), a GPCR (115, 116) that is part of the Wnt signaling pathway (117), are located at
the crypt base (114, 118). These stem cells produce rapidly dividing transit-amplifying cells that
give rise to all the differentiated cell types of the intestine, which migrate up the crypt-villus axis
(113).
In the last decade it has become possible to propagate intestinal stem cells in vitro due to
advancements in understanding the growth requirements of the intestinal epithelium.
Specifically, Wnt signaling is necessary for crypt proliferation (119), overexpression of Noggin
16

drives expansion of crypt numbers (120), and isolated intestinal epithelial cells will undergo
anoikis if cell-cell and cell-matrix contacts are disrupted (121). The first two discoveries led to
the inclusion of different growth factors, such as Wnt3a, noggin, and R-spondin 3 (Wnt agonist),
in the medium used to grow stem cells (122-125) and the latter finding led researchers to using
Matrigel, a mix of basement membrane proteins extracted from the EHS mouse sarcoma, as a
growth substrate in order to prevent apoptosis (122, 125).
There are various platforms available to propagate stem cells which differ in terms of
medium composition and whether the cells are grown as organoids or spheroids. Organoids are a
mix of stem cells and differentiated cells and are grown in medium containing Wnt3a, R-spondin
1, and Noggin (122). Spheroids are enriched for stem cells and are grown in medium containing
Wnt3a, R-spondin-3, and Noggin (125, 126). Systemic doses of R-spondin 1 induce crypt cell
proliferation in mice (127), but R-spondin 3 is expressed by intestinal mesenchymal cells (125,
128) and therefore may be the more relevant R-spondin family member for intestinal stem cells,
partially explaining the difference in the two culture systems. In both cases, the Wnts and Rspondins enhance canonical Wnt signaling, which is necessary for self-renewal of stem cells
(129) and noggin, a BMP signaling inhibitor (120), has been found to be necessary to passage
small intestinal organoids in vitro (122).
Initially, the growth factors required for stem cell proliferation had to be added to the
medium separately, as recombinant proteins, making the medium very expensive (122). The
creation of the L-WRN cell line, which secretes biologically active Wnt3a, R-spondin 3, and
noggin (125), made this method unnecessary. The L-WRN line is a modification of the L-Wnt3a
line, an L cell (neuroendocrine cell found in small intestine) line modified to secrete Wnt3a
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(130). The L-WRN cell line can be used to create “conditioned medium” containing the required
factors; this medium is then used to propagate intestinal stem cells as spheroids (125, 126).
Primary cell monolayers can be derived from spheroids in order to study intestinal
function in a 2D model. Spheroids are trypsinized and plated onto a transwell membrane coated
with Matrigel; L-WRN conditioned medium is removed and replaced with growth medium
lacking stem cell growth factors in order to induce cell differentiation (131). These monolayers
are polarized and contain the major intestinal epithelial lineages such as enterocytes and
secretory cells (enteroendocrine, goblet, Paneth). These monolayers lose their proliferative
potential and therefore only maintain viability for about 2-3 days. This system can be used to
study aspects of intestinal function, such as IgA transcytosis across the epithelial cell layer (131).
In the last several years, a new method for creating primary intestinal monolayers from
spheroids has been developed. This system differs from the above method in three major ways:
inclusion of a feeder cell layer in addition to the Matrigel coating, continuous exposure to stem
cell growth factors, and the creation of an air-liquid interface (ALI) at the surface of the cells
(132). In this system, spheroids are trypsinized and plated onto the feeder cell layer in a
Matrigel-coated transwell. The monolayer is grown in medium containing stem cell growth
factors such as R-spondin 1 and Noggin. After 7 days of growth, the medium in the top chamber
is removed, creating the ALI. This triggers a dramatic differentiation of the cells, leading to
development of enterocytes and other differentiated cells such as goblet cells; there is even
formation of structures resembling crypts (132). The mechanism behind ALI inducing
differentiation is unclear, however, ALI has historically been used to improve differentiation of
airway tract epithelial monolayers (133-135). ALI has recently been used in intestinal epithelial
cell culture, causing major metabolic changes and also upregulation of markers associated with
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cell differentiation (136, 137). Monolayers with ALI maintain viability for weeks because a
portion of the monolayer continues to proliferate, replacing cells as they undergo apoptosis
(132). This long-term proliferation is likely due to maintaining the cells in stem cell growth
medium. The differentiation status and long-term viability of these monolayers makes them a
great candidate for modeling the intestinal environment.
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Aim and scope of thesis
The central aim of this thesis was to use the recent advancements in stem cell culture to
develop a platform for C. parvum growth and development in vitro. The majority of cell culture
systems currently used to study Cryptosporidium infection rely on cancer cell lines that do not
resemble the intestinal epithelial cell the parasite encounters in vivo. The use of transformed cell
lines likely explains why attempts to achieve propagation or complete life cycle development of
C. parvum in vitro have failed. Recent systems claiming continuous culture and oocyst
development also use cancer cell lines (HCT-8 or COLO-680N) to serve as “enterocytes” (9597); the reproducibility of these systems has yet to be demonstrated. A primary cell culture
system with intestinal epithelial cells would provide a great model for investigating C. parvum’s
interactions with the host cell, and potentially support complete life development.
Propagating intestinal stem cells as spheroids using L-WRN conditioned medium was
first developed using mouse cells (125, 126) and then later adapted to human cells (138). These
stem cells can be induced to differentiate into enterocytes and secretory cells by plating them on
transwell membranes and changing the medium composition (131, 138). The mouse and human
monolayers created using this method only survive 3 or 6 days, respectively (131, 138). The
viability of these monolayers could be improved by incorporating aspects of the model described
by Wang et al (132), which creates primary monolayers that continue to proliferate for weeks.
This model uses medium containing stem cell growth factors and creates an air-liquid interface at
the surface of cells to induce differentiation. The main aim of this thesis was to test monolayers
developed using this method for their ability to support C. parvum growth and oocyst
development.
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Even though adult, non-immunocompromised mice are resistant to C. parvum infection,
this thesis focused on monolayers created using stem cells isolated from the small intestine of
adult C57BL/6 mice. We hypothesized that murine monolayers would be susceptible to infection
because they lack the cellular and humoral immunity of the whole animal. Additionally, creating
a platform for robust C. parvum growth in mouse cells would potentially enable us to create
novel antibodies against intracellular stages of C. parvum by immunizing mice with infected
cells, something not previously possible.
An in vitro culture system that has the major lineages of the intestinal epithelium as well
as long-term viability could be the key to unlocking Cryptosporidium development in vitro.
Developing and characterizing this system would support future investigation into
Cryptosporidium biology, such as host-receptor interactions, role of metabolism in infection, and
the efficacy of potential treatment options. Additionally, if this system could be used to generate
novel antibodies against different life cycle stages, it would be filling in a major reagent gap in
the field. Essentially, this thesis aims to create two tools for Cryptosporidium research: a
platform for growth and unique antibodies against all life cycle stages.
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Figures and legends

Figure 1.1. Life cycle of Cryptosporidium parvum.
Cartoon depicting the life cycle of C. parvum (courtesy of Laura Kyro, reproduced with
permission). A host becomes infected when they ingest oocysts. The oocysts travel through the
stomach and excyst in the small intestine, releasing 4 sporozoites. The sporozoites invade the
epithelial cells of the intestinal lining and develop into trophozoites, residing in a host
membrane-enclosed vacuole in an “intracellular but extracytoplasmic” niche in the apical region
of the cell. Trophozoites develop into type I meronts, which contain 8 merozoites when mature.
The merozoites are released and they can either initiate another round of asexual development by
becoming trophozoites or initiate the sexual part of the life cycle by becoming type II meronts.
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Mature type II meronts contain 4 merozoites, these are released and become micro- or
macrogamonts. Microgamonts fertilize macrogamonts, which develop into zygotes and
eventually thin- or thick-walled oocysts. Thin-walled oocysts are believed to rupture within the
intestine, initiating another round of infection, while thick-walled oocysts exit the host to spread
the infection.

23

Chapter 2
Monoclonal antibodies to intracellular
stages of Cryptosporidium parvum define
life cycle progression in vitro
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Summary
Among the obstacles hindering Cryptosporidium research is the lack of an in vitro culture
system that supports complete life development and propagation. This major barrier has led to
shortage of widely available anti-Cryptosporidium antibodies, and a lack of markers for staging
developmental progression. Previously developed antibodies against Cryptosporidium were
raised against extracellular stages or recombinant proteins, leading to antibodies with limited
reactivity across the parasite life cycle. Here we sought to create antibodies that recognize novel
epitopes that could be used to define intracellular development. We identified a mouse epithelial
cell line that supported C. parvum growth, enabling immunization of mice with infected cells to
create a bank of monoclonal antibodies (mAbs) against intracellular parasite stages while
avoiding the development of host-specific antibodies. From this bank, we identified 12
antibodies with a range of reactivity across the parasite life cycle. Importantly, we identified
specific mAbs that can distinguish different life cycle stages, such as trophozoites, merozoites,
type I vs. II meronts and macrogamonts. These mAbs provide valuable tools for the
Cryptosporidium research community and will facilitate future investigation into parasite
biology.
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Introduction
Cryptosporidium is a genus of protozoan parasites that causes diarrheal disease
(cryptosporidiosis) in humans and other animals. Over 20 species are recognized, but the
majority of human cases is caused by C. parvum or C. hominis (1). For decades,
Cryptosporidium was mainly recognized as a cause of chronic diarrhea in patients
immunocompromised from HIV/AIDS (139). However, an investigation into the etiologies of
diarrheal illnesses in children in Africa and South Asia found that Cryptosporidium is second
only to rotavirus as a cause of diarrhea in infants in these regions (19). Since diarrheal disease is
a significant cause of child mortality (26), this discovery has led to increased interest in
cryptosporidiosis and a reexamination of the barriers to studying Cryptosporidium (28). The
main obstacle hindering research on this parasite is that it cannot be propagated in vitro and
instead must be passaged through large animals such as calves to generate infectious oocysts. C.
parvum can also infect mice, although susceptible mouse models are limited to immunodeficient
(140) or neonatal animals (141). Current cell culture models rely on human adenocarcinoma cell
lines (e.g. Caco-2, HCT-8) that do not support complete life cycle development (142). Without
the ability to propagate, clonal lines cannot be established and in vitro studies are restricted to
studying limited rounds of asexual replication and incomplete sexual development. Genetic
manipulation is possible if the parasites are passed through immunocompromised mice (66),
however it is not feasible to examine the cellular basis of complex phenotypes without a parallel
in vitro system for development.
Cryptosporidium has a complex life cycle consisting of both an asexual phase
(merogony) and a sexual phase (gametogony) that culminates in oocyst formation (143). There
are a limited number of antibodies that identify different life cycle stages of Cryptosporidium,
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especially intracellular stages. In part, this limitation is due to the fact that antibodies have
typically been generated against extracellular stages such as oocysts (144) and sporozoites (108),
and many of these recognize widely conserved epitopes found in intracellular stages (145). For
example, it has been reported that epitopes shared on gp60, a glycoprotein involved in parasite
adhesion to host cells, and its processed components of gp15 and gp45, are expressed on both
sporozoites and merozoites (110, 111, 146). Antibodies have also been made against specific
proteins (44, 112, 146); however this method of antibody production does not typically allow for
the discovery of novel antigens. Additionally, many antibodies previously raised against
Cryptosporidium were made in rabbits (44, 146, 147), which is a non-renewable source of
antibody. Collectively, these available reagents do not allow the specific life cycle stages to be
clearly delineated with unique markers, confounding attempts to track development during in
vitro growth.
Our goal was to create a mouse hybridoma bank against Cryptosporidium to provide
reagents to easily identify life stages, discover new antigens and provide a renewable reagent
source. One barrier to making antibodies against intracellular stages of Cryptosporidium is that
there is no mouse cell line that supports robust parasite growth (142). Although human
adenocarcinoma lines allow for limited intracellular growth, immunizing with culture material
derived from such heterologous sources would likely generate many host-specific antibodies.
Here, we tested primary murine ileal epithelial cells (IECs) and found that C. parvum underwent
efficient amplification in these cells. The use of mouse IECs allowed us to immunize mice with
infected cell lysates without the risk of generating host-specific antibodies. Using this strategy,
we created a hybridoma bank expressing novel monoclonal antibodies (mAbs) against
intracellular parasite stages. By examining the timing of expression and patterns of staining, we
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identified antibodies with distinctive reactivity against specific life cycle stages, such as
trophozoites, merozoites, type I and II meronts, and macrogamonts. Collectively, this “antibody
toolkit” should lead to a deeper understanding of parasite biology and foster efforts to define
conditions for complete development and propagation in vitro.
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Results and discussion
Establishing a mouse hybridoma bank against C. parvum
We initially sought to identify a mouse cell type that would support robust parasite
growth in vitro. It has been reported that bovine and human isolates of Cryptosporidium will
grow in mouse L929 fibroblasts (148) and peritoneal macrophages (149), but these cell types are
not commonly infected in vivo. Instead, Cryptosporidium spp. primarily grows in the epithelial
cells of the small intestine (150). Recent developments have shown that mouse intestinal stem
cells can be maintained in culture as spheroids using media containing a cocktail of specific
growth factors (126). When these stem cells are grown as monolayers on transwells, they
develop into polarized epithelial monolayers that include enteroendocrine cells, Paneth cells,
mucin-producing goblet cells, and enterocytes (131). As shown previously, these different
lineages are present in the monolayers at rates similar to what is found in the mouse intestine
(131). Such monolayers could provide a much more natural niche for growth of C. parvum than
typical transformed cell lines. Consequently, we tested primary mouse ileal epithelial cells
(mIECs) that were differentiated from intestinal stem cells for their ability to support C. parvum
growth in vitro. C. parvum was able to achieve high levels of amplification over a 3-day period
in mIECs grown in transwells as shown by qPCR (Figure 2.1).
Having successfully identified a mouse cell line that supported robust development of C.
parvum, we immunized mice with infected mIEC lysates, performed a fusion, and screened the
resulting hybridomas by microscopy to identify novel antibodies to C. parvum. Following
sequential subcloning, individual monoclonal antibodies (mAbs) were screened on infected
mIECs and HCT-8 cells to investigate their reactivity against different life cycle stages of C.
parvum. To monitor C. parvum infection, we stained the monolayers with a rabbit polyclonal
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antibody raised against the Toxoplasma gondii strain RH that was broadly cross-reactive to C.
parvum antigens based on western blot (Figure 2.2). As shown in Figure 2.3, this anti-RH
antibody (labeled “Cp” in figures) recognized both asexual and sexual stages of C. parvum by
immunofluorescence (IFA).
Starting from a total of 31 mAbs, we identified 12 antibodies with distinctive staining
patterns (Table 1). Other mAbs with positive reactivity showed similar patterns to those
described here and therefore they were not pursued further. Overall, most mAbs reacted to
multiple stages (see table 1, Figure 2.4, Figure 2.5), suggesting that they recognize epitopes that
are expressed broadly across the intracellular life cycle. We identified one antibody, 1E12, that
recognized every life stage, excluding oocysts (table 1, Figure 2.4, Figure 2.5). Based on its
reactivity pattern, 1E12 recognizes an epitope associated with the membrane of all life cycle
stages (figure 2.3). Due to its broad spectrum and membrane pattern of reactivity, 1E12 can be
used to identify specific stages based on appearance, size, and number of nuclei. For example,
1E12 can be used to distinguished type I meronts, which have 4 nuclei but a single cytoplasmic
mass (figure 2.3B), from type II meronts, which have four nuclei, but have separated into 4
distinct merozoites (figure 2.3D). MAb 1E12 also stains the surface of type I merozoites (figure
2.3C), allowing mature type I meronts to be clearly distinguished from immature type I meronts.
MAb 1E12 also recognized the membrane of macrogamonts (figure 2.3E) and one end of the
small microgametocytes within the microgamont (figure 2.3F).
MAb 1E12 has great utility as a “pan-crypto” antibody; it can be used to easily assess the
ability of different cell culture platforms to support Cryptosporidium growth as it recognized all
the major stages, which are distinguishable by their surface morphology. Other antibodies
identified through the screen did not have this broad reactivity but rather identified specific life
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cycle stages in distinguishable patterns, making them useful for understanding life cycle
progression in different culture systems. These antibodies are described in detail below.

mAb 1B6 recognizes the oocyst outer wall
Only one antibody from the hybridoma library was specific for a single stage; mAb 1B6
only recognized oocysts and did not show any reactivity towards asexual (Figure 2.4, Figure 2.5)
or sexual stages (table 1). MAb 1B6 detected residual oocysts from the inoculum that were
present in mIECs (Figure 2.4). MAb 1B6 stained the oocyst wall in a continuous pattern (Figure
2.6), similar to Crypt-a-gloTM, a commercial reagent that is an oocyst-specific monoclonal
antibody (Waterborne Inc.) (151). MAb 1B6 equally recognized oocysts that were either left
unstimulated or stimulated to excyst (Figure 2.6), suggesting it recognizes an epitope on the
outer wall of the oocyst. MAb 1B6 preferentially stained bleached oocysts (figure 2.6), a process
that removes the outer veil (152). Based on this result, it is likely that bleach treatment removes
the veil and exposes the 1B6 epitope on the outer wall. Interestingly, 1B6 did not stain
macrogamonts (table 1), unlike the previously described mAb OW50, which also reacts to an
outer oocyst wall protein, and stains wall-forming bodies in mature macrogamonts (153).

mAbs 1B5 and 1F9 have distinctive trophozoite-specific patterns
Although many of the antibodies generated here react to multiple life cycle stages, they
still provide markers for defining development due to the unique patterns of staining they detect
in specific stages. For example, mAbs 1B5 and 1F9 detect a distinctive “doughnut-shaped”
pattern in trophozoites during the initial stages of asexual development (Figure 2.7C, E).
Although both mAbs have a circular staining pattern on trophozoites, 1B5 staining has a smooth,
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continuous appearance while 1F9 is punctate, implying the two antibodies recognize different
epitopes. While 1F9 did not show reactivity by western blot, 1B5 recognized a 230 kDa product
in sporozoites (Figure 2.2).
When images of trophozoites were acquired by laser scanning confocal microscopy and
the Z-stacks were rendered in 3D, the resulting images revealed that the epitope recognized by
1B5 is mostly confined to the base of the parasite where it contacts the host cell, while 1F9
staining begins at the base and extends up the side of the vacuole or parasite membrane (Figure
2.7D, F). Because these antibodies have a polarized recognition pattern in sporozoites (Figure
2.8), their targets likely relocalize following invasion to this interface during initial trophozoite
growth.
The host-parasite interface is where the host cytoskeleton is reorganized into an actin-rich
pedestal during intracellular development (154-156). When infected HCT-8 cells were stained
with fluorescently labeled phalloidin to visualize this actin pedestal, labeling with 1B5 and 1F9
revealed that both mAbs formed a ring around the nascent pedestal in trophozoites (Figure 2.9A).
Examination of Z-slices generated by laser scanning confocal microscopy revealed that the ring
formed by 1B5 is within the same plane as the pedestal, whereas the 1F9-labeled ring is
positioned above the pedestal (Figure 2.9A). As trophozoites develop into meronts, the epitopes
recognized by 1B5 and 1F9 redistributed, leading to more diffuse labeling that was no longer
confined to the base of the parasite (Figure 2.9B, table 1, Figure 2.4).
The host-parasite interface is also the site where the parasite elaborates a membrane-rich
feeder organelle (157) (Figure 2.7A). The nature of this feeder organelle is uncertain, although
the genomes of C. parvum (43) and C. hominis (158) contain a large number of transporters and
it has been speculated that this interface is responsible for transport of nutrients from the host
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(159). Consistent with this, a C. parvum ATP-binding cassette protein that shares features with
transporters has previously been localized to this interface (44). Attempts to localize the epitopes
recognized by 1B5 or 1F9 using immunoelectron microscopy were not successful, however,
based on their localization pattern in trophozoites by fluorescent microscopy, it is possible that
the targets recognized by either mAb are involved in the reorganization of the host cytoskeleton
and the generation of the feeder organelle. Hence, these mAbs may facilitate future investigation
into these two developmental processes.

mAb 5E3 recognizes mature type I merozoites in a polarized manner
Moving forward in the parasite life cycle, the parasite progresses through asexual
development to replicate mitotically and generate 8 mature merozoites within type I meronts
(Figure 2.10A). Transmission electron microscopy reveals that the apical end of merozoites in
mature type I meronts is characterized by many small secretory vesicles corresponding to
micronemes and cross-sections of rhoptries (Figure 2.10B, C), similar to what is seen in
sporozoites (160). Four mAbs (1A5, 1A12, 5E3, 5F7) recognized both type I and type II
merozoites in a distinctive polarized pattern reminiscent of this apical specialization (Table 1)
and these mAbs, along with others, also stain the apical end of sporozoites (Figure 2.8). An
example of this polarized staining pattern is shown for 5E3 staining of fully developed
merozoites in mature type I meronts (Figure 2.10E, F, Figure 2.5). mAb 5E3 was also able to
recognize immature type I meronts, where the epitope is fainter and distributed along the
membrane (Table 1) from mature type I meronts that contain 8 merozoites, which demonstrate
strong polarized staining (Figure 2.5). Three-dimensional rendering of Z-stacks acquired by laser
scanning confocal microscopy revealed that the epitope recognized by 5E3 is concentrated at one
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end of the parasite (Figure 2.10E, F). This polarized pattern is similar to that of a previously
published mouse monoclonal 4E9, which stains the apical end of sporozoites and also recognizes
trails of protein shed by the sporozoite during gliding motility (108). Attempts to label the apical
end of sporozoites directly with 5E3 by immunoelectron microscopy were unsuccessful, but
based on its recognition pattern by fluorescence microscopy, it is likely that mAb 5E3, and other
antibodies that stain in a highly polarized pattern (Table 1), recognize components of apical
secretory organelles, which are implicated in host cell attachment and invasion (161, 162).

Antibodies that distinguish type I from type II meronts
The life cycle of Cryptosporidium spp. proceeds through two rounds of merogony, the
first of which culminates in eight merozoites (type I), while the second terminates with four
merozoites (type II) (157). Because the type I merogony cycle also proceeds through a 4 nuclear
stage, it can be difficult to distinguish these immature type I stages from mature type II stages
based on the number of nuclei alone. To identify antibodies that recognize type II meronts, we
established a method to reliably distinguish type II meronts, which contain 4 nuclei within
mature merozoites, from “early stage” or immature type I meronts, which can also contain 4
nuclei. To distinguish between these stages, we pulse-labeled parasites growing in HCT-8 cells
using EdU, which labels replicating DNA (66), and detected incorporation fluorescently using
click labeling (see methods). By adding EdU in specific intervals after infection, we identified
actively replicating stages that were further defined by nuclear morphology and number. Type II
meronts were most commonly detected from 30-32 hr post-infection. When EdU was added
during this 2 hr interval, type II meronts were identified by the presence of 4 nuclei that lacked
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EdU positivity, as they were mature and no longer replicating, whereas 4 nuclei type I meronts
were EdU positive because they were still actively replicating (Figure 2.11).
Based on differential EdU labeling, we identified several antibodies that recognized type
II meronts with different staining patterns (Table 1). For example, mAb 1A5 did not stain
immature type 1 meronts (Figure 2.11A) but did stain mature type I (Figure 2.11B) and type II
(Figure 2.11C) meronts. Because of this pattern of reactivity, mAb 1A5 can be used to positively
identify type II meronts from immature type I meronts, which also contain 4 nuclei. By western
blot, 1A5 recognized a 125 kDa band (Figure 2.2) and this protein serves as a marker of mature
merozoites, whether they are type I or II.
Despite their superficial similarity, merozoites produced by these two rounds of
merogony have different fates. Type I merozoites are thought to reinitiate multiple rounds of
asexual replication, while type II merozoites are thought to give rise to gamonts (143).
Unfortunately we did not identify any mAbs that only stain type II meronts, nor have such
reagents been described previously, although differences have been detected by ultrastructure
(157). Consequently, the ability to track type II meronts using mAbs like 1A5 combined with
EdU staining provides a convenient means of monitoring development of stages that are
committed to undergo sexual development.

Antibodies that distinguish sexual stage development
Merozoites released by type II meronts are thought to give rise to micro- and
macrogamonts, which eventually undergo fertilization to form oocysts, although this last step
does not occur efficiently in vitro. The majority of mAbs studied here did not recognize sexual
stages, with two exceptions (table 1). For example, mAbs 1A5 and 1B5 broadly stain asexual
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stages but fail to stain either micro- or macrogamonts (table 1). The membrane-reactive mAb
1E12 did stain the membranes of both microgamonts and macrogamonts (figure 2.3, table 1),
although the staining of macrogamonts did not provide a unique recognition pattern that
differentiated it from asexual stages such as meronts. In contrast, mAb 4D8 showed a
characteristic “V” (figure 2.12C) or line pattern (figure 2.12D) in macrogamonts (table 1), a
reactivity pattern not reported in any published studies with other Cryptosporidium antibodies.
When examined by transmission electron microscopy, macrogamonts were found to contain a
prominent striated fiber running through the center of the cytoplasm (figure 2.12B). This striated
fiber is not seen in all thin sections, possibly explaining why some electron microscopy studies
of in vivo infection do not mention the fiber at all (157) and only one published study contains an
image of a macrogamont with a fiber, although it is not described in detail (163). Attempts to
label the fiber directly with 4D8 by immunoelectron microscopy were not successful, so while
we cannot definitively say 4D8 recognizes this structure, it seems highly likely based on its
appearance. The molecular nature of this striated fiber is also uncertain, as the streamlined
genome of C. parvum contains homologs for tubulin, actin, and several actin-related proteins
(http://cryptoDB.org). The genome also contains orthologues of articulins, which are known in
other apicomplexans as inner membrane complex proteins (IMCs) (164), although they are not
annotated as such in C. parvum (http://cryptoDB.org). The striated fiber observed in
macrogamonts does not resemble microtubules that are typically found apically, or the
meshwork of IMC proteins that are localized under the membrane of motile stages (164). Hence,
this striated fiber may represent a novel assemblage of actin filaments, or a novel cytoskeletal
element that imparts some form of structural integrity within macrogamonts. Currently,
macrogamonts are recognized by their size and diffuse nucleus. In contrast, the staining pattern
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of 4D8 provides definitive marker for this stage based on the strongly striated pattern, while it
stains other stages much more diffusely (Figure 2.5).
We did not identify any antibodies that specifically stain microgamonts, although they
are recognizable by their many small nuclei, which number 16 in mature microgamonts (figure
2.12E). These small, replicating nuclei were easily visualized using a commercially available
anti-phospho-histone H3 antibody (figure 2.12G), which stains DNA during mitosis (165), or
through the incorporation of EdU during DNA replication (figure 2.12H).
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Conclusions
Previous studies on the development of C. parvum in vitro have been hampered both by
the lack of an efficient in vitro system for propagation and lack of specific reagents to stage
development. We have taken advantage of developments in stem cell biology to propagate C.
parvum in mouse IECs, which more closely resemble the intestinal cells that support growth in
vivo compared to adenocarcinoma cell lines. Although attempts to achieve complete
development of C. parvum in mIECs are ongoing, here we have used this system to generate
antigens for production of novel mAbs to intracellular stages. This approach has been effective at
generating reagents that define stage-specific patterns of expression, which greatly enhances our
ability to define specific stages during in vitro growth. Collectively these reagents should be
useful for future studies to 1) define developmental progression during in vitro culture, 2)
identify conditions necessary to support complete development in vitro, and 3) pinpoint the
stages that are susceptible to chemotherapy, thereby supporting efforts at target identification.

39

Materials and methods

Ethics Statement
Animal studies were conducted according to the U.S.A. Public Health Service Policy on Humane
Care and Use of Laboratory Animals. Animals were maintained in an Association for
Assessment and Accreditation of Laboratory Animal Care – approved facilities. Animal studies
were approved by the Institutional Animal Studies Committee at the School of Medicine,
Washington University in St. Louis, protocol number 20170163.

Adenocarcinoma cell culture
Human ileocecal adenocarcinoma cells (HCT-8; CCL-244TM ATCC) were maintained in RPMI1640 medium (Gibco, ATCC modification) supplemented with 10% FBS. Human colorectal
adenocarcinoma cells (Caco-2; HTB-37TM ATCC) were maintained in Minimum Essential
Medium (Corning CellGro) supplemented with 20% FBS. Cell lines were tested for the presence
of mycoplasma and confirmed negative with the e-Myco plus Mycoplasma PCR Detection Kit
(Boca Scientific).

3D spheroid cell culture
Primary ileal epithelial stem cells isolated from 8-10 week old C57BL/6 mice were obtained
from the laboratory of Dr. Thad Stappenbeck, Washington University in St. Louis. Ileal stem
cells were expanded and maintained as 3D spheroid cultures in Matrigel (BD Biosciences), as
described previously (125). Spheroid cultures were grown in 50% L-WRN conditioned medium
(CM) containing 10 µm Y-27632 (ROCK inhibitor; Tocris Bioscience). The medium was
changed every 2 days and the cells were passaged every 3 days in a 1:6 split.
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Formation of transwell monolayers
To form monolayers, spheroids from 3-day-old stem cell cultures were recovered from Matrigel
and dissociated with trypsin as described previously (131). Transwells (polyester membrane, 0.4
µm pore; Corning Costar) were prepared for cell seeding by coating the upper compartment with
100 µl of 1:40 dilution of Matrigel for 20 min at 37°C. Excess Matrigel was aspirated off the
membrane and approximately 2x105 cells, diluted in 100 ul CM with 10 µm Y-27632, were
seeded onto the coated membrane. Media (700 µl of CM with Y-27632) was added to the bottom
compartment of the transwell. About 24 hr after seeding, the media in the top and bottom
compartments of the transwell was changed to 0% CM referred to as “primary medium”
(consisting of advanced DMEM/F12 containing 20% fetal bovine serum, 100 U of penicillin,
0.1 mg/ml streptomycin, and 2 mM L-glutamine; Sigma). Monolayers were infected with oocysts
24 hr after seeding.

Oocyst preparation and excystation
Oocysts were provided by the Kuhlenschmidt lab (University of Illinois at Urbana Champaign).
The AUCP-1 isolate of C. parvum was maintained in male Holstein calves and oocysts were
purified as described previously (107). Oocysts were stored at 4°C in 50 mM Tris-10 mM
EDTA, pH 7.2. Before infection, 1x108 purified oocysts were diluted into 1 ml of Dulbecco’s
Phosphate Buffered Saline (DPBS; Corning Cellgro) and treated with 1 ml of 40% bleach
(commercial laundry bleach containing 8.25% sodium hypochlorite) for 10 min on ice. Oocysts
were then washed 4 times in DPBS containing 1% (wt/vol) bovine serum albumin (BSA; Sigma)
and resuspended in 1 ml DPBS with 1% BSA. For some experiments, oocysts were excysted
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prior to infection by incubating the oocysts with 0.75% sodium taurocholate (w/v; Sigma) at
37°C for 60 min. Excysted oocysts were washed once with cell media prior to adding to cells.
For sporozoite and oocyst labeling experiments, coverslips were coated with Poly-LLysine (PLL, Sigma) overnight at room temperature. After aspirating the PLL and allowing the
coverslips to dry, unexcysted oocysts or a mixture of excysted oocysts and sporozoites were
added to the coverslips and allowed to settle for 20 min. Unbleached oocysts were washed three
times with sterile DPBS before being plated onto coverslips. The oocysts or sporozoites were
fixed in 4% formaldehyde, permeabilized with 0.05% saponin (except where stated) and stained.

Growth of C. parvum in transwell mIEC monolayers
At 24 hr after plating, mIECs were infected with 2x106 oocysts diluted in primary medium added
to the top compartment of the transwell. Media was changed in the top and bottom compartments
of the transwell daily during infection. To measure C. parvum growth in infected monolayers,
the media in the top compartment was removed and 50 µl of buffer (5 mM Tris/HCl, pH 8.5)
containing 50 µg/ml proteinase K (Sigma) was added. Cells were scraped into the lysis buffer
using a pipette tip and the lysate was transferred to a PCR tube and incubated at 37°C for 60 min,
56°C for 60 min, and 95°C for 10 min. Two µl of the lysate was used as a template in the qPCR
reaction with SYBR Green PCR Master Mix (Applied Biosystems). Reactions were performed
on a Stratagene MX3000P qRT-PCR system with the following amplification conditions: initial
denaturation at 95°C for 10 min and 45 cycles of denaturation at 95°C for 5 seconds, annealing
at 55°C for 10 seconds, and extension at 72°C for 30 seconds. Primer sequences targeting C.
parvum GAPDH were as follows: forward primer 5’ AAGGACTGGAGAGCAGGAAG 3’ and
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reverse primer 5’ AAAGCTGGGATGACCTTACC 3’. A standard curve for C. parvum genomic
DNA was generated by lysing a known number of oocysts and creating a dilution series.

Antigen preparation
About 48 hr post-infection, medium in the top compartment of the infected transwells was
removed. Groups of 10 transwells were lysed in 100 µl of NP-40 lysis buffer (150 mM sodium
chloride, 1% NP-40, 50 mM Tris pH 8.0) with protease inhibitor cocktail (Roche Diagnostics).
Protein concentration of lysate was checked by BCA assay (Thermo Scientific) and adjusted to 1
mg/ml and stored at -20°C. Antigen was emulsified with TiterMax Classic Adjuvant (Sigma) in a
1:1 ratio prior to injecting into mice.

Mouse immunization
Five 8-10 week old female inbred BALB/c mice (Charles River Laboratories) were immunized
with 6 injections of antigen over 2 weeks. Mice were injected in the same footpad every 3 or 4
days. The first two injections consisted of a 1:1 emulsion of antigen and adjuvant, the remaining
4 injections consisted of antigen only. Each injection was 20 µl in volume; when using
antigen/adjuvant mix, the mice received 10 µg of antigen, when using antigen alone, the mice
received 20 µg of antigen. Seventeen days after the initial injection, the mice were sacrificed and
the popliteal lymph nodes draining the injected footpads were isolated and kept in serum-free
medium on ice until fusion.
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Hybridoma fusion and screening
The popliteal lymph nodes cells were fused with myeloma cells (P3X63Ag8.653) at a 5:1 ratio
with polyethylene glycol (PEG)-1500 (Sigma Aldrich) following standard procedures by the
Washington University Hybridoma Center (166). Supernatants were harvested for screening
when the cells were 50% confluent (about 2 weeks after fusion). Hybridomas were screened for
reactivity against C. parvum grown in Caco-2 cells plated on 96-well plates (Greiner Bio-One).
Monolayers were fixed with 4% formaldehyde (Polysciences), permeabilized with 0.05%
saponin (Sigma) and blocked with a solution containing 0.05% saponin, 5% normal goat serum
and 5% FBS. Hybridoma supernatants were added to the wells in addition to a solution
containing anti-RH antibody (rabbit polyclonal sera raised against Toxoplasma gondii strain RH;
WU 1047, Covance) at 1:1000 dilution and 0.02% saponin. After 1 hr incubation, cells were
washed and then stained with secondary antibodies conjugated to Alexa Fluor dyes
(Thermofisher) diluted in 0.01% saponin solution. Positive hybridomas were expanded in
Iscoves’ medium (Sigma) supplemented with 20% FBS, cryopreserved in culture medium
supplemented with 10% DMSO, and stored in liquid nitrogen.

Hybridoma subcloning and expansion
Positive hybridomas were taken through two rounds of subcloning by single-cell limiting
dilution to ensure clonality. At each stage, the hybridoma suicide supernatants (collected when
overgrowth of cells results in a decrease in viability to 20%) were screened for reactivity.
Hybridomas were weaned in a step-wise manner into 10% FBS before being transferred into a
CELLine flask (Wheaton) for concentrated monoclonal antibody production. The isotype
identification for the hybridomas was done with the Pierce Rapid Isotyping Kit (ThermoFisher).
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Some of the hybridoma isotyping results were confirmed with the Hybridoma Core at
Washington University or Rapid Mouse Immunoglobulin Isotyping kit (Antagen).

Immunofluorescence analysis of C. parvum in mIECs
mIECs grown on transwells were infected with 1x106 oocysts 24 hr after plating. After 4 hr,
monolayers were washed with DPBS and the media in the top transwell compartment was
replaced. Monolayers were fixed 24 hr post infection, permeabilized and blocked as described
above. Both primary (hybridoma supernatants listed in Table 1) and secondary antibodies (antiIgG or anti-IgM) conjugated to Alexa Fluor dyes, (Thermofisher) were diluted in 0.01% saponin
solution for staining. Samples were stained with Hoechst (Thermofisher) and the membrane was
cut out from the transwell insert and mounted with Prolong Diamond Antifade Mountant
(Thermofisher). Imaging was done on a Zeiss Axioskop Mot Plus fluorescence microscope
equipped with a 100x, 1.4 N.A. Zeiss Plan Apochromat oil objective and an AxioCam MRm
monochrome digital camera. Exposure times for each antibody were established based on
optimal auto exposure times for the most intensely staining stages and then maintained
consistently for all stages for a given antibody. Images were acquired using Axiovision software
(Carl Zeiss Inc.).

Immunofluorescence analysis of C. parvum in HCT-8 cells
HCT-8 cells grown on coverslips were infected 24 hr post-seeding with 1x106 oocysts per well
and fixed at 24 hr post-infection for asexual stages or 48-72 hr post-infection for sexual stages
then stained for IFA as described above. To identify type II meronts, cells were infected with
1x106 excysted oocysts per well then incubated with 10 µM EdU for two hours starting 30 hr
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post-infection before fixation and permeabilized as described above. Cells were then treated with
the Click-iT Plus EdU Alexa Fluor 488 Imaging kit (Thermofisher) for 30 min, then stained with
mouse monoclonal antibodies and rabbit anti-RH to detect C. parvum, followed by secondary
antibodies conjugated to Alexa Fluor dyes (Thermofisher). Cells were stained with Hoechst and
mounted as described previously. To detect individual microgametocyte nuclei, infected HCT-8
cells were either stained with anti-phosphohistone H3 (Cell Signaling Technology; 1:200) or
treated with 10 µM EdU for two hours starting 46 hr post-infection before fixing and staining as
described above. To detect host actin, infected HCT-8 cells were fixed and permeabilized as
described above, and then incubated with Alexa Fluor 488 phalloidin (Thermo Fisher) for 20 min
before proceeding with antibody staining, as described above. Epifluorescent images were
acquired as described for the mIECs. For confocal images, infected monolayers were prepared as
described and then viewed with a Zeiss LSM880 laser scanning confocal microscope (Carl Zeiss
Inc.) equipped with a 63X, 1.4 N.A. Zeiss Plan Apochromat oil objective and a GaAsP detector.
ZEN 2.1 Black Edition software was used to obtain Z-stacks through the entire height of the
parasites with confocal Z-slices of 0.230 µm. Three-dimensional images were generated using
the visualization module of Volocity version 6.3 (Improvision).

Western blot analysis
Oocysts and sporozoites were lysed in 1% NP-40 lysis buffer containing protease inhibitor
cocktail (Roche Diagnostics). Oocysts were bleached prior to lysis. Sporozoites were prepared
from excysted oocysts that were filtered through a 1 µm filter (Whatman) to remove unexcysted
oocysts and excysted oocyst shells. Samples were lysed on ice for 30 min with occasional
vortexing and then centrifuged at 14,000 for 3 min; the supernatant was moved to a new tube and
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frozen at -20°C. Prior to use, lysates were thawed and reduced using DTT (dithiothreitol) at a
final concentration of 100 mM. Samples were resolved on a 10% SDS-PAGE gel then
transferred to a nitrocellulose membrane, blocked with the Odyssey blocking buffer (LI-COR).
Anti-RH antibody was used at a concentration of 1:500. A secondary goat anti-mouse IR dye
800CW (LI-COR) was used at a concentration of 1:10,000. Samples were imaged with a LICOR Odyssey imaging system.
For detection with monoclonal antibodies, sporozoite samples obtained after oocyst
excystation were lysed in sample buffer and boiled for 5 min at 95ºC. They were then
centrifuged at 14,000 g for 1 min and the supernatant was used for loading. Samples were
resolved on a 10% SDS-PAGE gel, transferred to a nitrocellulose membrane and blocked with
5% BSA. Monoclonal antibodies against C. parvum were used at 1:250 and secondary goat antimouse conjugated to horse-radish peroxidase (HRP) was used at 1:10,000. Signal detection was
done using the Amersham ECL prime western kit (GE Health care). Among the antibodies
highlighted here, we were only able to detect reliable signals in sporozoites for two of them (i.e.
1B5 and 1A5).

Transmission electron microscopy
For ultrastructural analyses, infected mIECs on transwell membranes or trypsinized HCT-8
monolayers were fixed in a freshly prepared mixture of 1% glutaraldehyde (Polysciences, Inc)
and 1% osmium tetroxide (Polysciences, Inc.) in 50 mM phosphate buffer at 4ºC for 30 min.
Samples were then rinsed multiple times in cold dH20 prior to en bloc staining with 1% aqueous
uranyl acetate (Ted Pella Inc.) at 4ºC for 3 hr. Transwell membranes were removed from insert
using a scalpel. Following several rinses in dH20, samples were dehydrated in a graded series of
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ethanol and embedded in Eponate 12 resin (Ted Pella, Inc.). Sections of 95 nm were cut with a
Leica Ultracut UCT ultramicrotome (Leica Microsystems, Inc.), stained with uranyl acetate and
lead citrate, and viewed on a JEOL 1200 EX transmission electron microscope (JEOL USA,
Inc.) equipped with an AMT 8-megapixel digital camera and AMT Image Capture Engine V602
software (Advanced Microscopy Techniques).
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Figures and legends

Figure 2.1. Infecting primary mouse ileal epithelial cells (mIECs) and immunization of
mice.
A) Mouse intestinal stem cells were passaged as spheroids. To establish monolayers, spheroids
were trypsinized and the cells seeded onto transwell membranes.
B) Twenty-four hr after plating the monolayer, the cells were infected with oocysts and samples
were harvested at intervals to isolate genomic DNA for estimation of growth by qPCR. Data
shown is from one experiment but is representative of the growth seen in 3 or more experiments.
N = 3 transwells at each time point. Mean ± S.D.
C) Five mice were immunized with infected mIEC lysates, obtained at 48 hr post-infection,
following a series of 6 footpad injections over 2 weeks. Seventeen days after the initial injection,
the mice were sacrificed and the popliteal lymph nodes were isolated.
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Figure 2.2. Antibody reactivity by western blot.
A) Western blot analysis of samples separated by SDS-PAGE. Loading of samples: oocyst at
1x104 (lane 2) and 2x104 (lane 3), sporozoites at 1x106 (lane 4) and 2x106 (lane 5). The blot was
probed with anti-RH antibody at 1:500 and goat anti-rabbit IR dye 800CW was used at a
1:10,000 dilution.
B) Western blot analysis of samples separated by 10% SDS-PAGE. Each lane was loaded with
4x106 sporozoites. The blot was probed with the respective monoclonal antibodies at 1:250 each
and a secondary goat anti-mouse HRP at 1:10,000. Detection was done with an ECL prime
western kit at an exposure time of 2 min.
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Figure 2.3. mAb 1E12 recognizes the parasite membrane of all life cycle stages.
Cartoons depicting life cycle stages (courtesy of Laura Kyro, reproduced with permission) are
shown above or below their respective fluorescent images. Infected HCT-8 cells were fixed and
stained with mAb 1E12 (green), rabbit anti-RH (Cp, red) to detect C. parvum, and Hoechst to
detect DNA. Samples from 4 hr post-infection were used to image trophozoites (A) and
immature (B) and mature type I meronts (C), 32 hr post-infection for type II meronts (D), or 48
hr post-infection for macrogamonts (E) and microgamonts (F). Scale bars = 3 µm.
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Figure 2.4. Staining patterns of monoclonal antibodies in infected mIECs.
mIECs were infected with C. parvum oocysts and fixed 24 hours after infection. Cells were
stained with the specified mouse mAbs and rabbit-anti-RH to detect C. parvum (Cp). Secondary
antibodies used were goat anti-mouse Alexa Fluor 488 and goat anti-rabbit Alexa Fluor 594.
Scale bar = 5 µm.
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Figure 2.5. Staining patterns of monoclonal antibodies in infected mIECs.
mIECs were infected with C. parvum oocysts and fixed 24 hours after infection. Cells were
stained with the specified mouse mAbs and rabbit-anti-RH to detect C. parvum (Cp). Secondary
antibodies used were goat anti-mouse Alexa Fluor 488 and goat anti-rabbit Alexa Fluor 594.
Scale bar = 5 µm.
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Figure 2.6. mAb 1B6 stains the outer oocyst wall.
Oocysts were either left unbleached or bleached for 10 min in a 40% bleach solution, and then
were either left unexcysted, or excysted in a 0.75% sodium taurocholate solution for 60 min at
37°C. Oocysts were then plated on coverslips coated with poly-L-lysine. Samples were fixed and
stained with 1B6 (green) and rabbit-anti-RH (Cp, red) to detect C. parvum. Arrows indicate
sporozoites. Scale bars = 5 µm.
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Figure 2.7. Antibodies that recognize unique patterns in trophozoites.
A) Cartoon representing the trophozoite stage.
B) Transmission electron micrograph of trophozoite growing in mIEC, 24 hr post-infection. The
actin-rich host cell cytoskeleton is denoted by brackets. The membrane-rich feeder organelle is
indicated by arrows. Scale bar = 500 nm.
C, D,) Pattern of staining with mAb 1B5 (green) and rabbit-anti-RH (Cp, red) to detect C.
parvum.
E, F) Pattern of staining for mAb 1F9 and rabbit-anti-RH (Cp, red) to detect C. parvum. For C-F,
HCT-8 cells were infected with oocysts and fixed and stained 24 hr post-infection. C and E show
single Z-slices acquired by laser scanning confocal microscopy, D and F show 3D rendering of a
full Z-stack. Scale bars in C and E = 2 µm. Scale bars in D and F = 1 µm.
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Figure 2.8. Monoclonal antibodies that recognize sporozoites.
Oocysts were excysted and plated onto PLL-coated coverslips. Sporozoites were fixed and
stained with the specified mouse mAbs and rabbit-anti-RH to detect C. parvum (Cp). For 1B5
staining, samples were permeabilized with 0.1% Triton X-100. Secondary antibodies used were
goat anti-mouse Alexa Fluor 488 and goat anti-rabbit Alexa Fluor 594. Scale bar = 5 µm.
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Figure 2.9. Distribution of 1B5 and 1F9 staining in trophozoites and meronts relative to the
actin pedestal.
A) HCT-8 cells were infected with oocysts and fixed 2 hr post infection to detect trophozoites.
Cells were stained with phalloidin, mAbs 1F9 or 1B5, and rabbit-anti-RH to detect C. parvum
(Cp). Secondary antibodies used were goat anti-mouse Alexa Fluor 555 and goat anti-rabbit
Alexa Fluor 647. First panel is the 3D rendered images from a Z-stack acquired by laser
scanning confocal microscopy; additional image is a single Z-slice from the Z-stack. Scale bar =
3 µm.
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B) HCT-8 cells were infected with oocysts and fixed 24 hr post infection to detect meronts. Cells
were stained with phalloidin, 1F9 or 1B5, and rabbit-anti-RH to detect C. parvum (Cp).
Secondary antibodies used were the same as for (A). First panel is the 3D rendered images from
a Z-stack acquired by laser scanning confocal microscopy; additional image is a single Z-slice
from the Z-stack. Scale bar = 3 µm.
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Figure 2.10. mAb 5E3 recognizes the apical end of merozoites.
A, D) Cartoons representing Type I meront and merozoite, respectively.
B, C) Transmission electron micrograph of a mature meront in HCT-8 cells 24 hr post-infection.
Brackets denote micronemes at the apical end of merozoite. Scale bar = 500 nm.
E, F) HCT-8 cells were infected with oocysts and fixed at 24 hr post-infection and stained with
mAb 5E3 (green) and rabbit-anti-RH (Cp, red) to detect C. parvum. Side (E) and top view (F)
images of 3D rendered images from a Z-stack acquired by laser scanning confocal microscopy.
Scale bars = 1 µm.
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Figure 2.11. mAb 1A5 recognizes mature Type I and Type II meronts but not immature
Type I meronts.
A) Staining of immature type I meronts defined by four EdU-positive nuclei and lack of defined
merozoites by phase contrast (Merge + Phase).
B) Staining of mature type I meronts defined by a lack of EdU staining and presence of defined
merozoites by phase contrast microscopy (Merge + Phase).
C) Staining of type II meronts as defined by four nuclei that lack EdU staining as well as the
presence of 4 individual merozoites by phase contrast microscopy (Merge + Phase).
Infected HCT-8 cells were incubated with the thymidine analog EdU for two hours starting 30 hr
post-infection then were fixed and treated with an EdU Click-It 488 labeling kit (green) and
stained with mAb 1A5 (red) and Hoechst DNA stain (blue). Scale bar = 3 µm.
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Figure 2.12. Antibodies with reactivity to C. parvum sexual stages.
A, E) Cartoon representing macrogamont and microgamont, respectively.
B) Transmission electron micrograph of macrogamont within an HCT-8 cell 48 hr post-infection.
Scale bar = 5 µm.
C, D) Infected HCT-8 cells were fixed and stained 72 hr post-infection with rabbit-anti-RH (Cp,
red) to detect C. parvum and mAb 4D8 (green). Scale bars = 3 µm.
F) Transmission electron micrograph of microgamont within an HCT-8 cell 48 hr post-infection.
G) Infected HCT-8 cells were fixed and stained 72 hr post-infection with an anti-phospho-histone
H3 (Ser10) antibody (green). Scale bar = 3 µm.
H) Infected HCT-8 cells were incubated with the thymidine analog EdU for two hours starting 46
hr post-infection before fixation. Cells were treated with an EdU Click-It 488 labeling kit (green)
to detect microgametocyte nuclei undergoing replication (arrows) and stained with rabbit-antiRH (Cp, red) to detect C. parvum. Scale bar = 3 µm.
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Table 1. Staining patterns of mouse monoclonal antibodies against C. parvum.a
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Chapter 3
Complete life cycle development of
Cryptosporidium parvum in vitro
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Summary
Recent investigation into the etiology of pediatric diarrhea in Africa and southeast Asia
identified Cryptosporidium as a frequent infection in patients studied. Cryptosporidium has long
been recognized as an opportunistic infection in immunocompromised patients, but its
importance in global health was underestimated until now. There are no effective treatments for
cryptosporidiosis in immunocompromised or malnourished patients, the two populations most
affected by the disease. The lack of treatment options is due to the many barriers hindering
investigation into Cryptosporidium biology, such as difficult animal models, genetic tools that
rely on passage through an animal, and lack of accessible systems that support complete
development in vitro. We describe here a cell culture platform that enables complete life cycle
development and long-term growth of C. parvum in vitro. Primary intestinal epithelial cell
monolayers, derived from stem cell spheroids, were grown on transwells in medium containing
stem cell growth factors. The cells were induced to differentiate by removing the medium from
the top chamber of the transwell, creating an “air-liquid interface”. These monolayers supported
C. parvum replication over several weeks and produced viable oocysts. These oocysts
incorporated EdU added to the culture medium, indicating they were produced de novo. Oocysts
were recovered from bleached cell monolayers and used to productively infect mice. This system
will be a valuable tool for investigating the complete parasite life cycle in vitro and
understanding host-parasite interactions in a model that replicates the intestinal environment.
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Introduction
Cryptosporidium is a gastrointestinal parasite that causes long-term illness in
immunocompromised patients (139) and contributes to malnourishment and impaired growth in
children in low- to middle-income countries (24). For years, investigation into the biology of
Cryptosporidium has been stalled due to the intractability of the parasite: it lacks a continuous
culture system and molecular genetic tools. The latter has recently experienced a breakthrough
with the successful genetic modification of C. parvum using the CRISPR/Cas9 system (66).
However, stable transgenic parasites still cannot be selected for or propagated in vitro due to the
lack of robust cell culture platforms, making it difficult to create and maintain lines, as well as
study genes that are required for life cycle completion. Adenocarcinoma cell lines such as HCT8 can support 2-3 days of growth, but when the parasite reaches the sexual part of its life cycle, it
stops before oocyst formation (83). There have been recent reports of systems enabling complete
life development and passage in vitro (95, 96), but these systems require specialized equipment
and are not easily scalable. Additionally, these systems use HCT-8 cells, which do not resemble
the intestinal epithelial cells Cryptosporidium infects in vivo. Another recent report of continuous
culture in vitro utilized a different cancer cell line, COLO-680N (97); however, this result has
not been validated by another lab.
It is possible to create primary intestinal cell cultures that replicate aspects of the gut
environment (131, 138). These cultures are grown as monolayers on transwells and are derived
from intestinal stem cell spheroids (125, 126). These monolayers can support robust C. parvum
growth over a 3-day period and were essential in creating a novel library of monoclonal
antibodies against intracellular stages of the parasite (167). However, C. parvum cannot
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complete its life cycle in this system, likely due to the limited lifespan of the monolayers, which
only last a few days.
A recent report described a method for creating primary intestinal monolayers that
maintained viability for weeks (132). This system also derived cells from spheroids and used
transwells but incorporated a feeder cell layer and an “air-liquid interface” (ALI) in the top
chamber of the transwell. The ALI induced dramatic differentiation of the cells into enterocytes
and secretory cells of the gut, as well as the formation of structures resembling crypts.
Additionally, the cells were grown in medium containing stem cell growth factors, leading to the
maintenance of a population of cells that continually proliferated, replacing terminally
differentiated cells as they died. The latter modification likely explains the long-term viability of
these monolayers.
The differentiation status and long lifespan makes ALI monolayers an ideal candidate for
supporting complete life cycle development of C. parvum. Here, we describe long-term growth
of C. parvum and oocyst development in vitro in the ALI system.

68

Results

ALI monolayers support long-term C. parvum infection

The recently published ALI system (132) was modified to be compatible with the
spheroid system we had previously used to generate primary monolayers for C. parvum infection
(167). There were three primary changes needed to adapt the system. First, stem cells for
establishing ALI monolayers were obtained from a spheroid line isolated from the mouse ileum
(126) instead of a human fetal line. Second, the medium used to grow the ALI monolayers was
switched to L-WRN conditioned medium (126) from the original medium used in the publication
(SCM-6F8 medium). SCM-6F8 medium contains a cocktail of recombinant growth factors; using
L-WRN conditioned medium allows us to bypass the need to purchase each growth factor
individually. Finally, mouse ileal stem cells were expanded as spheroids (126) and plated onto a
feeder cell layer of irradiated fibroblasts in a transwell coated with Matrigel. Cells were
maintained in conditioned medium and allowed to proliferate for 7 days before removing the
medium from the top part of the chamber to create the ALI culture (figure 3.1A). Within days of
the initiation of ALI, the monolayer began to undergo differentiation into enterocyte and
secretory cell lineages found in the small intestine, such as goblet cells (data not shown).
To determine if ALI monolayers supported C. parvum growth, we infected monolayers
with oocysts and tracked parasite growth using qPCR to measure parasite genomic DNA
equivalents. We found C. parvum numbers increased for at least 20 days post infection (figure
3.1B), amplifying ~ 70-fold from the initial infection. This high parasite burden did not appear to
affect monolayer viability, however, because qPCR of mouse genomic DNA equivalents showed
that host cell numbers increased over the same period (figure 3.1B). Additionally, visual
69

inspection of the infected transwells did not show signs of barrier breakdown such as leakage of
medium into the top chamber (data not shown). H&E-stained sections of ALI monolayers
showed a continuous monolayer of cells with height comparable to that found in vivo, a strong
sign of cellular differentiation (168) (figure 3.1C, 3.2). Electron microscopy of infected
monolayers revealed the presence of a brush border on the apical side of the cells (figure 3.2). In
IHC-stained sections as well as electron microscopy images, C. parvum vacuoles were easily
visualized growing at the apical end of the cell (36) (figure 3.1C, 3.2).

All developmental stages of C. parvum can be found in ALI monolayers

We utilized a recently described panel of mAbs (167) to examine the life cycle
development of C. parvum in the ALI cultures. Fluorescent microscopy of infected monolayers
confirmed the appearance of asexual life cycle stages of C. parvum. mAb 1B5 detected
trophozoites by their distinct donut-shaped pattern (167) (figure 3.1D). Trophozoites were also
detected by electron microscopy (figure 3.3A). Type I and II meronts were identified by mAb
1A5, which stains mature merozoites within meronts in a polarized manner (167) (figure 3.1D).
Type II meronts are distinguished from immature type I meronts, which also contain 4 nuclei,
because 1A5 does not have polarized staining in immature type I meronts (167). Type I and II
meronts were also differentiated in electron microscopy images. Type I meronts had round
vacuoles with 8 merozoites (figure 3.3B, C) while type II meronts had taller, narrower vacuoles
with 4 merozoites (figure 3.4A).
Sexual stages of C. parvum appeared by day 2 post-infection and were abundant in the
ALI cultures. Microgamonts were identified by their multiple tiny nuclei and membrane staining
pattern by pan-Cp, which recognized the developing septations between microgamonts within
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the parasitophorous vacuole (figure 3.1D). Microgamonts were also identified by electron
microscopy as vacuoles containing multiple small bullet-shaped parasites (figure 3.4C, D).
Interestingly, microgamonts were recognized by Crypt-a-GloTM (Waterborne, Inc) (figure 3.6A)
and OW50 (153) (data not shown), mAbs that both recognize oocyst wall proteins. These mAbs
stained the surface of early macrogamonts and then the individual membranes around each
microgamont in late and extracellular microgamonts. These Crypt-a-GloTM-positive structures
were confirmed to be replicating parasites by adding EdU, a thymidine analog that is
incorporated into replicating DNA, to the cell culture medium, (figure 3.6B). This recognition of
microgamonts by oocyst wall-specific mAbs has not been reported previously and we did not
observe this phenomenon in infected HCT-8 cells (data not shown).
Macrogamonts were identified by the presence of wall-forming bodies (WFBs, clusters of
oocyst wall proteins (36, 169)), which are recognized by both Crypt-a-gloTM (figure 3.1D) and
OW50 (data not shown). Macrogamonts could also be identified by electron microscopy, which
revealed the numerous lipid and glycogen vacuoles within the parasite cytoplasm, as well as the
striated fiber previously observed to be present in macrogamonts (167) (figure 3.4B). In some
macrogamonts, the WFBs coalesced into a ring (figure 3.1D); we termed these “late-stage”
macrogamonts because the WFBs appeared to be organizing in preparation for oocyst formation.
This ring-like structure of WFBs has not previously been reported in other cell culture systems.
We potentially identified this stage by electron microscopy; some macrogamonts had numerous
small vesicles lined up against the parasite membrane (figure 3.5A, B), which resembles the
pattern of WFBs seen by fluorescent microscopy. We could not identify a similar observation in
other published electron microscopy studies of C. parvum growth in vitro or in vivo.
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Robust C. parvum growth requires ALI and initiation of cell differentiation and proliferation
To confirm that the ALI was required for C. parvum growth, we infected “submerged”
transwells (monolayers without an ALI) as well as transwells 3 days after initiation of ALI. C.
parvum grew significantly better over a 3-day period in the ALI transwells compared to the
submerged transwells (figure 3.7A). Interestingly, host cell viability during infection was
improved in the ALI transwells compared to the submerged transwells, despite the high level of
infection in the former (figure 3.7A).
After the ALI is established in this culture system, the cells begin to differentiate into
terminal lineages such as goblet cells. To determine if cell differentiation was required for C.
parvum growth, we infected transwells on day 0 of ALI initiation and day 3 post-ALI initiation,
when monolayers begin to show signs of differentiation (data not shown). C. parvum grew
significantly better in the transwells infected 3 days after ALI initiation compared to the day 0
group (figure 3.7B). Similar to the ALI vs. no ALI experiment, host cell viability during
infection was improved in the transwells infected on day 3 (figure 3.7B).
From these two types of experiments, it appeared that improved host cell viability and
proliferation were tied to C. parvum growth. To visualize cell proliferation during infection, we
infected submerged transwells and transwells 3 days after ALI initiation; on day 2 post-infection,
we added EdU to the medium in the bottom chamber of the transwells for an 8-hour pulse.
Microscopy showed higher numbers of both C. parvum and proliferating cells in the transwells
infected 3 days after ALI initiation (figure 3.7C) compared to the submerged transwells. The
EdU microscopy in addition to the qPCR of mouse genomic equivalents supports the presence of
dividing cells within the ALI monolayers, something the previous primary cell transwell system
lacked (131, 167).
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ALI monolayers support oocyst development

The continued amplification of parasite numbers over 20 days suggested that C. parvum
may be undergoing multiple rounds of its life cycle in the ALI system, which implies the
production of oocysts in vitro. When we were investigating the possibility of oocyst development
in vitro in ALI culture, a report was published claiming oocyst development in a cancer cell line,
COLO-680N (97). When we attempted to replicate these results, we identified a potential issue
with interpreting the presence of oocysts in cultures: they may represent input from the inoculum
rather than newly produced structures. In our experiments, COLO-680N monolayers infected
with oocysts showed very little parasite growth over a 10-day period compared to HCT-8 cells
(figure 3.8A). However, oocyst counts over the same time period revealed that oocysts were
present on each day examined (figure 3.8B). Fluorescence microscopy showed almost equivalent
numbers of oocysts in COLO-680N monolayers at day 1 and 10 post-infection (figure 3.8C).
Since there was very little parasite growth and the total number of oocysts in the culture did not
increase over time (figure 3.8B), it appears that the oocysts from the initial inoculum bound
tightly to the monolayer and remained there for the duration of the experiment, and there was no
in vitro-production of oocysts. It is possible that in the original publication, the presence of
oocysts at later time points was misconstrued as production of oocysts. Similarly one of the
earliest studies claiming oocyst production in vitro was later found to be incorrect due to
misinterpretation of the appearance of input oocysts (103).
Based on the above findings, when we began investigating oocyst production in ALI
culture, we wanted to avoid mis-identifying input oocysts as new oocysts. Monolayers can be
infected with oocysts that have been excysted to release the sporozoites; the excysted oocysts can
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be filtered to remove the oocyst shells, leaving behind only sporozoites. We tested different filter
pore sizes to remove oocysts from excysted sporozoites. We found that filters with a 3 µm pore
size were insufficient to completely remove oocysts from sporozoites, it was necessary to use a 1
µm pore size to completely remove input oocyst contamination from sporozoites (figure 3.8D).
When COLO-680N cells were infected with 1 µm-filtered sporozoites, there was no sign of
oocyst development (figure 3.8E), again suggesting that the “oocyst production” reported in this
line was due to input oocysts that remained stuck to the monolayers.
In order to determine if oocysts were being produced in the ALI monolayers, we infected
the cells with excysted sporozoites that had been passed through filters with a 1 µm pore size to
remove unexcysted oocysts and oocyst shells. To visualize oocyst development, we stained the
monolayers with Crypt-a-gloTM and counted the number of oocysts per field. We found that
oocysts began to appear by day 3 and that there was variation in the number of oocysts seen on
each day, suggesting the possibility of cycles of oocyst formation occurring (figure 3.9A). The
oocysts produced were numerous and easily visible, as seen in the example low magnification
image in figure 3.9B, taken at day 10 post-infection.
To confirm the oocysts observed by staining were indeed newly produced in culture, we
added EdU to the culture medium overnight and then looked for EdU incorporation into the
oocysts. We found EdU-positive oocysts in the monolayers (figure 3.9C), confirming the oocysts
were produced in vitro and not the result of possible contamination from the original inoculum.
It has been shown previously that C. parvum oocysts bind the GalNAc-binding lectin Maclura
pomifera agglutinin (MPA) and the fucose-binding lectin Ulex europaeus agglutinin I (UEA-1)
(170). To confirm that the in vitro-produced oocysts shared these characteristics, we isolated the
oocysts from the ALI monolayers by bleaching the monolayers to remove cell debris and plating
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the remaining material on poly-L-lysine-coated coverslips. We stained the material with the
MPA and UEA-1 and observed lectin-positive oocysts (figure 3.9D), confirming the oocysts
shared this phenotype with in vivo-produced oocysts.
One interesting observation related to the oocyst production in vitro was unusual
reactivity patterns in the ALI culture with the 4D8 mAb, which recognizes several life cycle
stages but is most useful for identifying macrogamonts (167). In infected ALI cultures, 4D8
revealed its typical “V” or line reactivity pattern in macrogamonts (figure 3.10A), but it also
stained very long lines that were not associated with any parasite (figure 3.10B, C). These long
lines were not seen in infected HCT-8 cultures (data not shown). These lines resemble “trails” of
protein left behind during gliding motility, which have been observed with C. parvum
sporozoites with other mAbs (108). 4D8 recognizes C. parvum sporozoites in a polarized manner
(figure 3.10D), suggesting it might recognize a protein that is stored in apical secretory
organelles, which play a role in host cell attachment and invasion (161, 162). It is possible these
4D8 “trails” seen in ALI cultures are left behind by sporozoites as they traverse the monolayer
after oocyst excystation.

Oocysts produced in vitro are infectious to mice

To confirm the oocysts produced in vitro were viable and capable of infection, we
infected ALI monolayers with filtered sporozoites and then bleached the monolayers on days 1
and 3 post infection and used this material to infect mice. C. parvum oocysts are resistant to
bleach treatment (171) and oocysts purified from calves are normally treated with bleach to
remove surface contamination prior to using the oocysts in cell culture. We hypothesized that on
day 1, only asexual/intracellular stages of C. parvum are present, which are not resistant to
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bleach treatment; but that by day 3, oocysts are present, which should survive the bleach
treatment and be able to productively infect the mice.
We confirmed oocyst development in the ALI cultures (figure 3.11A) and also confirmed
the presence of oocysts in the material after bleaching (figure 3.11A). Oocysts resembled in vivoproduced oocysts: they were recognized by both pan-Cp and Crypt-a-GloTM and appeared to
contain sporozoites (figure 3.11B). Ifngr1-/- mice, which are susceptible to C. parvum
(unpublished), were orally gavaged with bleached material from day 1 and day 3 cultures. Mice
that received day 1 material survived for the duration of the experiment, while mice that received
day 3 material had 100% mortality by day 12 post-gavage (figure 3.11C). We collected pellets
from both groups of mice to measure levels of C. parvum DNA, a proxy for oocyst shedding. We
found that the animals that received the day 3 bleached material began shedding oocysts by day 5
post-gavage, the number of oocysts increased almost two logs before the animals died. Animals
that received day 1 material did not show any evidence of oocyst shedding above the background
signal in the assay. We observed similar results in a repeat experiment (figure 3.12). Intestinal
tissue sections from mice that received the day 1 and day 3 material showed robust infection by
anti-C. parvum IHC in the latter but no sign of infection in the former (figure 3.11D).
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Discussion
Development of novel therapeutics for cryptosporidiosis and investigation into the
pathogenesis of the disease have been slowed by the lack of in vitro models that support
complete C. parvum development in a system that resembles the intestinal environment. Such
systems are necessary for furthering our understanding of the parasite and how it interacts with
the host, which will help guide innovative approaches to treatment.
In this report, we demonstrated that primary intestinal epithelial cell monolayers with an
ALI supported C. parvum growth for at least 20 days. We identified all life cycle stages of C.
parvum in the monolayers, including oocysts. Oocysts appeared by day 3 post-infection and
resembled in vivo-derived oocysts by microscopy. The oocysts also incorporated EdU, signifying
they are produced in vitro. This is a novel finding since EdU incorporation to validate oocyst
production in vitro has not been utilized by other systems claiming complete oocyst development
(95-97). Additionally, we carefully controlled for oocyst contamination in the input inoculum by
testing different filter pore sizes and found that the pore size most commonly used (3 µm) was
insufficient to remove oocysts from sporozoites and 1 µm was necessary. Between the EdU
incorporation and complete removal of contaminating oocysts, we are confident that C. parvum
is completing its life cycle in the ALI monolayers. Additionally, we showed that the in vitroproduced oocysts were viable by demonstrating they were infectious to mice and caused robust
oocyst shedding.
The ALI system has several features that likely contribute to its ability to enable longterm C. parvum growth and complete life cycle development in vitro. The monolayers are grown
in medium containing factors that support stem cell growth, which likely maintains a population
of stem cells in the monolayer that continually give rise to differentiated cell types. In a previous
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iteration of our primary intestinal cell culture system, the monolayers were grown in medium
lacking stem cell growth factors; the cells lost their proliferative potential and the monolayers
only lasted a few days (131). This system only supported 2-3 days of parasite growth before the
monolayers collapsed (167). In ALI monolayers, we observed many dividing cells in the
presence of infection, visualized by EdU incorporation. Apoptosis occurs during C. parvum
infection both in vivo (172) and in vitro (173, 174), so the proliferative capacity of the ALI
monolayer likely allows continual replacement of dying infected cells at a rate that enables
constant parasite growth without compromising monolayer integrity. Additionally, the inclusion
of a feeder cell layer, something the previous primary cell culture system lacked, likely creates a
temporary extracellular matrix that supports initial stem cell growth before the cells can start
making their own matrix proteins, ensuring a robust monolayer.
In addition to the self-renewing ability, the ALI monolayers contain the major
differentiated cell types of the intestinal epithelium. These differentiated cells appear after the
introduction of the ALI in this culture system. The mechanism for how ALI induces cellular
differentiation is unknown, but ALI has been used in airway tract epithelial cell culture for many
years to enhance cell differentiation (133-135). It has also recently been applied to intestinal
epithelial cell culture, leading to increased expression of markers associated with cell
differentiation, significant changes in cell metabolism, and increased monolayer longevity (132,
136, 137). The development of all intestinal lineages that we see in our ALI cultures likely
creates a great facsimile of the gut environment for C. parvum. Though C. parvum infection does
not appear to be restricted to a specific cell type in the intestine because parasitophorous
vacuoles are seen along the length of the villus in various animal models (175-177) and even in
the base of the crypt in the neonatal mouse model (172). So, while we cannot pinpoint a specific
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cell type that is required for C. parvum growth, the cells of the ALI monolayer likely generally
resemble the cells C. parvum encounters in vivo in terms of metabolism, differentiation state,
surface expression of different receptors, etc. The primary cells may deliver the right signals to
C. parvum to turn on expression of genes involved in fertilization, meiosis, and oocyst wall
development, leading to complete life cycle development in vitro. These signals may be lacking
in cell culture systems that rely on adenocarcinoma cell lines. Further studies are needed to
identify differences in gene expression in C. parvum in different culture systems.
The gene expression program triggered in the parasite by interaction with the primary
cells could also explain the novel microscopic findings we observed in this system. We saw
evidence of oocyst wall protein expression by microgamonts, since two mAbs that recognize
oocyst wall proteins (OW50 and Crypt-a-GloTM) reacted to microgamonts, something not seen in
adenocarcinoma cell models. There is no previous report of this in the literature, and it is a
difficult observation to explain. It is possible that the antibodies are cross-reacting to a surface
protein expressed by microgamonts that is involved in a receptor-ligand interaction with
macrogamonts. This surface protein could be critical for fertilization, explaining why its
expression is not seen in adenocarcinoma cell cultures.
Another interesting microscopic finding in the ALI system was the appearance of what
we termed “late-stage macrogamonts”, which had WFBs organized in a circular pattern, as if
preparing for oocyst formation. This life cycle stage does not appear in HCT-8 cultures, which
do contain macrogamonts, but their WFBs are spread throughout the parasite cytoplasm without
any apparent organization. The WFB “ring” could represent the step after fertilization of the
macrogamont by the microgamont, explaining why it is not seen in culture systems that do not
support oocyst development. This life cycle stage could be further investigated by live-imaging
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fluorescently tagged parasites in ALI culture to see if WFB ring formation coincides with
fertilization. If this is the case, these “late-stage macrogamonts” are actually zygotes, a life cycle
stage that has been difficult to identify in vitro and in vivo.
In addition to the WFB rings, another interesting microscopic finding we observed in ALI
culture was the unusual reactivity pattern of mAb 4D8; it recognized long “trials” of protein that
were not clearly associated with any parasite. mAb 4D8 recognizes many life cycle stages but
most notably has a line or V-shaped reactivity pattern in macrogamonts and a polarized reactivity
pattern in sporozoites. As mentioned earlier, the 4D8-positive trails could be proteins shed
during gliding motility by the sporozoite. This would explain why the trails are not seen in other
cell culture systems, since they do not support oocyst/sporozoite development.
There have been two recent reports of systems that enable complete C. parvum
development and propagation in vitro (95, 96). One system utilizes hollow fiber technology to
mimic the intestine by having separately controlled apical and basolateral compartments with
different redox and nutrient conditions (95). While this system can produce oocysts for months at
a time, it is a difficult system to scale up for testing a variety of growth conditions or drug
screening purposes. It is also not well-suited to studies that require multiple time points for
microscopy or RNA/DNA collection, since the hollow fiber must be opened and thereby
destroyed to obtain a sample, terminating the experiment. Another system employs a
bioengineered silk 3D intestinal model to grow C. parvum (96); this system is more easily
scalable than the hollow fiber system but relies on specialized equipment to make the silk
scaffolds. Both systems use adenocarcinoma cell lines, which do not accurately replicate the cell
types C. parvum encounters in vivo, making them poor models for studying host-parasite
interactions.
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The ALI system described here relies on commercially available transwells and reagents,
so it can easily be adapted for small-scale drug studies, as well as other types of experiments
testing multiple conditions in parallel where many samples are required for microscopy, gene
expression analysis, etc. The system builds upon previously published methods for propagating
intestinal stem cells as spheroids (126) and growing primary intestinal epithelial cells as
monolayers on transwells (131, 132, 138), so it has a strong foundation as a model of the
intestinal environment. C. parvum encounters the same differentiated cells in the ALI
monolayers that it infects in vivo, making this system a great candidate for examining hostparasite interactions. Additionally, this system is very amenable to microscopy studies, which
will facilitate investigation into the processes behind fertilization, meiosis, etc., which could not
previously be studied in vitro.
There are limitations to the ALI system: efforts to propagate C. parvum using ALI
monolayers are ongoing, and the amount of oocysts produced by the monolayers is too small to
replace standard methods of producing oocysts in vivo. However, the system could potentially be
used to select for transgenic parasites in vitro before amplification in the mouse, bypassing the
need for surgery to infect mice with transgenic parasites (66). Additionally, the long-term growth
and complete life cycle development in vitro makes the system very useful for investigating drug
mechanism and effect – for example, determining if a drug is static or cidal, and what specific
life cycle stage is targeted. We believe this system is an accessible model of the gut environment
and will enable innovative studies into Cryptosporidium biology and its interaction with the host.
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Materials and methods
Ethics Statement

Animal studies were conducted according to the U.S.A. Public Health Service Policy on Humane
Care and Use of Laboratory Animals. Animals were maintained in an Association for
Assessment and Accreditation of Laboratory Animal Care – approved facilities. Animal studies
were approved by the Institutional Animal Studies Committee at the School of Medicine,
Washington University in St. Louis.

3D spheroid cell culture

Primary ileal epithelial stem cells isolated from 8-10 week old C57BL/6 mice were obtained
from the laboratory of Dr. Thad Stappenbeck, Washington University in St. Louis. Ileal stem
cells were expanded and maintained as 3D spheroid cultures in Matrigel (BD Biosciences), as
described previously (125). Spheroid cultures were grown in 50% L-WRN conditioned medium
(CM) containing 10 µm Y-27632 (ROCK inhibitor; Tocris Bioscience). Cells were cultured at
37°C in a 5% CO2 incubator. The medium was changed every 2 days and the cells were passaged
every 3 days in a 1:6 split.

Irradiating fibroblasts and seeding feeder cell layer
Mouse fibroblast cells (NIH/3T3; CRL-1658TM ATCC) were maintained in Dulbecco’s Modified
Eagle’s Medium (DMEM; ATCC, 30-2002) with 10% FBS (Sigma) and penicillin/streptomycin
(Sigma). Cells were cultured at 37°C in a 5% CO2 incubator. Cells were passaged every 3 days
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in a 1:5 split. For irradiation, cells were trypsinized, suspended in growth medium and irradiated
at 3000 rads using the Small Animal Radiation Research Platform (SARRP, Xstrahl). After
irradiation, cell viability was assessed with Trypan Blue staining (Thermo Fisher), cells were
quantified and aliquoted in freezing medium (growth medium with 30% FBS and 5% DMSO).
Irradiated cells were kept at -80°C for short-term use (weeks) and in liquid nitrogen for longterm use (months). In order to create feeder cell layers, transwells (polyester membrane, 0.4 µm
pore; Corning Costar) were coated with Matrigel (Corning) diluted 1:10 in cold PBS. After
incubating at 37°C for 15-20 min, excess Matrigel solution was aspirated immediately before
adding irradiated 3T3 (i3T3) cells. i3T3 cells were thawed, resuspended in growth medium, and
seeded onto transwells at 8x10^4 cells/transwell. Growth medium was added to the top and
bottom of the transwell.

Seeding epithelial cell monolayers and creating ALI

To form monolayers, spheroids from 3-day-old stem cell cultures were recovered from Matrigel
and dissociated with trypsin as described previously (131). Cells were quantified, suspended in
50% CM with 10 µm Y-27632, and plated onto i3T3 monolayers that were seeded 24 hours
previously. Cells were seeded at 5x10^4/transwell. 3T3 growth medium was removed from
bottom of transwells and replaced with 50% CM with 10 µm Y-27632. Medium was replaced in
the top and bottom compartments of the transwell every other day. After 7 days, the medium in
the top compartment was removed to create the ALI. Medium in the bottom compartment of the
transwell continued to be changed every other day. Liquid/mucus that appeared in top
compartment was removed every other day.
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Oocyst preparation and excystation

Oocysts were provided by the Kuhlenschmidt or Witola laboratories (University of Illinois at
Urbana Champaign). The AUCP-1 isolate of C. parvum was maintained in male Holstein calves
and oocysts were purified as described previously (107). Oocysts were stored at 4°C in 50 mM
Tris-10 mM EDTA, pH 7.2. Before infection, 1x108 purified oocysts were diluted into 1 ml of
Dulbecco’s Phosphate Buffered Saline (DPBS; Corning Cellgro) and treated with 1 ml of 40%
bleach (commercial laundry bleach containing 8.25% sodium hypochlorite) for 10 min on ice.
Oocysts were then washed 4 times in DPBS containing 1% (wt/vol) bovine serum albumin
(BSA; Sigma) and resuspended in 1 ml DPBS with 1% BSA. For some experiments, oocysts
were excysted prior to infection by incubating the oocysts with 0.75% sodium taurocholate (w/v;
Sigma) in DPBS at 37°C for 60 min. If required, excysted oocysts were filtered through a
membrane with 1 µm pore size (Whatman, VWR International) to remove oocysts from
sporozoites. Sporozoites were spun down at 1250 x g for 3 min and then resuspended in 50%
CM prior to adding to ALI monolayers.

Infecting ALI monolayers and measuring C. parvum growth and host cell viability by qPCR

Oocysts or filtered sporozoites were added to monolayers in 30 µl volume. After 3 hr,
monolayers were washed twice with DPBS. The Qiagen QIAamp kit was used to collect DNA
from the infected transwells. Briefly, 100 µl Buffer ATL (provided by kit) was added to
monolayer; cells were scraped into buffer using a blunt pipette tip. Lysed cells were incubated in
Buffer ATL and proteinase K (both reagents provided by kit) at 56°C for 3-24 hr before
proceeding with the rest of the protocol. Purified DNA was diluted 1:10 with H2O before adding
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to qPCR reaction mix. Two µl of the diluted DNA was used as a template in the qPCR reaction
with TB GreenTM Advantage® qPCR premix (Takara, Clontech). Primer sequences targeting C.
parvum GAPDH were as follows: forward primer 5’ CGGATGGCCATACCTGTGAG 3’ and
reverse primer 5’ GAAGATGCGCTGGGAACAAC 3’. A standard curve for C. parvum
genomic DNA was generated by purifying DNA from a known number of oocysts and creating a
dilution series. Primer sequences targeting mouse GAPDH were as follows: forward primer 5’
GCCATGAGTGGACCCTTCTT 3’ and reverse primer 5’ GAAAACACGGGGGCAATGAG
3’. A standard curve for mouse genomic DNA was generated by purifying DNA from a known
number of mouse ileal stem cells and creating a dilution series. Reactions were performed on a
QuantStudio 3 Real-Time PCR System (Thermo Fisher) with the following amplification
conditions: priming at 95°C for 2 min then 40 cycles of denaturing at 95°C for 10 sec, annealing
at 60°C for 20 sec, extension at 72°C for 30 sec. Genomic DNA equivalents present in each
sample were determined by the QuantStudio Design & Analysis software.

Development of pan-Cp antibody

Antigen for the pan-Cp polyclonal antisera was generated by excysting 8x10^8 bleached oocysts
in 0.75% sodium taurocholate at 37°C for 1 hour; excysted oocysts were then freeze-thawed 6
times (3 min on dry ice mixed with ethanol, then 3 min at 37°C). Sample was sent to Covance
for immunization. One rabbit was injected subcutaneously with 250 mg antigen with Freund’s
Complete Adjuvant (FCA) then boosted three times at 21-day intervals with 125 mg antigen in
Freund’s Incomplete Adjuvant (FIA).
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Fluorescent microscopy

Transwells were moved to a new 24-well plate; DPBS was added to bottom chamber.
Monolayers were fixed by adding 100 µl 4% formaldehyde (Polysciences) for 10-15 min. Cells
were washed twice with DPBS and then permeabilized with DPBS containing 1% BSA and
0.1% Triton X-100 (Sigma) for 20 min. Primary and secondary antibodies were diluted in this
“permeabilization buffer” for staining. Cells were incubated with primary antibody for 60 min at
room temperature. Antibodies were used at different concentrations; 1B5 and 1A5 (purified
mouse mAbs) were used at 1:500 , pan Cp (rabbit pAb) was used at 1:1000, Crypt-a-gloTM
(mouse mAb, Waterborne, Inc) was used at 1 drop per 2 transwells, and 4D8 (hybridoma
supernatant) was used at 1:5. After primary antibody incubation, transwells were washed twice
with PBS and then incubated with secondary antibodies conjugated to Alexa Fluor dyes
(Thermofisher) for 60 min at room temperature. Secondary antibodies were used at 1:1000
concentration. Samples were stained with Hoechst (Thermofisher) and the membrane was cut out
from the transwell insert using a scalpel and mounted with Prolong Diamond Antifade Mountant
(Thermofisher).

For lectin staining of bleached ALI monolayers, bleached material was pipetted onto coverslip in
24-well plate (150-200 µl total volume per well), allowed to settle for 30 min, then fixed and
permeabilized as above and then stained with specified lectin for 30 minutes, followed by pan Cp
staining for 60 min and secondary antibody staining for 60 min. Lectins used were FITAconjugated Maclura pomifera (MPA) lectin (E Y Laboratories, F-3901-1) and FITC-conjugated
Ulex europaeus (UEA-1) lectin (E Y Laboratories, F-2201-2), both used at 100 µg/ml.
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For EdU staining, 10 µM EdU was added to medium in the bottom chamber of the transwell.
After a defined time period, the transwell was fixed with 4% formaldehyde and permeabilized as
above. EdU was labeled with the Click-iT Plus EdU Alexa Fluor 488 (Invitrogen, C10637) or
594 (Invitrogen, C10339) Imaging Kit. Primary and secondary antibody staining were done after
EdU labeling.

Imaging was done on a Zeiss Axioskop Mot Plus fluorescence microscope equipped with a 100x,
1.4 N.A. Zeiss Plan Apochromat oil objective and an AxioCam MRm monochrome digital
camera. Images were acquired using Axiovision software (Carl Zeiss Inc.).

Transwell sections

Transwells were moved to a new plate; 4% formaldehyde added to the top and bottom chambers.
After 20 min, the cells were washed 3 times in 70% ethanol in both the top and bottom
chambers, and then incubated in 70% ethanol for 20 min. The transwell membranes were cut
from the insert using a scalpel and embedded in 1% agar and then processed for paraffin
embedding. For hematoxylin and eosin staining and immunohistochemistry, five µm thick
transverse sections were cut and processed for staining following standard procedures of the
Digestive Disease Research Core Center (DDRC, Washington University in St. Louis). Sections
were imaged using a Zeiss Observer.D1 inverted wide-field fluorescence microscope with
Axiocam 503 dual B/W and color camera.
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Electron microscopy

For ultrastructural analyses, ALI cultures were fixed in a freshly prepared mixture of 1%
glutaraldehyde (Polysciences, Inc) and 1% osmium tetroxide (Polysciences, Inc.) in 50 mM
phosphate buffer at 4ºC for 30 min. Samples were then rinsed multiple times in cold dH 20 prior
to en bloc staining with 1% aqueous uranyl acetate (Ted Pella Inc.) at 4ºC for 3 hr. Transwell
membranes were removed from insert using a scalpel. Following several rinses in dH20, samples
were dehydrated in a graded series of ethanol and embedded in Eponate 12 resin (Ted Pella,
Inc.). Sections of 95 nm were cut with a Leica Ultracut UCT ultramicrotome (Leica
Microsystems, Inc.), stained with uranyl acetate and lead citrate, and viewed on a JEOL 1200 EX
transmission electron microscope (JEOL USA, Inc.) equipped with an AMT 8-megapixel digital
camera and AMT Image Capture Engine V602 software (Advanced Microscopy Techniques).

COLO-680N and HCT-8 cell culture
Human ileocecal adenocarcinoma cells (HCT-8; CCL-244TM ATCC) were maintained in RPMI1640 medium (Gibco, ATCC modification) supplemented with 10% FBS. Human esophageal
squamous cell carcinoma cells (COLO-680N, CLS Cell Line Services) were maintained in
RPMI-1640 medium (Sigma, R8758) supplemented with 10% FBS. Cell lines were tested for the
presence of mycoplasma and confirmed negative with the e-Myco plus Mycoplasma PCR
Detection Kit (Boca Scientific). For infection studies, cells were plated in 96-well plates for
DNA collection or 24-well plates with coverslips for microscopy studies. DNA was purified
using method described above and microscopy also performed as described above.
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Bleaching ALI monolayers for microscopy and animal infection

ALI monolayers were infected on day 3 post top medium removal with filtered sporozoites.
After 2 hr, monolayers were washed twice with DPBS. On days 1 and 3 post infection,
monolayers were scraped into cold 40% bleach diluted in DPBS. Bleached material was
combined into one Eppendorf tube. Monolayers were bleached on ice for 10-15 min before
spinning down at maximum speed for 2 min. The supernatant was removed, the pellet
resuspended in 1 ml cold DPBS, and centrifuged again. The bleached material was washed 5
times and then resuspended in the desired volume of cold DPBS.

Animal infection and pellet DNA extraction
Female 8- to 10-week-old Ifngr1-/- mice (Jackson Laboratories) were orally gavaged with 150 µl
of bleached ALI material (equivalent to 4-5 transwells) from either day 1 or day 3 post-infection
cultures. After gavaging, mice were housed separately for the duration of the experiment to avoid
cross-infection. One mouse infected with bleached, day 1 ALI culture material was sacrificed on
day 30 post-infection and one mouse infected with bleached, day 3 ALI culture material was
sacrificed on day 9 post-infection in order to collect the small intestine for histology. Mouse
pellets were collected every 2-3 days and the mice were monitored for signs of sickness. Mouse
pellets were kept at -80°C until they were processed for DNA extraction, which was performed
using the QIAamp DNA Stool Kit. Pellets were moved to Lysing Matrix E 2 ml tubes (MP
Biomedicals) and 1.4 ml ASL Buffer (from Qiagen kit) was added. Samples were homogenized
using the FastPrep-24TM 5G High-Speed Homogenizer. The samples were then processed
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according to the kit’s directions. qPCR was used to quantify the number of C. parvum genomic
DNA equivalents were present in the sample using the above primers and cycling protocol.
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Figures and legends

Figure 3.1. ALI cultures support robust C. parvum growth.
A) Cartoon depicting ALI culture method. Spheroids are trypsinized and plated on top of feeder
cell and Matrigel layers. Monolayers are grown in 50% conditioned medium + 10 µM ROCK
inhibitor. After 7 days, the medium in the top chamber of the transwell is removed to create the
ALI.
B) ALI monolayers were infected 3 days post top medium removal with 2x10^5 oocysts.
Monolayers were incubated with oocysts for 4 hr and then washed 3 times. DNA samples were
collected daily. Graph depicts qPCR measuring C. parvum and mouse GAPDH equivalents (eq.)
in DNA samples. Each data point represents the mean and standard deviation of two transwells.
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C) Sections of uninfected and infected transwells stained with hematoxylin and eosin (H&E), or
rabbit pAb Cp using immunohistochemistry. White arrows in middle panel are highlighting C.
parvum vacuoles on the apical side of the cell. Scale bar = 20 µm.
D) Infected ALI transwells were fixed and stained with specified mouse mAb (1B5, 1A5, Crypta-gloTM) and rabbit pAb Cp to detect C. parvum. Hoechst staining is shown for the type II
meront to confirm the presence of 4 nuclei. Secondary antibodies used were goat anti-mouse
Alexa Fluor 488 and goat anti-rabbit Alexa Fluor 568. Scale bar = 3 µm.
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Figure 3.2. Electron microscopy images of ALI culture.
A) Uninfected region of ALI monolayer. Note cell height and presence of brush border. Scale
bar = 5 µm.
B) Region of ALI monolayer with infected cells. Cell height and brush border are maintained in
the presence of infection. Life cycle stages present in this image are early- and middle-stage
macrogamonts. Scale bar = 5 µm.
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Figure 3.3. Electron microscopy images of asexual life cycle stages in ALI culture.
A) Trophozoite. Note disruption of brush border in the area of parasite attachment. Scale bar = 1
µm.
B, C) Type I meronts. Note multiple mature merozoites within the parasitophorous vacuole.
Scale bar = 1 µm.
D) Extracellular merozoite. Scale bar = 1 µm.
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Figure 3.4. Electron microscopy images of sexual life cycle stages in ALI culture.
A) Macrogamont (right) and type II meront (left). Scale bar = 2 µm.
B) Macrogamont. Arrow is highlighting the presence of striated fiber. Scale bar = 1 µm.
C, D) Microgamonts. Note bullet-shaped parasites within vacuole. Scale bar = 1 µm.
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Figure 3.5. Electron microscopy images of late-stage macrogamonts and unsporulated
oocysts in ALI culture.
A, B) Late-stage macrogamonts. Arrows pointing towards multiple vesicles lining up near the
parasite surface. Scale bar = 2 µm.
C, D) Unsporulated oocysts. Note dense cytoplasm and the presence of a wall instead of vacuole
membrane. Scale bar = 1 µm.
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Figure 3.6. Microgamonts are recognized by Crypt-a-gloTM in ALI culture.
A) Transwells were infected with filtered sporozoites. On day 2 post-infection, transwells were
fixed and stained with pan Cp, Crypt-a-gloTM, and Hoechst. Secondary antibodies used were goat
anti-rabbit 555. First row depicts early microgamonts, defined by their small size, multiple tiny
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nuclei, and surface staining by pan Cp and Crypt-a-gloTM. Second row depicts late
microgamonts, which are identifiable by the rings forming around each nucleus, recognized by
pan Cp and Crypt-a-glo, implying the formation of separate microgamonts. Third row depicts
extracellular microgamonts that have been released from the parasitophorous vacuole. Scale bar
= 5 µm.
B) Transwells were infected with filtered sporozoites. On day 1 post-infection, 10 µM EdU was
added to the medium in the bottom chamber and left overnight. On day 2 post-infection,
transwells were fixed and EdU labeled with click chemistry and microgamonts with pan Cp and
Crypt-a-gloTM. First row depicts late microgamonts and second row depicts extracellular
microgamonts. Scale bar = 5 µm.
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Figure 3.7. C. parvum growth in primary cell culture requires ALI and differentiated
monolayers.
A) Top medium was removed from half of transwell to create “ALI” group; “no ALI” group
continued to have top medium. Three days after the top medium was removed, both sets of
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transwells were infected with 2x10^5 oocysts. Monolayers were incubated with oocysts for 4 hr
and then washed 3 times. DNA samples were collected daily. Left graph depicts qPCR
measuring C. parvum GAPDH in DNA samples; data is presented as C. parvum genomic DNA
equivalents (Cp gDNA eq.). Right graph depicts qPCR measuring mouse GAPDH in DNA
samples; data is presented as mouse genomic DNA equivalents (mouse gDNA eq.). * P ≤ 0.05,
*** P ≤ 0.001, **** P ≤ 0.0001.
B) Top medium was removed from transwells to create ALI. One group of transwells were
infected the same day of top medium removal with 2x10^5 oocysts (ID0); the other group was
infected 3 days post top medium removal with 2x10^5 oocysts (ID3). Monolayers were
incubated with oocysts for 4 hr and then washed 3 times. DNA samples were collected daily.
Left graph depicts qPCR measuring C. parvum GAPDH in DNA samples; data is presented as C.
parvum genomic DNA equivalents (Cp gDNA eq.). Right graph depicts qPCR measuring mouse
GAPDH in DNA samples; data is presented as mouse genomic DNA equivalents (mouse gDNA
eq.). * P ≤ 0.05, ** P ≤ 0.01.
C) Top medium was removed from half of transwell to create “ALI” group; “no ALI” group
continued to have top medium. Three days after the top medium was removed, both sets of
transwells were infected with 2x10^5 oocysts. Monolayers were incubated with oocysts for 4 hr
and then washed 3 times. On day 2 post infection, 10 µM EdU was added to the bottom chamber
of both groups of transwells. After 8 hours, the transwells were fixed; EdU was labeled through a
click-chemistry reaction, C. parvum was labeled with pan Cp, and host cell DNA was labeled
with Hoechst. Secondary antibodies used were goat anti-rabbit Alexa Fluor 568. Scale bar = 50
µm.
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Figure 3.8. Testing COLO-680N line for ability to support C. parvum growth and oocyst
development.
A) HCT-8 and COLO-680N cells were infected with 1.2x10^6 oocysts; after 4 hr, cells were
washed 3x and cell medium was replaced. Samples were collected at indicated time points for
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DNA samples. qPCR was used to determine the level of C. parvum GAPDH equivalents in the
sample.
B) Oocysts counts for the same experiment in (A). Cells were fixed and stained with Pan Cp and
Crypt-a-gloTM. The number of oocysts were counted per field; each data point is the number of
oocysts in a single 63X field.
C) Fluorescent microscopy images from the same experiment in (A) and (B). Cells were fixed
and stained with Pan Cp and Crypt-a-gloTM. COLO-680N monolayers are shown from day 1 and
10 post-infection. Scale bar = 20 µm.
D) Oocysts were excysted and either left unfiltered or filtered using filters with the indicated
pore sizes. The oocysts/sporozoites were added to PLL-coated coverslips, fixed, and stained with
Pan Cp and Crypt-a-gloTM. The number of oocysts were counted per field; each data point is the
number of oocysts in a single 63X field.
E) HCT-8 and COLO-680N cells were infected with oocysts filtered through a 3 or 1 µm filter.
On the days indicated, Cells were fixed and stained with Pan Cp and Crypt-a-gloTM. The number
of oocysts were counted per field; each data point is the number of oocysts in a single 63X field.
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Figure 3.9. In vitro production of oocysts in ALI culture.
A) In three separate experiments, transwells were infected on day 3 post-top medium removal
with filtered sporozoites. On days 1, 3, 6, and 10, transwells were fixed and stained with Crypt-agloTM and pan Cp to monitor oocyst development. Images were taken at 63X magnification and
oocysts counted. Each data point is the number of oocysts in a single field. Statistical analysis:
Two-way ANOVA corrected for multiple comparisons using the Dunnett method. The mean of
each time point was compared to the mean of day 1. **** P ≤ 0.0001.
B) Transwells were infected on day 3 post-top medium removal with filtered sporozoites. On day
2 post-infection, 10 µM EdU was added to the medium in bottom chamber and left overnight.
Cells were fixed and EdU was labeled through a click chemistry reaction. C. parvum was labeled
with pan-Cp and Crypt-a-gloTM. DNA was labeled with Hoechst. Secondary antibodies used
were goat anti-rabbit Alexa Fluor 647. White arrows in Hoechst images are highlighting the
nuclei within the oocyst. Scale bar = 5 µm.
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C) Low magnification (20X) image of transwell infected with filtered sporozoites on day 10
post-infection. Transwell is stained with Crypt-a-gloTM to detect oocysts and Hoechst to stain
DNA. Inset picture is on day 1 post-infection. Scale bar = 50 µm.
D) Transwells were infected with filtered sporozoites and bleached on day 3 post-infection.
Bleached material was placed on PLL-coated coverslip and stained with pan Cp, Hoechst, and
either MPA or UEA-1. Secondary antibodies used were goat anti-rabbit Alexa Fluor 568. Scale
bar = 5 µm.
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Figure 3.10. Unusual 4D8 reactivity pattern seen in infected ALI culture.
For A, B, and C) Transwells were infected with filtered sporozoites. On day 2 post infection,
transwells were fixed and stained with pan Cp and 4D8. Secondary antibodies used were goat
anti-rabbit Alexa Fluor 568 and goat anti-mouse Alexa Fluor 488. White arrows highlight
“trails” recognized by 4D8. Scale bar = 50 µm.
D) Oocysts were excysted and plated onto PLL-coated coverslip, fixed and stained as above.
Scale bar = 5 µm.
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Figure 3.11. Oocysts produced in vitro are infectious to mice.
A) Transwells were infected with filtered sporozoites. On days 1 and 3 post-infection, transwells
were either fixed and stained with pan Cp and Crypt-a-gloTM, or bleached and placed on PLLcoated coverslip, then stained with pan Cp and Crypt-a-gloTM. Left graph depicts oocyst counts
from whole mount images of infected ALI monolayers, right graph depicts oocyst counts from
bleached material. Images were taken at 63X; each data point is the number of oocysts in a single
field. Data was analyzed using an unpaired T test. **** P ≤ 0.0001.
B) Images of oocysts in bleached material of transwells on day 3 post infection. Oocysts were
stained with pan Cp, Crypt-a-gloTM, and Hoechst. Secondary antibodies used were goat antirabbit 568.
C) Transwells were infected with filtered sporozoites. On days 1 and 3 post-infection, transwells
were bleached and the material was orally gavaged into mice. Each mouse received about 4
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transwells’ worth of bleached material. Left graph shows survival curves of the mice in the two
groups. Data was analyzed using the log-rank (Mantel-Cox) test. In the right graph, fecal pellets
were collected from the mice on the days indicated. DNA was isolated from the pellets and
qPCR was used to determine the number of C. parvum gDNA equivalents present in each
sample. The gray line represents the mean value of both groups for day 1, the dotted lines are the
standard deviations. Data was analyzed using a 2-way ANOVA comparing the mean of each
group across all time points, corrected for multiple comparisons using the two-stage step-up
method of Benjamini, Kreieger, and Yektieli. ** P ≤ 0.01, **** P ≤ 0.0001.
D) Sections of small intestine collected from mice gavaged with the bleached material, stained
with pan Cp by IHC. The mouse that received day 1 material was sacrificed on day 30 postgavage (sections shown on left) and the mouse that received the day 3 material was sacrificed on
day 9 post-gavage (sections shown on right). Scale bar in top row = 20 µm, scale bar in bottom
row = 50 µm.
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Figure 3.12. Oocysts produced in vitro are infectious to mice (repeat experiment).
ALI transwells were infected with filtered sporozoites. On days 1 and 3 post-infection, transwells
were bleached and the material was orally gavaged into mice. Each mouse received about 4
transwells’ worth of bleached material. Mice were housed individually after inoculation.
A) Survival curves of the mice in the two groups. Data was analyzed using the log-rank (MantelCox) test.
B) Fecal pellets were collected from each mouse on the days specified. DNA was isolated from
the pellets and qPCR was used to determine the number of C. parvum gDNA equivalents present
in each sample. The gray line represents the mean value of both groups for day 1, the dotted lines
are the standard deviations. Data was analyzed using a 2-way ANOVA comparing the mean of
each group across all time points, corrected for multiple comparisons using the two-stage step-up
method of Benjamini, Kreieger, and Yektieli., **** P ≤ 0.0001.
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Appendix: Attempts to serial passage C. parvum in vitro
When we found that the ALI system supported completed life cycle development of C.
parvum as well as long-term growth, we expected that the system would also support serial
passage of C. parvum. Historically, when long-term growth of a parasite is achieved in culture,
the step to serial passage is minimal, which was the case with Toxoplasma and Plasmodium spp.
(178, 179). However, there are exceptions; complete development of Isospora suis, the causative
agent of piglet coccidiosis, has been achieved in vitro but not propagation (180). Serial passage
would enable us to maintain Cryptosporidium in vitro, making it unnecessary to use the mouse or
calf to amplify infection and make oocysts. It would also make genetic modification of C.
parvum significantly easier, since lines could be selected for and maintained in vitro.
When I first began attempting to passage C. parvum with the ALI system, I approached it
very simply and mimicked Toxoplasma passage in HFF cells (see row in Appendix table 1
describing syringe-lysing attempts). I scraped infected ALI cultures into warm cell culture
medium using a blunt yellow tip, combined the material (about 1 ml total volume), syringe-lysed
the mixture to shear the host cells and release the parasites, and then passaged to fresh transwells
at roughly 1:3 or 1:4 ratio. The passaged inoculum was left on the cells for about 3-4 hours and
then removed in order to maintain the ALI. I tested passaging at different time points postinfection to see if I could pinpoint what life cycle stage was capable of propagating infection:
early passage (day 1-2) for asexual stages and late passage (day 3 or later) for sexual stages and
oocysts. Some experiments indicated that late passage worked better and led to earlier
outgrowth, but it was unclear if this was due to the presence of in vitro-produced oocysts or just
higher numbers of parasites in the inoculum. In all experiments, it took at least 10-14 days to see
any sign of growth in the transwells that received the passaged infection, and the growth was
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stunted compared to what you would see in a “normal” infection. It seemed that some life cycle
stage was capable of propagating infection, but it was present at a very low frequency. We know
that the ALI system can amplify small doses of C. parvum (appendix figure 1), so even if only a
few parasites can make it through the passaging process, they should be able to amplify.
The biggest issue, however, was the inconsistency in infection levels between samples
that were collected at the same time point; if three samples were collected, often only one
showed signs of parasite growth. I want to emphasize that this level of variability is not seen in a
normal infection; while transwells from the same time point can have some variation in parasite
levels, there are never transwells that are negative for infection. This inconsistency implied that
whatever parasite stage, or growth promoting condition, was capable of passaging the infection
was being unevenly distributed between the new monolayers. This was a major issue because it
made it impractical to try serial propagation attempts, since there was no way of identifying
which transwells were productively infected without looking by qPCR or microscopy, which
consumes the sample.
When simple passaging methods do not seem to work or produced inconsistent infection
I began testing other variables. I tested different needle gauge sizes to create a more homogenous
lysate, which I thought would lead to more consistent infection in the recipient transwells. I
would first syringe-lyse using a large needle gauge, like 20G, and then move to a smaller needle
gauge, like 23G or 25G. This did create a more homogenous mixture, but it did not completely
remove clumps of mucus and cell debris. The later the infection was passaged, the clumpier the
lysate, due to the presence of increased mucus in the ALI cultures. Using different needle gauges
did not solve the problem of inconsistent or unsuccessful passage.
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One concern was that the parasites were being exposed to too much oxygen during the
syringe-lysing process, so a few steps were taken to minimize this. I syringe-lysed the cultures in
large volumes of medium (5 ml) and kept the needle below the surface and was careful to avoid
making bubbles. This required centrifuging the material (2500 rpm x 3 min) after syringe lysis
and resuspending in a small volume to passage the infection. I also added glutathione (GSH) to
the medium at the same concentration (5 mM) used in Cytomix, a buffer used during transfection
of Toxoplasma. Lysing the cells in a large volume and/or using GSH did not improve passaging.
I also tried syringe-lysing cultures in an anaerobic hood (gas mix present: 75% N2/20% CO2/5%
H2) to completely remove the presence of oxygen and passing the material to fresh monolayers
while still inside the hood cells (see row in Appendix table 1 describing anaerobic passage
attempts). I kept the monolayers inside the hood for 60 min to allow for infection, and then
moved the monolayers back to a normal incubator. This treatment did not improve passaging.
When syringe-lysing did not yield consistent positive results, I tried trypsinizing the
infected cells and using the intact cells to passage infection, the logic being that the parasites
could naturally egress from the cell instead of being prematurely forced out by syringe lysis cells
(see row in Appendix table 1 describing trypsinizing attempts). The ALI monolayers were
resistant to trypsinization, so the protocol required adding trypsin/EDTA to both the top and
bottom chambers of the transwell and incubating for 20 min. This dissociated the monolayer and
the cells were centrifuged at 1000 rpm for 3 min and then resuspended in a small volume to
passage the infection. I tried leaving the trypsinized material on the new monolayers for short (34 hr) and long (overnight) periods of time to allow the parasites to egress and infect the new
monolayer. I did not see any evidence of successful passage with this method. Same as syringe-
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lysing, I tried trypsinizing the cells in an anaerobic hood to minimize exposure to oxygen, but
this did not improve passaging.
With both syringe-lysing in a large volume and trypsinizing the cells, the infected
material was centrifuged before being added to the new monolayers. I became concerned that the
centrifugation step was shearing off the parasitophorous vacuoles and therefore decreasing the
inoculum size, possibly explaining the poor outgrowth. So, with both conditions (syringe-lysing
and trypsinization), I avoided centrifugation and directly added the material to the new
transwells. This adjustment did not improve passaging outcome.
The Stappenbeck lab had preliminary evidence showing that ALI monolayers could be
trypsinized and the cells split and seeded into new transwells, leading to the formation of new
monolayers without using spheroids. I tried to trypsinize and split infected monolayers, combine
the infected cells with uninfected cells from trypsinized spheroids, and plate the mixture into
transwells cells (see row in Appendix table 1 describing splitting infected monolayers attempts).
I then removed the top medium at different days post-seeding, either day 1 or day 4. I did not
wait the full 7 days because we had found in other experiments that submerged transwells did not
support parasite growth as well as ALI transwells. I did not find any evidence of robust
outgrowth in the new transwells.
I thought that inducing parasite egress with a chemical agent like Zaprinast or A23187
could help improve passaging cells (see row in Appendix table 1 describing Zaprinast/A23187
attempts). Zaprinast is a cGMP-specific phosphodiesterase inhibitor that activates cyclic GMPdependent protein kinase (PKG) and stimulates tachyzoite egress in Toxoplasma (181). A23187
is a calcium ionophore that also induces egress in Toxoplasma tachyzoites (181). I treated
infected monolayers with both reagents separately, at concentrations used to induce egress in
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Toxoplasma, for 10 min. I scraped the monolayers and passaged the infection without syringelysing. I did not see any outgrowth in the new transwells.
There are two caveats to interpreting data from early passaging experiments. Experiments
from before June 2017 used 3 µm filters to filter out oocysts from the initial infection; later this
was switched to 1 µm filters when it was found 3 µm was not sufficient to completely remove
oocysts from the input inoculum. I am concerned that the partial successes of some of the earliest
experiments may be due to contaminating oocysts in the input inoculum; these may have
excysted after passaging and led to more outgrowth than would be expected. Also, experiments
before January 2018 infected monolayers on day 0 post top media removal, but this was later
changed when it was found infecting on day 3 post top media removal led to consistently better
growth; therefore, all initial infections were started on day 3 ALI cultures and infections were
also passaged to day 3 ALI cultures.
The lack of success with propagation using the ALI system is particularly frustrating
given that we have found that Ifngr1-/- mice can become productively infected with syringe-lysed
monolayers, even from day 1 post-infection cultures (appendix figure 2). This is possible even
with monolayers that have been infected with sporozoites that have been filtered with a 1 µm
filter, meaning there is no oocyst contamination. This result suggests that there is a life cycle
stage besides oocysts that is capable of transmitting the infection, but for some reason, it does not
occur in vitro. It is possible that passage through the gut “activates” the infectious stage in some
way that syringe-lysing, trypsinization, etc. are not able to mimic. It is also possible that lysed
cultures contain some inhibitor that prevents subsequent growth in vitro, but which is neutralized
or eliminated in vivo.
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Advice for future attempts
When designing propagation experiments, it is important to infect the initial monolayers
that will be used for passaging with 1 µm filtered sporozoites. I believe infecting the initial
monolayers with oocysts may lead to false positives in the set of transwells that receive the
passaged infection. Set aside transwells from the initial infection to check for growth by qPCR
and microscopy, to confirm robust infection and oocyst development. The set of transwells that
receive the passaged infection should have a set of control transwells that are infected normally
with either sporozoites or oocysts to confirm that the monolayers are able to support infection.
Each time point for the passaged infection should have 3 transwells for DNA samples to check
for the level of variability in infection. It is not necessary to look for evidence of infection by
both microscopy and qPCR for pilot experiments; I have found qPCR to be more useful.
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Appendix Table 2. Attempts at propagating C. parvum
Type

Basic description

Variables tested

Notes

Syringelysing

Scraping monolayers
with blunt yellow
pipette tip; collecting
material and lysing
using syringe and needle

No consistent
outcomes; large
variability in
growth between
transwells that
received the
passaged infection

Trypsinizing

Washing monolayers in
PBS-EDTA (0.5 mM),
adding trypsin to top
and bottom chamber,
then collecting cells
after 20 min

Splitting
infected
monolayers

Trypsinizing infected
monolayers (see text for
explanation) and adding
the cells to freshly
trypsinized spheroids to
create new monolayers

• Passaging on days 1, 2, 3,
6, 9, and 10
• Using different needle
gauges (25G, 23G, and
21G); combining multiple
needle gauges
• Adding 5 mM GSH to
medium during lysis to
protect against oxidation
• Lysing in large volume (5
ml) to limit air exposure
• Skipping centrifugation
step (1250 g x 3 min) to
avoid shearing
parasitophorous vacuoles
• Infecting original
monolayer with high dose
(1x10^6 oocysts) instead
of usual low dose (2x10^5
oocysts or sporozoites)
• Passaging on days 1, 2, 3,
6, 9, and 10
• Incubating monolayers
with passaged material for
short pulse (2-4 hours) or
overnight
• Skipping centrifugation to
avoid shearing
parasitophorous vacuoles
(200 g x 3 min)
• Passaging from
monolayers infected with
a high and low dose of
oocysts
• Removing top medium
day 1 or day 4 postseeding
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No growth

No growth

Zaprinast
and A23187

Treating monolayers
with agents to induce
egress

Anaerobic

Manipulating transwells
under anaerobic
conditions (75%
N2/20% CO2/5% H2)
when passaging
infection (see text for
explanation)

• Treated monolayers on
day 3 post-infection with
either Zaprinast (100 µm)
or A23187 (2 µm) for 10
min at 37°C; scraped
monolayers and passaged
• Syringe-lysing or
trypsinizing
• Day 3 and 6 postinfection
• Incubated monolayers
with passaged material
overnight in normal 5%
CO2 incubator
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No growth

No growth

Appendix Figure 1. Oocyst dose response in ALI culture.
Transwells were infected with oocysts on day 0 of top medium removal. Samples were collected
every 7 days for DNA collection. C. parvum genomic DNA equivalents were determined by
using qPCR to measure C. parvum GAPDH levels.
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Appendix Figure 2. Inoculating Ifngr1-/- mice with C. parvum-infected ALI cultures.
ALI monolayers were infected on day 3 post-top medium removal with sporozoites filtered
through 1 µm filter. On days 1 and 6 post-infection, monolayers were scraped and syringe-lysed
with 20G and 23G needles. Each mouse received 1 transwells’ worth of material in a 200 µl
volume by oral gavage. 4 mice per group. The mice were housed individually after inoculation.
Graph in (A) depicts the survival curve of each group of mice. Data was analyzed using the logrank (Mantel-Cox) test. Graph in (B) shows the result of the qPCR performed on the DNA
extracted from the fecal pellets of the mice measuring levels of genomic C. parvum equivalents.
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Chapter 4
In vitro culture of Cryptosporidium parvum
in primary cells
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Preface
The first complete draft of this chapter was written by GW. Comments from LDS were
incorporated into the final version presented here. GW, YW and SR optimized the ALI system
for C. parvum infection. TSS, YW and WW provided key biological reagents and advice. TSS
and LDS provided advice and supervision.

This chapter is an invited review for Methods and Molecular Biology, to be submitted:
Wilke, G., Wang, Y., Ravindran, S., Stappenbeck, T.S., Witola, W., Sibley, L.D. (2018) In vitro
culture of Cryptosporidium parvum using primary/stem cells.
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Summary
C. parvum has a complex life cycle consisting of asexual and sexual phases that
culminate in oocyst formation in vivo. The most widely used cell culture platforms to study C.
parvum only support a few days of growth and do not allow the parasite to proceed past the
sexual stages to complete oocyst formation. Additionally, these cell culture platforms are mostly
adenocarcinoma cell lines, which do not adequately model the parasite’s natural environment in
the small intestine. We describe here a method to create primary intestinal epithelial cell
monolayers that support long-term C. parvum growth. Monolayers were derived from intestinal
stem cells grown as spheroids and plated onto transwells, allowing for separate apical and
basolateral compartments. In the apical chamber, the cell growth medium was removed to create
an “air-liquid interface” that enhanced host cell differentiation and C. parvum growth. The use of
primary intestinal cells to grow C. parvum in vitro will be a valuable tool for studying hostparasite interactions using a convenient in vitro model that resembles the intestinal environment.
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1 Introduction
A significant barrier to Cryptosporidium research is the lack of a cell culture system that
enables long-term growth in vitro. Historically, human adenocarcinoma cells have been used to
study asexual and early sexual growth of the parasite (142). These cell lines support growth of
the parasite over 2-3 days but after the parasite enters the sexual part of its life cycle, numbers
rapidly diminish because oocyst formation is blocked (78, 79, 142). This limitation greatly
affects the type of studies researchers can pursue when investigating Cryptosporidium biology.
Recently, there have been several reports of cell culture platforms capable of supporting
complete life cycle development of C. parvum, a species of Cryptosporidium frequently
associated with disease in humans and animals. (2-4). One platform utilizes a hollow fiber
system to mimic the intestine by allowing for separate control of the apical and basolateral
compartments (95); this system enables the creation of an environment with redox and nutrient
conditions optimal for parasite growth. However, it requires the use of expensive equipment and
the hollow fiber cannot be “opened” during the experiment, making microscopy studies difficult.
Also, the expense of the hollow fiber system means that experiments are not easily scalable, and
perturbations to the system are often done serially, instead of in parallel, a major limitation for
any kind of drug study. Another novel platform is a 3D intestinal model that uses silk protein as
a scaffold for cell growth (96); this model also has a lumen, creating two separate compartments.
This platform involves the use of specialized equipment to create the 3D scaffolds, making it
more challenging for other researchers to adopt. While both platforms have limitations, they are
capable of producing oocysts that are infectious to cells (95, 96) and mice (95), which enables
continuous culture in vitro.
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The two new platforms use adenocarcinoma cells (HCT-8 and Caco-2 cells), which are
likely very different from the cell types C. parvum infects in vivo, in terms of differentiation
status, metabolism, and proliferation rate. To accurately reproduce in vivo host-parasite
interactions in cell culture, it is necessary to utilize primary cells. Advancements in stem cell
biology have made it possible to propagate intestinal stem cells as spheroids in medium
containing specific growth factors (125, 126). The required cell culture medium has become
relatively easy to make due to the creation of a supportive cell line, L-WRN, that secretes Wnt,
R-spondin, and noggin, creating conditioned medium that is used to support spheroid growth
(125). Cells derived from spheroids can be used to create primary intestinal epithelial cell
monolayers grown on transwell membranes that recapitulate aspects of the gut, including
development of specific cell lineages such as goblet and Paneth cells (131, 138). Murine ileal
monolayers derived from this method support robust C. parvum growth, which enabled the
creation of novel antibodies to intracellular parasite stages (167). These monolayers, however,
typically only last 2-5 days, which make them unsuitable for studying long-term C. parvum
growth.
In the last few years, a protocol for creating primary intestinal monolayers that exhibit
dramatic differentiation and long-term viability has been published (132). This method relies on
the inclusion of a feeder cell layer to support stem cell growth and the introduction of an airliquid interface (ALI) at the surface of the cells. ALI has been used to enhance differentiation of
airway tract epithelial cells for many years (133-135) and has also recently been applied to
intestinal epithelial cell culture, resulting in increased expression of markers associated with cell
differentiation and also significant changes in cell metabolism (136, 137).
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Epithelial monolayers grown with an ALI and feeder cell layer can survive for weeks
(132), making them attractive candidates for a cell culture platform for C. parvum. We have
found that primary intestinal monolayers grown on transwells in L-WRN-conditioned medium
with an ALI support long-term C. parvum growth. Parasite growth can last for weeks in this
system without affecting host cell viability. We believe that this cell culture system will support
further research into the life cycle of C. parvum and enable more thorough investigation of
potential growth inhibitors.
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2 Materials

2.1 Creating irradiated 3T3 (i3T3) cell stocks for feeder cell layer
1. Biosafety cabinet and 37°C, 5% CO2 incubator
2. Mouse fibroblast cells (NIH/3T3, ATCC, cat. no. CRL-1658)
3. 37°C water bath
4. 15 and 50 ml polypropylene conical tubes
5. 3T3 growth medium: For 500 ml, combine 445 ml of Dulbecco’s Modified Eagle’s
Medium (DMEM) modified to contain 4 mM L-glutamine, 4500 mg/L glucose, 1 mM
sodium pyruvate, and 1500 mg/L sodium bicarbonate (ATCC, cat. no. 30-2002) with 50
ml heat-inactivated fetal bovine serum (FBS; Sigma, cat. no. F6178) and 5 ml 100X
penicillin/streptomycin (Sigma, cat. no. P4333).
6. Centrifuge capable of holding 15 and 50 ml conical tubes that can spin at 200 x g
7. Tissue culture supplies such as 25, 75, and 150 cm2 cell culture flasks (T-25, T-75, T150) and disposable plastic pipettes
8. Dulbecco’s Phosphate-Buffered Saline (DPBS)-EDTA: For 500 ml, add 500 µl 0.5 M
EDTA pH 8.0 solution (Invitrogen, cat. no. 15575020) to 500 ml tissue culture grade
DPBS.
9. Trypsin-EDTA: For 100 ml, add 10 ml 10X trypsin solution (Sigma, cat. no. T4549) to
90 ml DPBS-EDTA. Can be aliquoted and stored at -20°C for months; aliquots can be
thawed and stored at 4°C for 7-10 days.
10. Machine capable of irradiating 15 ml conical at 3000 rads (such as the Xstrahl Small
Animal Radiation Research Platform or SARRP)
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11. Hemocytometer and cover glass
12. 3T3 freezing medium: For 50 ml, combine 10 ml FBS, 2.5 ml DMSO, and 37.5 ml 3T3
growth medium.
13. Cryovials, 1.5 ml volume
14. -80°C freezer
15. LN2 tank

2.2 Plating i3T3 cells on transwells
1. Biosafety cabinet
2. Matrigel (Corning, cat. no. 354234)
3. Cold DPBS
4. Transwell with 0.4 µm pore polyester membrane insert (Corning Costar, cat. no. 3470)
5. Tissue culture supplies such as 15 ml conicals, 1.7 ml Eppendorf tubes
6. Vacuum flask and sterile disposable glass Pasteur pipettes
7. 37°C, 5% CO2 incubator

2.3 Passaging spheroids
1. Spheroid line established according to Miyoshi & Stappenbeck 2013; for our purposes,
we used a line isolated from the ileum of 8-10 week old C57BL/6J mouse. Lines can be
frozen 1-2 passages after the original derivation and thawed as needed; use single line for
20-25 passages.
2. 37°C water bath
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3. Tissue culture supplies such as 12 well plates, disposable pipettes, 15 and 50 ml conical
centrifuge tubes, 1.7 ml Eppendorf tubes
4. Washing medium: Add 50 ml FBS, 5 ml 100X penicillin/streptomycin, 5 ml100X Lglutamine to DMEM/F12 with HEPES (Sigma, cat. no. D6421-500ML).
5. Matrigel (Corning, cat. no. 354234)
6. Biosafety cabinet
7. Cell scrapers (Biotium, cat. no. 22003)
8. Centrifuge capable of holding 15 conical tubes that can spin at 200 x g
9. Centrifuge capable of holding 1.7 ml Eppendorf tubes that can spin at 200 x g
10. DPBS-EDTA and trypsin-EDTA
11. Conditioned medium prepared according to Miyoshi & Stappenbeck 2013; requires LWRN cell line (ATCC CRL-3276).
12. Primary medium: Add 6.25 ml 100X L-glutamine (Sigma, cat. no. G7513), 6.25 ml 100X
penicillin/streptomycin (Sigma, cat. no. P4333), and 125 ml heat-inactivated FBS
(Sigma, cat. no. F6178) to 500 ml Advanced DMEM/F12 (Thermo Fisher, cat. no.
12634)
13. ROCK inhibitor (Tocris, Y-27632)
14. 37°C, 5% CO2 incubator.

2.4 Creating primary cell monolayers for C. parvum infection
1. Biosafety cabinet
2. Cell scrapers (Biotium, cat. no. 22003)
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3. Tissue culture supplies such as 12 well plates, disposable pipettes, 15 and 50 ml conical
centrifuge tubes
4. Centrifuge capable of holding 15 conical tubes that can spin at 200 x g
5. DPBS-EDTA and trypsin-EDTA
6. 37°C water bath
7. Washing medium: Add 50 ml FBS, 5 ml 100X penicillin/streptomycin, 5 ml100X Lglutamine to DMEM/F12 with HEPES (Sigma, cat. no. D6421-500ML).
8. Conditioned medium prepared according to Miyoshi & Stappenbeck 2013; requires LWRN cell line (ATCC CRL-3276).
9. Primary medium: Add 6.25 ml 100X L-glutamine (Sigma, cat. no. G7513), 6.25 ml 100X
penicillin/streptomycin (Sigma, cat. no. P4333), and 125 ml heat-inactivated FBS
(Sigma, cat. no. F6178) to 500 ml Advanced DMEM/F12 (Thermo Fisher, cat. no.
12634)
10. ROCK inhibitor (Tocris, Y-27632)
11. ROCK inhibitor (Tocris, Y-27632)
12. Sterile cell strainers, 40 µm (Fisher, cat. no. 22363547)
13. 37°C, 5% CO2 incubator.

2.5 Preparing and maintaining C. parvum oocysts for infection
1. Biosafety cabinet
2. Purified oocysts, stored in 50 mM Tris-10 mM EDTA, pH 7.2.
3. Cold DPBS
4. 15 ml conical tubes
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5. Commercial laundry bleach containing 8.25% sodium hypochlorite
6. Centrifuge capable of holding 15 conical tubes that can spin at 800 and 1250 x g
7. Centrifuge buckets with sealed biohazard caps
8. Cold DPBS + 1% BSA
9. Excystation buffer: To make 5 ml, dissolve 0.75 g sodium taurocholate (Sigma, cat. no.
86339) into 5 ml DPBS (1.5% w/v sodium taurocholate solution). May need vortexing to
dissolve completely. Filter steril9ize with 0.2 µm filter. Can be stored at 4°C for several
weeks.
10. 37°C water bath
11. Glass slides and square coverslips (22x22 mm)
12. Swin-Lok filter holders (source), 25 mm
13. Whatman Nuclepore hydrophilic membranes, 25 mm circle, 1.0 µm pore size (VWR
International, cat. no. 28158-373)
14. 3 or 5 ml plastic syringe
15. Cell growth medium (e.g. conditioned medium for ALI)

2.6 Measuring host and parasite replication in primary cell monolayers by qPCR
1. Qiagen QIAamp DNA Mini Kit (cat. no. 51394 or 51306)
2. Blunt pipette tips (20-200 µl pipette tips with ends snipped off)
3. 1.7 ml Eppendorf tubes
4. 56°C water bath
5. 70°C heat block
6. Ethanol, 200 proof
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7. Centrifuge capable of spinning Eppendorf tubes and spin columns at 7000 x g
8. Sterile H2O
9. 2X SYBR Green mix or similar qPCR reaction mix (e.g. TB Green Advantage qPCR
premix, Takara Bio)
10. 96-well reaction plate compatible with qPCR machine (e.g. MicroAmp Optical 96-well
Reaction Plate with Barcode, Applied Biosystems)
11. Adhesive film for sealing reaction plate (e.g. MicroAmp Optical Adhesive Film, Applied
Biosystems)
12. Centrifuge capable of spinning 96-well plates
13. qPCR machine with 96-well block (such as the QuantStudio 3 Real-Time PCR system,
Thermo Fisher Scientific)

2.7 Monitoring life cycle progression in primary cell monolayers by microscopy
1. PBS
2. Fixative such as 4% formaldehyde (Polysciences, cat. no. 04018)
3. Permeabilization agent such as Triton X-100 or saponin
4. Normal goat serum
5. Fetal bovine serum
6. Hoechst (Thermo Fisher, cat. no. 33258; 1 mg/ml stock solution) or another DNA stain
7. Scalpel and forceps
8. Mounting reagent such as ProLong Gold (Thermo Fisher, cat. no. P36930)
9. Glass slides and square coverslips (22x22 mm)
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3 Methods
3.1 Creating irradiated 3T3 (i3T3) cell stocks for feeder cell layer

This protocol is based on the standard protocols for maintaining 3T3 cells in culture and
preparing 3T3 cells for feeder cell layers. All cell manipulation is performed inside a biosafety
cabinet under sterile conditions.

1. Thaw a frozen vial of 3T3 cells (see note 4.1) in 37°C water bath. Remove vial
immediately when cells have thawed.
2. Add thawed cell mixture to 15 ml conical containing 10 ml 3T3 growth medium.
3. Spin at 200 x g for 3 min. Remove supernatant.
4. Resuspend pellet in 5 ml growth medium and pipette 8-10 times to evenly distribute cells.
5. Transfer to T-25 flask and culture in 37°C, 5% CO2 incubator.
6. When cells are ~90% confluent, remove the medium from the flask and wash with 10 ml
DPBS-EDTA.
7. Add trypsin-EDTA to flask in a volume sufficient to cover cell monolayer (1 ml for T-25,
3 ml for T-75, 6 ml for T-150). Swirl flask to ensure complete cell coverage.
8. Keep flask at room temperature for 2-3 minutes. Swirl flask to see if cells have detached.
9. Once cells have detached, add sufficient volume of growth medium to cover flask and
resuspend the cells (4 ml for T-25, 6 ml for T-75, 7 ml for T-150). The medium will stop
the action of the trypsin.
10. Pipette the medium over the surface of the flask 3 times to ensure all cells are in
suspension. Pipette up and down 8-10 times to create a single cell suspension.
11. Transfer cell mixture to 15 ml conical and spin at 200 x g for 3 min.
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12. Remove supernatant and resuspend pellet in desired amount of medium.
13. Pipette mixture up and down 5-10 times to ensure even distribution of cells and transfer
desired amount of cell to new flasks. Swirl flasks to ensure cells are covering flask
surface.
14. The passage ratio determines the length of time it takes the flask to reach 90-100%
confluency. Passage ratio of 1:2.5 will reach confluency in 2 days, 1:5 in 3 days, and 1:10
in 4 days.
15. Expand the cells into the number of flasks desired for the irradiation process.
16. When final flasks become confluent, trypsinize cells as described in steps 1-6. The
irradiation protocol can be scaled up or down depending on the number of irradiated cells
required. For example, 3 T-T150s, once trypsinized, can be pooled into one 50 ml conical
and spun down at 200 x g for 3 min.
17. Remove supernatant and resuspend pellet in 10 ml growth medium and transfer cell
mixture to 15 ml conical.
18. Irradiate cells at 3000 rads. We use the Xstrahl SARRP for this purpose.
19. Pipette cells to ensure even distribution and take 10 µl to determine cell density using
hemocytometer. Cells should not be clumpy and should appear uniformly round.
20. Spin down cells at 200 x g for 3 min.
21. Resuspend pellet in sufficient volume of freezing medium to achieve 2x10^6 cells/0.5 ml.
22. Aliquot cells for freezing, 0.5 ml per cryovial. Three T-150s typically yield 20-25 vials at
the above cell density.
23. Move cryovials to -80°C freezer for short-term storage (days to weeks) and then to LN2
tank for long-term storage (months).
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3.2 Plating i3T3 cells on transwells

This step occurs the day before the stem cell spheroids are split and plated onto the transwells.
All cell manipulation is performed inside a biosafety cabinet under sterile conditions.

1. Make 10% Matrigel solution: dilute Matrigel (see note 4.2) in cold DPBS (keep DPBS
and Matrigel on ice), pipette to ensure even distribution. Prepare sufficient volume for
100 µl of solution per transwell.
2. Add 100 ul 10% Matrigel solution to each transwell. Move plate with transwells to 37°C
incubator for 20-30 minutes to allow the Matrigel to polymerize while finishing the
following steps.
3. Thaw vial(s) of frozen i3T3 cells in 37°C water bath. Once thawed, immediately add to
15 ml conical containing 10 ml 3T3 growth medium.
4. Spin down cells at 200 x g for 3 min.
5. Remove supernatant and resuspend cells in 1-3 ml of growth medium.
6. Count cells using hemocytometer. Each transwell will be plated with 8x10^4 cells in 100
µl volume; resuspend cells accordingly.
7. After transwells have been in 37°C incubator for at least 20 minutes, remove and aspirate
Matrigel using vacuum flask and glass pipette. Alternatively, Matrigel can be removed
with pipet tip.
8. Add i3T3 cell suspension to each transwell.
9. Add 400 µl growth medium to bottom chamber of each transwell.
10. Place transwells in 37°C, 5% CO2 incubator.
134

3.3 Passaging spheroids

This is a very brief summary of the protocol described in Miyoshi & Stappenbeck 2013.
Growing the spheroids (and primary cell monolayers described in 3.4) requires the use of
medium conditioned by the L-WRN cell line (“conditioned medium”). The production of this
medium is also described in Miyoshi & Stappenbeck 2013; it requires the L-WRN cell line
(ATCC CRL-3276). The paper also describes how to scale production of conditioned medium to
suit the needs of the researcher. The final step of preparing conditioned medium is to add the
conditioned medium to an equal volume of primary medium (recipe included in materials
section), therefore all conditioned medium used in these protocols is “50% conditioned
medium”.

1. Thaw vial of spheroids isolated and frozen according to Miyoshi & Stappenbeck 2013.
Place vial in 37°C water bath until contents are thawed (1-2 min).
2. Transfer cells to 15 ml conical containing 5 ml pre-warmed washing medium.
3. Centrifuge at 200 g x 5 min.
4. Aspirate supernatant, being careful not to disturb pellet.
5. Add 1 ml washing medium and resuspend cells by gentle pipetting. Transfer to 1.5 ml
Eppendorf tube.
6. Centrifuge at 200 g for 5 min.
7. Remove supernatant with a pipette, being careful not to disturb pellet.
8. Place tube on ice and chill for 5 min.
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9. Add Matrigel to cells for desired volume. For example, if plating a 12-well plate, the
volume of Matrigel/cell suspension for each well is 30 µl. Pipette cells gently, avoiding
bubbles. Hold tube by rim while pipetting to avoid warming Matrigel.
10. Place tissue culture plate (e.g. a 12-well plate) on ice. This can be done inside or outside
biosafety cabinet.
11. Remove lid from plate and place on sterile surface.
12. Pipette appropriate volume of Matrigel/cell suspension into the middle of each well.
Carefully spread out Matrigel using pipette tip; do not let Matrigel touch sides of well.
13. Cover plate with lid, remove from ice, flip upside down (this is done to prevent the cells
from touching plate bottom), and place into 37°C incubator for 10 min. Matrigel will
solidify.
14. Remove plate from incubator, flip right side-up, and add appropriate volume of 50%
conditioned medium with 10 µM ROCK inhibitor (e.g. 800 µl/well for 12-well plate).
15. Place cells in 37°C, 5% CO2 incubator.
16. Two days after plating, aspirate medium and add fresh 50% conditioned medium.
17. Three days after plating, scrape Matrigel/cell suspension into medium using a cell scraper
or pipette tip. Combine wells into 15 ml conical (6 wells of a 12 well plate can be
combined into 1 conical).
18. Spin cells at 200 g x 3 min.
19. Aspirate supernatant and resuspend cells in 5 ml DPBS-EDTA.
20. Spin cells at 200 g x 5 min (longer spin time is necessary to ensure adequate exposure to
DPBS-EDTA).
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21. Aspirate supernatant and add 300 µl trypsin-EDTA to cells. Pipette 2-3 times to ensure
even mix.
22. Add cells to 37°C water bath, incubate for 1.5 min.
23. Remove cells from water bath, pipette gently 10-12 times. Add 5 ml washing medium.
24. Spin cells at 200 x g for 3 min.
25. Aspirate supernatant and resuspend cells in 1 ml 50% conditioned medium with 10 µM
ROCK inhibitor. Move cell suspension to 1.7 ml Eppendorf tube.
26. Spin cells at 200 x g for 3 min.
27. Remove supernatant with pipette tip. Place tube on ice. Let chill for 5 min.
28. Add desired volume of Matrigel to cell pellet (volume is dependent on the number of
wells being plated). Spheroid lines have different optimal passage ratios; for the murine
ileal lines used to grow C. parvum, a 1:6 passage ratio is often used. Passage ratios will
need to be adjusted in response to spheroid density; murine ileal spheroids should not be
maintained at a very high density or else they will not grow well. Pipette Matrigel gently
to mix, avoid bubbles.
29. Plate spheroids as described in steps 10-15.
30. Passage spheroids every 3 days.

3.4 Creating primary cell monolayers for C. parvum infection

This protocol is based on the use of murine stem cells passaged as spheroids as described in
Miyoshi & Stappenbeck 2013, which also describes the protocol for making the conditioned
medium used to grow both the spheroids and primary cells. All cell manipulation is performed
inside a biosafety cabinet under sterile conditions.
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1. Scrape spheroids and Matrigel into medium using pipette tip or cell scraper. Combine
wells with 5 ml plastic pipette and move cell suspension into 15 ml conical tube. Six
wells of a 12-well plate can be combined in one 15 ml tube.
2. Spin spheroids down at 200 x g for 3 min.
3. Remove medium and resuspend spheroids in 5 ml DPBS-EDTA. At this time, warm
aliquot of trypsin-EDTA in 37°C water bath.
4. Spin spheroids down at 200 x g for 5 min (longer spin time is necessary to ensure
adequate exposure to DPBS-EDTA).
5. Remove DPBS-EDTA and add 300 µl warm trypsin-EDTA to pellet. Pipette up and
down to ensure cells are evenly exposed to trypsin.
6. Move cells to 37°C water bath, incubate for 1.5 min.
7. Remove cells from bath and pipette 20-30 times to break up spheroids.
8. Add 5 ml washing medium to cells.
9. Place sterile cell strainer (40 µm) on top of 50 ml conical tube. Pre-wet strainer with 2 ml
washing medium. Pipette cell mixture on top of strainer. Two 15 ml conicals’ worth of
cells (equivalent to one 12-well plate of spheroids) can be combined onto one cell
strainer.
10. Tap strainer against conical to force liquid through; move filtrate from 50 ml conical to
15 ml conical.
11. Spin at 200 x g for 3 min.
12. Remove washing medium and resuspend cells in 1-3 ml of 50% conditioned medium
with 10 µM ROCK inhibitor (Y-27632, see note 4.3). Count cells using hemocytometer.
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Cells will be very clumpy. Each transwell will be plated with 5x10^4 cells in 200 µl
medium, resuspend cells accordingly (see note 4.4).
13. Remove transwells plated with i3T3 cells from 37°C incubator; confirm i3T3 monolayer
is uniform under microscope.
14. Remove 3T3 growth medium from top chamber of compartment using pipette tip (do not
use vacuum flask because aspiration will disturb the monolayer).
15. Add stem cells to transwells.
16. Remove 3T3 growth medium from bottom chamber of transwell compartment and add
400 µl conditioned medium with 10 µM ROCK inhibitor.
17. Move transwells to 37°C, 5% CO2 incubator.
18. Change medium in top and bottom chambers of transwells every 2 days. Add 200 and
400 µl 50% conditioned medium with 10 µM ROCK inhibitor to the top and bottom
chambers, respectively. Remove medium from top chamber with pipette tip only;
aspiration can disturb cell layer. Cells can tolerate a 2-day gap between feedings; medium
can be changed on a Monday, Wednesday, Friday schedule with no ill effects.
19. After 7 days, remove medium from top chamber with pipette tip and do not replace. This
is “day 0 of top media removal” and the creation of the ALI.
20. Continue to change medium in bottom chamber 3 times weekly (see note 4.5).
21. On day 3 post top media removal, remove liquid/mucus from top chamber of transwells
(see note 4.6). Resuspend desired infectious dose of C. parvum oocysts or sporozoites in
30 µl 50% conditioned medium per transwell. Add oocysts or sporozoites to transwell.
22. After incubation period (1-2 hours for sporozoites, 3-4 hours for oocysts), remove liquid
and wash with DPBS if required for assay.
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3.5 Preparing and maintaining C. parvum oocysts for infection

We have used the AUCP-1 isolate of C. parvum for growth in the ALI system (see note 4.7) and
other lines would need to be tested for efficiency. It is a requirement of our biosafety protocol to
use plastic caps on the centrifuge buckets when spinning the oocysts. Only open the caps inside a
biosafety cabinet. Autoclave the buckets and caps after the protocol in case of accidental
contamination. All pipette tips and other material contaminated with oocysts should be disposed
of in a container that can be sealed before removing from the biosafety cabinet and placing in
biohazard waste. An absorbent mat pad can be placed in biosafety cabinet during this procedure
in case of spills.

1. Store purified oocysts at 4°C in 50 mM Tris-10 mM EDTA, pH 7.2.
2. Before infection, dilute 1x108 oocysts into 1 ml cold DPBS in a 15 ml conical. Place on
ice.
3. Add 1 ml of 40% bleach (diluted in cold DPBS) to oocysts. Pipette multiple times to
ensure even mix.
4. Bleach oocysts on ice for 10 min.
5. Spin at 800 x g for 3 min. Remove bleach, resuspend pellet in cold DPBS + 1% BSA.
Move oocyst mixture to new 15 ml conical.
6. Spin at 800 x g for 3 min. Remove supernatant and resuspend pellet in cold DPBS + 1%
BSA. Repeat centrifugation and washing step 3 times to remove all traces of bleach.
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7. After final centrifugation step, resuspend oocysts in cold DPBS + 1% BSA at a
concentration of 1x108/ml. Bleached oocysts can be stored at 4°C for up to 2 weeks.
After 2 weeks, the excystation rate will decline.
8. Oocysts can be diluted into cell culture medium at desired concentration for infection.
9. If sporozoites are needed for infection, add required amount of oocysts to the same
volume of excystation buffer in a 15 ml conical. For example, if 500 µl of oocysts
(0.5x108 oocysts total) is required, add the oocysts to 500 µl excystation buffer. Final
concentration of sodium taurocholate in solution will be 0.75% w/v.
10. Incubate oocysts in 37°C water bath for 45-60 min. Check excystation rate by pipetting
10 µl onto glass slide, cover sporozoites with glass coverslip, and look under microscope.
Sporozoites are best seen at 40X magnification. Excystation rate should be high (80100%) by 60 min. Lower excystation rates indicate that the viability of the oocysts is
declining and the subsequent growth in vitro will not be optimal.
11. After incubation period is over, remove plunger from 3 or 5 ml plastic syringe and place
upright in biosafety cabinet. Attach syringe to plastic filter holder containing filter
membrane with 1 µm pore size. Place filter with syringe on top of 15 ml conical.
12. Pipet 1 ml of cell growth medium into syringe. Pipet excysted oocysts into syringe. Insert
plunger into syringe and push contents through filter. Remove filter with syringe and
place aside. Filter can be carefully disassembled and dropped in an autoclave-safe
container filled with H2O and autoclaved. Autoclave cycle must not include any drying
time, because this can warp the filters. Membrane can be discarded after autoclaving.
13. Spin filtered sporozoites at 1250 x g for 3 min.
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14. Remove supernatant and resuspend sporozoites in desired volume of cell growth medium.
For infecting ALI monolayers, resuspend sporozoites in 50% conditioned medium
(without ROCK inhibitor), 30 µl per transwell.
15. To confirm oocysts have been completely removed from inoculum, check filtered
sporozoites under microscope by pipetting onto glass slide and covering with glass
coverslip. Infected monolayers can also be fixed on the same day of infection and stained
with an antibody that recognizes C. parvum oocysts, such as Crypt-a-gloTM (Waterborne,
Inc.)

3.6 Measuring host and parasite replication in primary cell monolayers by qPCR

This method relies on measuring parasite replication by measuring C. parvum genomic DNA
equivalents. Host viability can be assessed by measuring host genomic DNA equivalents from
the same sample. The following is a modified protocol from the Qiagen QIAamp DNA mini kit.
Buffers ATL, AL, AW1, AW2, and AE are provided in the kit.

1. Add 100 µl of Buffer ATL to transwell. Thoroughly scrape cells into buffer with blunt
pipette tip; be careful not to puncture transwell membrane. Lysed cells will be sticky and
clumpy.
2. Move entire contents of transwell (will likely be more than 100 µl due to presence of
mucus/liquid in top chamber) to 1.7 ml Eppendorf tube. Add 20 µl proteinase K. Vortex
to mix.
3. Incubate in 56°C water bath for 3-24 hr.
4. Briefly centrifuge tube to remove drops from inside of lid.
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5. Add 200 µl Buffer AL to sample, vortex briefly to mix. A white precipitate is likely to
form. Briefly centrifuge tube to remove drops from inside the lid.
6. Incubate in 70°C heat block for 10 min.
7. Add 200 µl ethanol to sample, vortex briefly to mix. Briefly centrifuge tube to remove
drops from inside the lid.
8. Move sample from Eppendorf tube to spin column. When pipetting sample, be careful
not to wet the rim of the spin column. Spin at 7000 x g for 1 min.
9. Place spin column in new collection tube, discard tube containing filtrate.
10. Add 500 µl Buffer AW1 to spin column (be sure not to wet the rim). Centrifuge at 7000 x
g for 1 min.
11. Place spin column in new collection tube, discard tube containing filtrate.
12. Add Buffer AW2 to spin column (be sure not to wet the rim). Centrifuge at maximum
speed for 3 min.
13. Place spin column in clean 1.7 ml Eppendorf tube and discard the tube containing filtrate.
Add 100 µl Buffer AE to the spin column, incubate at room temperature for 1 min, then
centrifuge at 7,000 x g for 1 min.
14. Dilute DNA sample 10-fold with sterile H2O.
15. To make primer mix for qPCR reaction mix: make 200 µM master stocks of forward and
reverse primers in sterile H2O. Combine equal volume of forward and reverse master
stocks to make 100 µM master mix. Dilute 100 µM master mix in sterile H 2O to make 5
µM working mix.

143

16. To make qPCR reaction mix: 9.0 µl 2X SYBR Green mix, 1.8 µl 5 µM primer mix, 5.2
µl H2O (16 µl total volume). Scale up volume for number of wells needed. Pipet mix into
required number of wells of 96-well qPCR reaction plate.
17. Add 2 µl of diluted DNA sample to well. Seal plate with optical film. Centrifuge briefly
to ensure DNA and mix are combined.
18. Primers to measure C. parvum GAPDH: forward – GAAGATGCGCTGGGAACAAC,
reverse – CGGATGGCCATACCTGTGAG.
19. Primers to measure mouse GAPDH: forward – GCCATGAGTGGACCCTTCTT, reverse
– GAAAACACGGGGGCAATGAG.
20. qPCR thermocycler protocol:
Step 1: Priming, 95°C for 2 min
Step 2: Denaturing, 95°C for 10 sec
Step 3: Annealing, 60°C for 20 sec
Step 4: Extension: 72°C for 30 sec (read fluorescence)
Step 5: Go to Step 2, 40X
Step 6: Melt curve, 95°C for 15 sec, 60°C to 95°C for 15 sec
Step 7: Hold at 4°C.
21. Place reaction plate in qPCR machine and run thermocycler protocol.
22. In order to correlate Ct values with actual genomic DNA numbers, it is necessary to make
a standard for C. parvum and mouse cells. For C. parvum, DNA from a known number of
oocysts can be extracted using the Qiagen QIAamp DNA Mini Kit and diluted to make a
standard. For example, DNA from 1x10^7 oocysts can be extracted. After extraction, the
number of gDNA equivalents will be 4x10^7 per 100 µl (since each oocyst contains 4
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sporozoites and the DNA is eluted in a 100 µl volume) or 4x10^5/µl. Create a dilution
series (1:2 to 1:16, for a total of 5 values including the undiluted sample to make up the
curve). For mouse cells, a known number of cells can be lysed after the cells are
quantified in step 12 of Method 2.2 and a dilution series set up in the same way as for C.
parvum.
23. Because the DNA sample was diluted 10X before running the qPCR reaction, the number
of gDNA equivalents determined to be present in 2 µl of sample needs to be multiplied
by 10 to be accurate. To determine the number of gDNA equivalents present in the entire
sample/transwell, multiple the adjusted number by 50 (since the sample was 100 µl
before diluting).
24. An example of qPCR data of C. parvum growth and host cell viability over 21 days in the
ALI system is shown in figure 4.1.

3.7 Monitoring life cycle progression in primary cell monolayers by microscopy

1. Move transwells to 24-well plate. Add 500 µl PBS to bottom chamber of transwell.
2. Fix transwells in desired fixative. For example, 4% formaldehyde for 10 min.
3. Wash transwells 2X with PBS. Use pipette to remove liquid from transwell because
aspiration may disturb cell layer. If there is a significant mucus layer present (likely if the
transwells are at day 7 or later of top media removal), the mucus layer can be removed
through pipetting.
4. After fixing, transwells can be stored at 4°C for up to 10 days before staining (helpful in
experiments that span over multiple days).
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5. Permeabilize and block cells with desired agents. For example, 0.1% Triton X-100 for 35 min or 0.05% saponin for 10 min. If using Triton X-100, dilute in PBS containing 1%
BSA. This buffer can be used throughout the staining protocol as a blocking buffer and as
a vehicle for primary and secondary antibodies. If using saponin, block with 0.05%
saponin in PBS containing 5% normal goat serum (NGS) and 5% fetal bovine serum. For
antibody dilution and wash steps, drop the saponin concentration down to 0.01% in PBS
containing 1% NGS.
6. After blocking, dilute primary antibody in buffer and stain for 60 min at room
temperature or overnight at 4°C.
7. Wash 3X with buffer.
8. Dilute secondary antibody (for example, goat anti-mouse IgG conjugated to Alexa Fluor
dyes, Invitrogen) in buffer and stain for 60 min at room temperature. Protect from light.
9. Wash 3X with buffer
10. Stain with 1 µg/ml Hoechst (1:1000 dilution of stock solution) for 10-30 min. Protect
from light.
11. Wash 1X with PBS.
12. Dot 30-50 µl of ProLong Gold or other antifade mountant onto glass slide. Cut membrane
from transwell insert with scalpel. Using forceps, place membrane onto mountant, cell
side up.
13. Place square coverslip over membrane and push firmly down to remove air pockets. If
there is an air pocket that will not go away, check membrane for plastic “curlicues” that
can be created during the cutting process – these will stop the coverslip from lying flush
with the membrane. Two membranes can fit under one coverslip, but this increases the
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chance the coverslip will not lie flush with the membranes and air pockets can develop
overnight as the mountant dries. It is important to thoroughly press down on the coverslip
to remove all bubbles. Excess mountant will be pushed out and can be wiped off.
14. Protect slides from light and let dry overnight at room temperature.
15. An example of fluorescent staining of C. parvum grown in ALI monolayers is shown in
figure 4.2.
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4 Notes

4.1 3T3 stocks should be kept at low passage numbers (<10). Check appearance of 3T3 cells;
unhealthy cells will grow slowly and have vacuolated cytoplasm.

4.2 Matrigel arrives from manufacturer in glass bottles containing 10 ml and should be stored at 20°C. To prepare Matrigel aliquots, thaw Matrigel overnight on ice in a Styrofoam container in a
4°C fridge. Remove cap and pipette Matrigel up and down 3 times using 10 ml pipette (only
draw up 9 ml to avoid creation of bubbles). Aliquot Matrigel in 1 ml aliquots in 1.7 ml
Eppendorf tubes and store at -20°C. Move aliquots to 4°C to thaw. Do not keep aliquots in
“warm spots” in fridge such as the door because they may solidify. Aliquots will keep at 4°C for
several weeks, but it is best to use quickly. Frozen aliquots can be thawed rapidly (30-60 min) by
placing in an ice slurry or placing on top of ice. Do not thaw aliquots in 37°C water bath or room
temperature because the Matrigel will solidify. Solidified Matrigel can be refrozen at -20°C and
will thaw into a liquid, though it is not clear if this negatively affects the product. When handling
thawed aliquots of Matrigel, do not grip tube with hand, because this will cause the mixture to
solidify. Keep the aliquots on ice as much as possible. Always dilute Matrigel into cold DPBS; if
the DPBS is warm, the Matrigel will solidify upon contact and will not create a homogenous
solution.

4.3 Y-27632 arrives from manufacturer as a powder that can be stored at room temperature. Add
sterile H2O to powder to make 10 mM stock solution. Aliquot in 50-150 µl amounts and store at
-20°C. Aliquots can be thawed and refrozen. Do not store aliquots at 4°C.
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4.4 The amount of spheroids required for different numbers of transwells can very slightly from
person to person. 15-20 wells (12-well plate format) of healthy spheroids should give enough
cells to plate 48 transwells at the 5x104 seeding density. If it takes significantly more wells, the
spheroids are likely too sparse. The 5x104 seeding density was determined to be optimal for C.
parvum growth (see figure 4.3); higher seeding densities lead to decreased cell growth. If C.
parvum is not growing well, try a dilution series of different seeding densities.

4.5 It is important to observe the color of the medium when feeding the cells, since it is an
indicator of viability. Four to six days after plating the stem cells, the medium should become
bright yellow in between feedings. After the ALI is created (7 days after plating the stem cells),
the medium will continue to turn yellow between feedings for 3-5 days, but the color change will
gradually become less dramatic. Eventually the medium will remain pink in between feedings. If
the medium is remaining pink before the creation of the ALI, it is likely the cells are unhealthy
and the monolayer is too sparse. Additionally, there will be some liquid and mucus that forms in
the top chamber after the start of the ALI; if there is copious liquid in the top chamber in addition
to pink medium, these are signs the monolayer is dead.

4.6 The day of infection strongly affects the outcome of infection. Infecting too early after the
creation of the ALI (day 0 to day 2) leads to poor growth and cell death. Infecting too late (day 7
and later) leads to poor growth, possibly due to the presence of the mucus layer, which may act
as a physical barrier to the oocysts and sporozoites (see figure 4.4).
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4.7 It is preferable that the oocysts are purified from cow feces using Sheather’s sugar flotation
and discontinuous sucrose density gradient centrifugation; oocysts purified using cesium chloride
gradients are less viable and exhibit lower excystation and infection rates in the ALI system.
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Figures and legends

Figure 4.1. ALI monolayers support long-term C. parvum growth and host cell viability.
ALI monolayers were infected 3 days post top medium removal with 2x10^5 oocysts.
Monolayers were incubated with oocysts for 4 hr and then washed 3 times. DNA samples were
collected daily. Graph depicts qPCR measuring C. parvum and mouse GAPDH in DNA samples;
data is presented as genomic DNA equivalents (gDNA eq.). Each data point represents the mean
and standard deviation of two transwells.
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Figure 4.2. Immunofluorescent staining of infected ALI monolayers.
ALI monolayers were infected on day 3 post top medium removal with 2x10^5 oocysts.
Monolayers were incubated with oocysts for 4 hr and then washed 3 times. On different days
post infection, monolayers were fixed and stained with pan-Cp (rabbit polyclonal raised against
C. parvum oocysts and sporozoites) and Hoechst. Secondary antibodies used were goat antirabbit Alexa Fluor 555. Scale bar = 50 µm.
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Figure 4.3. Lower cell seeding density improves C. parvum growth.
Stem cells were seeded at different densities. Seven days post-seeding, top media was removed
to create the ALI. Three days post top medium removal, monolayers were infected with 2x10^5
oocysts. Monolayers were incubated with oocysts for 4 hr and then washed 3 times. DNA
samples were collected daily. Graph depicts qPCR measuring C. parvum and mouse GAPDH in
DNA samples; data is presented as genomic DNA equivalents (gDNA eq.). Each data point
represents the mean and standard deviation of two transwells.
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Figure 4.4. Infecting on day 3 post top medium removal improves C. parvum growth.
ALI monolayers were infected on day 0, day 3, or day 7 (ID0, ID3, ID7) of top medium removal
with 2x10^5 oocysts. Monolayers were incubated with oocysts for 4 hr and then washed 3 times.
DNA samples were collected on day 0, 3, 5 and 7 post-infection. Graph depicts qPCR measuring
C. parvum and mouse GAPDH in DNA samples; data is presented as genomic DNA equivalents
(gDNA eq.). Each data point represents the mean and standard deviation of two transwells.
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Chapter 5
Conclusion and future directions

The first draft of this chapter was written by GW. Comments from LDS were incorporated into
the final chapter here.
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Conclusions
The significance of Cryptosporidium as a global health problem was underestimated for
many years; it was thought to primarily cause sporadic waterborne outbreaks of self-limiting
diarrhea as well as long-term disease only in immunocompromised patients. However, recent
studies have exposed Cryptosporidium as a major gastrointestinal pathogen in children in Africa
and southeast Asia, along with familiar culprits such as rotavirus and Shigella spp (19, 20).
Additionally, subclinical Cryptosporidium infections have been found to be associated with
growth faltering and declining cognitive function in children in the underdeveloped regions (23,
24, 182, 183). The prevalence of Cryptosporidium in these areas is extremely concerning
because the only drug available to treat cryptosporidiosis, nitazoxanide, is not effective in
malnourished children (30). Therapeutic interventions have already been implemented or are
currently in development for the other major gastrointestinal pathogens identified by these
studies, but research on Cryptosporidium has been slow-moving due to the intractability of the
parasite. However, the new understanding of Cryptosporidium’s significant contribution to
pediatric disease has led to more focused investigation into breaking down the barriers hindering
research in this field.
Currently, there are no accessible culture systems for Cryptosporidium that support
propagation and/or complete life cycle development in vitro. For years, this made the
development of any kind of genetics system for Cryptosporidium almost impossible, however,
this issue was recently circumvented by using immunodeficient mice to grow transgenic
parasites (66). This system was used to create luciferase-expressing line that enabled a drug
screen in C. parvum, which identified pyrazolopyridines as effective inhibitors of parasite growth
and potential drug candidates for cryptosporidiosis (33). This advance is a great example of how
157

a previous major gap in the Cryptosporidium research field – lack of a genetics system – has
been overcome, quickly enabling investigation into new therapies.
While genetic manipulation of Cryptosporidium is now possible, it is still a difficult
system to adopt because it requires a surgical procedure to inoculate the parasites into the
intestine and the parasites need to be passaged through a mouse to generate infectious oocysts.
Because of this requirement, essential genes are almost impossible to study; any perturbation to
life cycle progression cannot be visualized as the mouse intestine is a “black box”. Transgenic
parasites still cannot be selected for and maintained entirely in vitro due to the ongoing lack of a
culture system. The main purpose of this thesis was to develop an in vitro culture system for C.
parvum that would be a tool for the Cryptosporidium research community and facilitate
investigation into the parasite life cycle and hopefully enable continuous propagation. While
developing the culture system, we were also able to create library of monoclonal antibodies that
recognize different life cycle stages of C. parvum – another valuable tool for Cryptosporidium
research, since the previously available antibodies were limited in scope. The culture system and
antibodies fill two reagent gaps in the field and will enable new lines of investigation into C.
parvum biology.

Creation of a hybridoma library against intracellular stages of C. parvum
The first iteration of a primary cell culture system we used to grow C. parvum relied on
monolayers derived from murine intestinal stem cell spheroids (126). These monolayers were
grown on transwells and contained the differentiated lineages of the intestinal epithelium (131).
The system had been previously been used to study aspects of intestinal cell function (131) so it
was an accepted model of the intestinal environment. We found that these monolayers supported
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robust asexual growth of C. parvum over a 3-day period, but did not support complete life
development, or even sexual stage development. This may have been because the monolayers
only lasted a very short time; with or without infection, the host cells began to die by day 2 and
the monolayer was severely compromised by day 3. The monolayer could not replenish itself
because the primary cells had lost the ability to proliferate after being removed from the spheroid
culture system. It is likely the asexual stages of the parasite could not continue developing
because there were simply no healthy cells left to infect. We attempted to propagate the asexual
stages of the parasite using this system but were unsuccessful.
While the primary monolayers, or “1st generation transwells”, were not a viable system
for studying C. parvum development, they presented a unique opportunity. We realized we could
use this system to immunize mice with infected cell lysate in order to generate a panel of novel
antibodies to intracellular stages of C. parvum. Previously, there had been no reports of a mouse
epithelial cell line that supported robust Cryptosporidium growth, so generating antibodies using
this method was not possible. The adenocarcinoma cell lines routinely used to grow C. parvum
are all human in origin (HCT-8, Caco-2, HT-29) and could not be used for the same purpose due
to the unavoidable production of host-specific antibodies. Therefore, all available antibodies
against Cryptosporidium have been made against extracellular stages (oocysts, sporozoites) or
recombinant proteins. These antibodies can be useful in microscopy studies but the epitopes they
recognize do not have stage-specific expression, so identification of different life cycle stages
requires knowledge of other markers, such as nuclei number and timing of appearance.
We immunized mice with infected cell lysate and developed a hybridoma library against
C. parvum. We identified several antibodies with unique reactivity patterns in different life cycle
stages, enabling unambiguous identification of those stages. For example, two antibodies (1F9
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and 1B5) had a “doughnut-shaped” recognition pattern in trophozoites and appeared to localize
to the base of the parasite, which contains the feeder organelle. It is possible these mAbs
recognize transporters that are involved in nutrient uptake from the host cell cytoplasm or
proteins that direct host cytoskeletal rearrangement in the area around the parasite.
mAb 4D8 recognized an epitope with a striking line- or V-shaped pattern in
macrogamonts. We identified a “fiber” running through macrogamonts by electron microscopy
which resembles the object recognized by 4D8; this structure has not previously been described
in other EM studies of C. parvum. Unfortunately, attempts to show direct recognition of the fiber
by 4D8 by immuno-EM were unsuccessful for technical reasons. In the future, 4D8 could be
used to identify the components of the fiber via immunoprecipitation studies, which could lead to
new insight into macrogamont development.
Several antibodies (e.g. 1A5) had a polarized recognition pattern in mature meronts,
enabling the differentiation between mature type II meronts, which contain 4 merozoites/nuclei,
and immature type I meronts, which contain 4 nuclei but no fully-formed merozoites. Previously,
it was virtually impossible to distinguish type II meronts from early type I meronts in fluorescent
microscopy studies (they do however have ultrastructural differences that are visible by electron
microscopy); these antibodies can be used to study the timing and frequency of appearance of
type II meronts in culture. Many of these antibodies that had a polarized recognition pattern in
mature meronts also had a polarized pattern in sporozoites suggesting, that they recognize
proteins located in the apical secretory organelles and could be discharged during gliding
motility or host cell invasion.
Currently, these mAbs have great utility in facilitating life cycle description of C. parvum
in different culture systems. There are very few “maps” of the Cryptosporidium life cycle using
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fluorescent images, most are based on electron microscopy (36). Often papers quantify the
different stages of C. parvum present in a cell culture system but fail to provide any visual
evidence (86). This lack of clarity regarding the parasite life cycle can be frustrating as a new
investigator to the field; therefore, we hope that these mAbs will serve as a basic “antibody
toolkit” to simply life cycle stage identification of C. parvum. In future studies, the targets of the
mAbs could be identified to learn more about the structures they recognize; for example, 1B5
and the feeder organelle, 4D8 and the macrogamont fiber, and 1A5 and the apical secretory
organelles. The antibodies could also be screen in an invasion inhibition assay to identify
proteins involved in parasite adhesion, motility and invasion.

Complete life cycle development of C. parvum in vitro
When the “first generation transwells” did not support propagation or complete life cycle
development of C. parvum, we looked for ways to improve primary cell viability and
differentiation status to create a long-lasting monolayer that recapitulated aspects of the intestinal
environment. We incorporated aspects of a recently published protocol (132) that grew longlasting primary monolayers with our current methods for propagating stem cell spheroids and
creating primary monolayers. The main changes to our first-generation protocol involved using a
feeder cell layer to support the primary cells, maintaining the monolayers in medium containing
stem cell growth factors, and creating an “air-liquid interface” (ALI) at the surface of the
monolayer. The ALI triggered a dramatic differentiation cascade in the monolayers leading to the
development of enterocytes and secretory cells such as goblet cells. These “second generation”
or ALI transwells lasted for many weeks due to a portion of the cells remaining proliferative,
allowing the monolayer to be continually replenished as terminally differentiated cells sloughed
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off. This continuous cell division, something the first generation transwells lacked, was likely
due to the inclusion of the stem cell growth medium.
We found that the ALI monolayers supported weeks of continuous C. parvum growth.
This growth was dependent on the ALI, since submerged transwells did not support the same
quantity of growth. Optimal growth required infection of monolayers that were in the process of
differentiating, i.e. several days after the creation of the ALI. Infecting the monolayers on the
same day the top medium was removed, when the monolayers were undifferentiated, led to poor
growth and host cell viability. When infected at the optimal time, host cells continued to
proliferate and even increased in number during infection, implying that the monolayers
maintained integrity in the presence of continuous parasite replication. Sections of infected
transwells showed the cells retained their dramatic cell height, a marker of differentiation (168),
during infection, mimicking what is seen in vivo.
The long-term C. parvum growth in ALI cultures suggested the parasite was undergoing
complete life cycle development, leading to the production of oocysts and reinfection of the
monolayer by sporozoites. We identified all life cycle stages in the monolayers, and most
importantly, we found evidence of oocyst production in vitro. We infected ALI cultures with
sporozoites that had been filtered to remove unexcysted oocysts and oocyst shells and looked for
oocyst development by microscopy. We found that oocysts appeared as early as day 2 postinfection and continued to appear on subsequent days, without a clear pattern of “peaks” and
“troughs”. The numbers of oocysts did not increase dramatically as time went on, suggesting that
the oocysts were not simply accumulating on the surface of the monolayer; it is likely that the
oocysts were excysting almost immediately upon release from the host cell, leading to
reinfection.
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To determine if the in vitro-produced oocysts were infectious, we bleached infected
monolayers on day 1 and day 3 post infection and inoculated Ifngr1 -/- mice with the material by
oral gavage. Day 1 cultures only contain asexual parasite forms, which are not bleach-resistant,
while day 3 cultures contain oocysts, which are bleach-resistant. We found that only the mice
that received bleached material from day 3 cultures developed a productive infection, leading to
oocyst shedding and eventually death. This result supports the visual evidence of oocyst
production in ALI culture and demonstrates the infectivity of the in vitro-produced oocysts.
The long-term growth in ALI culture as well as infectious oocyst production suggested
these monolayers would also be able to support propagation of C. parvum. Unfortunately, all
attempts to passage C. parvum from one ALI culture to another were unsuccessful. It seems that
whatever life cycle stage is capable of propagating the infection is present in low numbers or is
damaged during the propagation process, which involves some form of dissociating the
monolayer, whether by syringe-lysing or trypsinizing.
Despite the (present) inability to passage the infection using the ALI system, the fact that
this cell culture platform supports robust, long-term growth and complete life cycle development
in vitro makes it a significantly better model for studying parasite biology than currently
available systems. Adenocarcinoma cell lines support only a few days of growth and no oocyst
development (142) and cell culture systems claiming oocyst production in vitro rely on
expensive or inaccessible equipment (95, 96). Due to the required equipment, these systems are
not easily scalable and make simple microscopy or gene expression studies difficult. These other
cell culture systems also use adenocarcinoma cell lines, which do not accurately model the
epithelial cell lining of the intestine. ALI monolayers are derived from stem cells that
differentiate into all of the lineages naturally found in the gut, making it an ideal system to study
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host-parasite interactions. The ALI system relies on commercially available cell culture supplies
and well-established protocols for stem cell propagation and is easily scalable for studies
requiring conditions to be examined in parallel. For these reasons, the ALI system is an excellent
platform for modeling how C. parvum develops in vivo and will aid future investigation into
pathogenesis mechanisms and drug target identification.
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Future Directions
Future efforts should be focused on expanding the utility of the ALI system for
investigating Cryptosporidium biology in vitro, such as enabling serial passage, selection of
transfected lines, cryopreservation, testing drug efficacy, and growth of C. hominis.

Propagating C. parvum in the ALI system
Past attempts to propagate C. parvum in ALI monolayers have been unsuccessful. A
summary of the attempted methods is provided in the appendix to Chapter 3. Essentially, all the
“obvious” methods have been tried and found insufficient, necessitating some unorthodox
thinking about how to passage the infection from one monolayer to another. The failure to
propagate infection by simply syringe-lysing the monolayer to release the intracellular parasites,
like what is done for T. gondii, is strange because we have found that syringe-lysed C. parvuminfected ALI cultures can productively infect Ifngr1-/- mice. Even syringe-lysed day 1 cultures,
which only contain asexual forms of the parasite and no oocysts, are infectious to mice and cause
productive oocyst shedding and even death. However, these same cultures are not infectious to
new ALI monolayers. It is possible that passage through the stomach and proximal small
intestine conditions the parasites in some way that prepares them for reinfection, but it is still
surprising that the asexual forms can survive the harsh conditions of the stomach. In fact, the
research group that used the CRISPR/Cas9 system to genetically modify C. parvum found that it
was necessary to use a surgical procedure to directly inoculate the small intestine with
transfected sporozoites (66) because oral gavage produced inconsistent results. It is possible that
in the syringe-lysed cultures, the mucus and host cell debris protect the asexual stages from the
acidic environment, allowing the parasites to reach the small intestine. This still does not explain
how those stages are able to reestablish infection in vivo but not in vitro. Also, the idea that the
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cultures need to be “activated” by some signal in the intestine in order to re-initiate their life
cycle does not explain how infections can last for weeks in ALI culture without any outside
intervention.
In light of the ability of syringe-lysed cultures to infect Ifngr1-/- mice, future attempts to
passage C. parvum could test treating the lysed cultures with acid or bile salts to try to mimic
passage through the gut, to see if these exposures “activate” the parasites for reinfection. Bile
acids have been demonstrated to positively affect protein secretion and gliding motility of
sporozoites, separate from their ability to trigger oocyst excystation (184). It is possible that bile
acids also affect the behavior of merozoites or other life cycle stages that could passage the
infection.
The activating signal might be more elusive, such as a metabolite or the absence/presence
of a nutrient. As of now, no metabolite or nutrient has been identified as having a positive effect
on C. parvum growth in the intestine. However, high fecal indole levels have been negatively
associated with susceptibility to C. parvum infection in humans (185) and depletion of intestinal
flora with antibiotics enhances susceptibility of mice to infection (66, 186), so there is precedent
for specific metabolites and the microbiota having an effect on C. parvum infection, albeit a
negative one. C. parvum infection causes changes to the intestinal microbiota (187) and the
metabolite profile of the gut in mice (188) and humans (189); it is possible that some of these
changes reflect active reshaping of the gut environment by C. parvum and may provide clues to
what nutrients have a positive impact on C. parvum infection. These nutrients could be added to
syringe-lysed cultures to see if they increase the efficiency of propagation.
We had assumed that any kind of pretreatment of the syringe-lysed cultures would not be
required for propagation because the parasite can grow uninterrupted for weeks in the ALI
166

culture. However, it is clear something about the propagation process disrupts the parasite’s
normal growth and a signal is needed to reboot the cycle. Passage through the mouse stomach
and intestine provides that signal; we just need to identify it.
The success of infecting of Ifngr1-/- mice with bleached ALI cultures suggests we should
try bleaching the monolayers before passage. Bleaching would restrict the parasite stages present
to oocysts, since intracellular parasites cannot survive bleaching. Bleaching the monolayers may
appear not worth testing – the oocysts are present in both bleached and unbleached cultures; if
unbleached cultures do not reliably passage the infection, why would bleaching increase the
infectiousness of the oocysts present? However, it is possible that syringe-lysing the cultures
releases an inhibitory factor that kills the parasite or blocks binding sites on host cells; passage
through the stomach may destroy this inhibitory factor, explaining why the cultures can infect
mice but not monolayers. Bleach could achieve the same effect while restricting the inoculum to
oocysts only. If bleached cultures can infect fresh monolayers, it would remove ambiguity about
which parasite stage is actually passaging the infection. It is true that syringe-lysed day 1 cultures
can productively infect mice, but we do not have a way of identifying which stage is transmitting
the infection in that model. Limiting the infection to oocysts only may make the results easier to
interpret.
One major obstacle to propagation has been the variability in infection levels in the
transwells that received the passage infection. This issue has made attempts to serially propagate
the infection impractical. Because there is a fair number of “negative” transwells at each time
point tested, it is not feasible to pool together transwells and try passaging the infection again –
the inoculum is likely to be extremely low and the inconsistency in infection will persist in the
second round. If the propagated infection was consistent, it could be possible to serially passage
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the parasite and eventually create a lab-adapted strain. If we had a way to track growth in vitro
without fixing the monolayer for microscopy or lysing the monolayer for DNA collection, we
could identify the positive transwells and pool them for the next passage. One way to do this
would be to use live cell imaging to visualize GFP-positive parasites in the transwells. With
enough passages, the line could become adapted to in vitro culture conditions and the
inconsistency in infection between transwells could disappear. It is quite common for parasites to
require some level of adaptation before thriving in in vitro culture conditions. For example, there
is significant variability in the time it takes different field-derived P. falciparum strains to adapt
to culture (190). When freshly isolated Leishmania spp are initially introduced to in vitro culture,
they require the addition of biopterin in the culture medium to significantly increase growth; over
serial passages, the requirement for biopterin goes away as the parasites adapt (191). It is
possible that other strains of C. parvum would be more amenable to serial passaging or the
addition of a nutrient is required for the first few serial passages to ensure success.
Successful propagation of C. parvum using the ALI system will require thinking outside
the box of typical methods used to passage parasites in vitro. For example, the first system that
supported continuous culture of P. falciparum required low oxygen (179), which is not a logical
requirement for Plasmodium growth in vitro since asexual stages of Plasmodium grow in red
blood cells. It is possible that continuous culture of Cryptosporidium will require something
equally unexpected.

Transfection of C. parvum in the ALI system
For decades, genetic modification of C. parvum was not possible due to several barriers:
inability to select for and propagate transfected lines in vitro, lack of non-homologous
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recombination in Cryptosporidium spp, and few known drugs with associated resistance genes
that could be used for selection. Despite these roadblocks, a recent breakthrough has
demonstrated that it is possible to both transiently and stably transfect C. parvum (66, 192). To
optimize transient transfection, the authors used nanoluciferase (Nluc) as a reporter, which is
more sensitive than firefly luciferase or fluorescent proteins. They also optimized the
electroporation protocol and determined the C. parvum enolase promoter to be the strongest at
driving reporter expression. Additionally, they tested codon optimization because the C. parvum
genome is AT rich (43) and found that this enhanced reporter expression as well. For selection,
they used a neomycin resistance marker (Neo), which confers resistance to paramomycin (193),
an aminoglycoside antibiotic that effectively targets C. parvum in tissue culture (66) and mice
(67). They found that transient expression of a fused Nluc-Neo cassette led to increased
resistance to paramomycin, which was determined by measuring the luciferase activity of the
transfected parasites.
After optimizing transient transfection, the authors developed a method for creating
stably transfected parasites using a modified CRISPR-Cas9 system. Sporozoites were transfected
two plasmids: a CRISPR/Cas9 plasmid containing the S. pyogenes cas9 gene and the C. parvum
U6 RNA promoter to drive guide RNA expression targeting the gene of interest, and a plasmid
containing a repair cassette with the Nluc-Neo fusion. Depending on the design of the repair
cassette, integration of the cassette can replace/delete the gene of interest or modify it by adding
an epitope tag, for example. The transfected sporozoites were inoculated directly onto the mouse
intestinal epithelium via a surgical procedure. The latter step was necessary because the
sporozoites could not survive passage through the stomach. Treating the mice with paramomycin
led to selection of stable transfectants within the mouse; oocysts shed in the fecal pellets were
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positive for the Nluc-Neo fusion protein and exhibited paramomycin resistance in subsequent
studies.
In the original publication describing the method for stable transfection, the authors
targeted the thymidine kinase (TK) locus for insertion of the Nluc-Neo cassette (66). Analysis of
the C. parvum genome has revealed that the parasite is dependent on salvage from the host for
both purines and pyrimidines (43, 194); TK is a salvage enzyme that provides an alternate route
to dTMP that bypasses DHFR-TS (dihydrofolate reductase-thymidylate synthase) (194). TK is
unique to C. parvum among apicomplexan parasites and it confers Cryptosporidium’s resistance
to antifolates (e.g. trimethoprim), which target DHFR-TS and are used to treat other
apicomplexan infections. The authors chose TK as the site of insertion to test the hypothesis that
TK was nonessential; they found that loss of TK did not impact parasite viability under normal
conditions, but it did increase C. parvum’s susceptibility to trimethoprim (66).
The protocol for stable transfection of C. parvum is well-tested and we could incorporate
the ALI system into the method to streamline the process. Maintaining transgenic C. parvum
lines entirely in vitro using the ALI system will not be possible until propagation is solved.
However, the ALI platform can still be useful for selecting and enriching for stably-transfected
parasites in vitro before inoculating mice to generate oocysts. Since we know syringe-lysed ALI
cultures can productively infect mice, we could avoid the surgical procedure required to
inoculate sporozoites directly into the intestine. The ALI system could also be used to
cryopreserve transgenic lines, as discussed later, in order to avoid continually passaging the line
through mice to maintain infectivity. In a lab where dozens of lines have been created, this
process can become incredibly burdensome.
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We could also use stably transfected lines to demonstrate sexual recombination in vitro,
which would bolster the evidence of oocyst development. This experiment would require
crossing two strains in vitro. Our lab has already modified the plasmid containing the Nluc-Neo
fusion gene and repair cassette to introduce GFP and mCherry genes (separate plasmids) into the
TK locus with expression driven by the C. parvum actin promoter. We are in the process of
identifying another non-essential gene to serve as a target locus. One candidate is uracil
phosphoribosyltransferase (UPRT), which is also involved pyrimidine salvage pathway. UPRT
may not be essential because C. parvum has another enzyme, uridine kinase-uracil
phosphoribosyltransferase (UK-UPRT) that is part of the same pathway and performs the same
function as UPRT. If UPRT is non-essential, it can be targeted for insertion of the mCherry or
GFP gene. We are in the process of making stable lines by inoculating mice with ALI cultures
infected with transfected parasites. The mice are treated with paramomycin to select for stable
transfectants. The level of shedding of stable transfectants can be measured by a luciferase
activity assay of the fecal pellets. We will then purify stably transfected oocysts from the fecal
pellets of the mice. If we have two stable lines – for example, one line with GFP in the TK locus
and one line with mCherry in the UPRT locus – we can infect ALI culture with both lines
simultaneously and look for visual evidence of recombination, i.e. a yellow parasite. This could
be done by microscopy or potentially flow cytometry, if the levels of recombination are high
enough. Demonstrating sexual recombination in vitro has not been accomplished in other cell
culture systems claiming complete life cycle development (95-97). This outcome would truly be
a novel finding and unambiguous evidence of meiosis and oocyst formation occurring in vitro.
Additionally, if the levels of recombination are high enough, it would be proof of principle that
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the system could be used to cross different lines/strains. This would be helpful for future studies
identifying virulence determinants or host restriction factors in different strains.
Stable lines of two different colors can also be used to observe parasite processes in real
time with live cell imaging. For example, fertilization of the macrogamont by the microgamont is
a poorly understood process. It is thought that the block in life cycle development in most cell
culture systems used to study C. parvum is the fertilization event; micro- and macrogamonts
develop but there is no zygote production. This could be true or alternatively, fertilization could
occur but the downstream processes of oocyst wall development, etc. are blocked. Observing
micro- and macrogamonts in the ALI system and a control system like HCT-8 cells could shed
light on the nature of the life cycle block.
We can also use the stable transfection protocol to tag different genes to visualize stagespecific gene expression. There has been one major study examining C. parvum gene expression
during in vitro infection (89); this data was analyzed and genes were organized into clusters
based on the timing of their expression (195). This data set has been used by our lab to identify
potential stage-specific genes, such as oocyst wall proteins for macrogamonts. We are most
interested in identifying a sporozoite-specific gene in order to visualize sporozoite development
within the ALI system. Successful tagging of sporozoite gene would contribute to the evidence
of complete life cycle development occurring in this cell platform. We could also tag oocyst wall
proteins to visualize their organization process as the macrogamont develops and becomes
fertilized. We observed wall-forming bodies (WFBs), which contain oocyst wall proteins,
forming a circular pattern in macrogamonts in ALI culture, something we have not observed in
other cell culture systems. We termed these macrogamonts “late-stage” because it appeared the
WFBs were organizing, either in response to fertilization or in preparation for it. If the WFBs
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organize after fertilization, these late-stage macrogamonts are actually zygotes, which have been
impossible to identify in cell culture or even in vivo studies.
Stable transfection can also be used to create a conditional knockdown system in C.
parvum to investigate genes that may be essential to life cycle progression. Our lab has recently
developed an auxin-inducible degron (AID) system in T. gondii (196) and it has also been used
in Plasmodium (197). This system has been adapted from plants, which use auxins (type of plant
hormone) to target proteins for proteasomal degradation. It requires a plant auxin receptor called
transport inhibitor response (TIR1) and a protein tagged with an AID. Treatment with auxin
activates a specific ubiquitin ligase complex that directs AID-tagged proteins to ubiquitindependent proteasomal degradation. This system allows depletion of a protein to be restricted to
a precise length of time during an experiment, allowing essential genes to be studied.
CRISPR/Cas9 genome editing can be used to introduce AID tags to genes of interest (196).
We could adapt the AID system to C. parvum and use it to study genes that are required
for life cycle development. For example, the continuous growth we see in ALI culture could
either be due to complete life cycle development of the parasite and reinfection of the monolayer
by new oocysts, or ongoing rounds of asexual division (merogony). In the latter scenario, oocyst
development clearly still occurs but does not significantly contribute to the high parasite burden
seen in the monolayers. It has been hypothesized that the parasite can undergo asexual division
continuously in the gut as an explanation for the long-lasting infections seen in
immunocompromised patients, but there is no concrete evidence of this. We could tag a microor macrogamont-specific gene with an AID and treat the infected cultures with auxin to induce
temporary depletion of the protein. Candidate genes would include transcription factors; there is
precedent in other apicomplexan parasites for stage-specific transcription factors, for example in
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T. gondii bradyzoites (198) and Plasmodium gametocytes (199, 200). There are also genes
associated with meiosis that could be targeted. Ablation of a transcription factor or other protein
required for micro- or macrogamont development in ALI culture and observation of its effect on
growth would provide significant insight into whether C. parvum can cycle asexually
indefinitely.
Temporary gene knockdown in C. parvum has been achieved by methods that do not
require stable transfection. Morpholinos have been used to knockdown C. parvum lactate
dehydrogenase and sporozoite 60K protein during infection both in vivo and in vitro (201, 202),
leading to a drop in parasite numbers, demonstrating that both genes are essential. This technique
is another approach that could be taken to interfere with sexual development in ALI culture if the
AID system cannot be adapted to C. parvum.

Cryopreservation
Currently, there are no established protocols for cryopreserving C. parvum. Because there
is no long-term culture system, there is no method for freezing infected cells, like what is
possible with T. gondii tachyzoites. There has been a lot of interest in cryopreserving oocysts in
order to avoid continually passaging lines through calves, mice, or pigs in order to maintain
infectivity. Also, for the purpose of drug screens and human challenge studies, cryopreservation
would enable the distribution of the same C. parvum or C. hominis line to all researchers,
allowing results to be directly compared without worrying about strain variability. A recent
preliminary report describes a method for cryopreservation of C. parvum oocysts that involves
permeabilization of the oocyst wall using bleach to allow uptake of cryoprotective agents and
loading oocysts into microcapillary tubes before submerging in liquid nitrogen (203). This
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protocol has some limitations (only been tested on two strains, <100 µl volume), but does show
that cryopreservation of oocysts is possible. Another recent publication reported
cryopreservation of C. parvum, but with infected cells instead of oocysts (97). In this model,
infected cells were frozen; after thawing, the cells began producing oocysts within three days.
This method is based on a cancer cell line that is reported to support complete life cycle
development in vitro, but we have been unable to replicate this initial result in our lab.
We plan to try cryopreserving infected ALI cultures, but it is likely that thawed cultures
will not be able to infect new monolayers for the same unknown reasons that propagation has not
yet worked in the ALI system. However, we could inoculate the thawed cultures into mice by
oral gavage and collect oocysts from the pellets. If this is successful, it would enable the
preservation of transgenic lines without needing to reintroduce them into mice to make new
infectious oocysts every 3-6 months (66). For labs that have adopted the stable transfection
system for C. parvum, this process has become incredibly burdensome as the number of lines
that need to be maintained steadily multiplies. Successful cryopreservation would allow valuable
resources and time to be directed elsewhere.

Transcriptomics
In order to identify host pathways that help create a supportive environment for C.
parvum growth, we have performed RNA-seq studies comparing gene expression of uninfected
monolayers on day 0 of top medium removal and day 3 post-top medium removal. We chose
these time points because we had found that infecting on day 3 post-top medium removal led to
robust parasite growth as well as increased host cell viability while infecting on day 0 led to poor
parasite growth and monolayer disruption. After the top medium is removed to create the ALI,
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the cells begin to differentiate, leading to the development of terminal cell types such as goblet
and endocrine cells. This differentiation cascade is seen in initial analyses of the RNA-seq data,
which show upregulation of notch signaling, a known regulator of intestinal stem cell
proliferation and differentiation (204) as well upregulation of genes associated with DNA
replication and G1 to S cell cycle transition, which mirrors the increased host cell proliferation
we saw in the monolayers after the ALI was established. While these results are not surprising, it
is important to establish what pathways are up- and downregulated in the monolayers after the
introduction of the ALI in order to begin to understand why this system supports complete
development of C. parvum.
If we can identify certain metabolic pathways that are differentially regulated in the ALI
vs. non-ALI monolayers, that could provide clues to the ideal nutrient conditions for C. parvum
within the host. For example, genes associated with glycolysis are downregulated in ALI
monolayers on day 3 post-top medium removal compared to day 0, which is a reflection of the
restriction of the stem cell population and development of terminally differentiated cells that
occurs after ALI is introduced. Many types of stem cells are heavily dependent on anaerobic
glycolysis (205) and high levels of glycolysis occur at the base of the crypt, where the intestinal
stem cells are located (206, 207). C. parvum did not grow well in “submerged” transwells
compared to ALI transwells, suggesting that stem cells, which are the predominant population in
submerged transwells, do not support parasite growth. This result could partly be due to the stem
cells’ reliance on glycolysis, the byproducts of which would create a very different pool of
nutrients for C. parvum to scavenge compared to oxidative phosphorylation. Similarly, cancer
cell lines such as HCT-8 and Caco-2, which are used to study short-term C. parvum growth,
heavily rely on glycolysis (208). Long-term growth of C. parvum could require a pool of host
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cells primarily relying on oxidative phosphorylation, which is likely present in the ALI
monolayers. There has been a report of increased oxidative phosphorylation occurring in porcine
epithelial cells when they are grown under ALI conditions (137). This outcome could be
confirmed in our system using a Seahorse assay, which can measure oxygen consumption rate
and extracellular acidification rate; this assay has previously been used to study metabolism of
colonic spheroids (207). Directly manipulating oxidative phosphorylation rates in the ALI
monolayer to prove a connection with C. parvum growth will be difficult, however, since most
inhibitors of oxidative phosphorylation are toxic to the cell.
Specific host genes that are up- or downregulated during C. parvum infection could be
investigated by establishing ALI monolayers from knockout cell lines. For example, a recent
report described the upregulation of type I interferon signaling in intestinal organoids infected
with C. parvum (209); if we see the same signal in our RNA-seq data, we could pursue this
phenotype by studying infection in monolayers that are deficient for different components of the
interferon signaling pathway.
Host gene expression analysis will definitely play a key role in understanding the success
of the ALI system in supporting robust C. parvum growth, but it would also be interesting to
look at parasite gene expression in different culture systems to identify gene signatures
associated with continuous growth. Currently, there is very limited gene expression data
available for C. parvum; there is one study that looked at growth in HCT-8 cells and examined
gene expression by RT-qPCR (89). It would be valuable to examine parasite gene expression in
ALI cultures to identify genes that are turned on during complete life cycle development. If we
could compare this to parasite gene expression in HCT-8 cells, we could identify the block in life
cycle development in cancer cell lines. The potential issue with this experiment is the low growth
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of C. parvum in HCT-8 cells compared to the ALI monolayers; it is possible that the parasite
gene signature will be overwhelmed by host gene expression. However, if we able to create
stable lines with stage-specific reporters, we could flow-sort infected cells and perform single
cell RNA-seq to identify gene expression associated with each life stage. If we did this in both
HCT-8 and primary cells, we could compare gene expression throughout the life cycle directly
between the two cell types and identify pathways that are positively associated with complete life
development. Fluorescent microscopy studies that we have performed in infected ALI
monolayers already hint at differential gene expression in C. parvum in this system; for example,
the reactivity of microgamonts to antibodies that recognize oocyst wall proteins (OW50 and
Crypt-a-gloTM), something that does not occur in HCT-8 cells. Identification of unique parasite
signaling pathways in ALI culture will provide the basis for much future investigation into the C.
parvum life cycle.

Culturing C. hominis in vitro
The majority of human cryptosporidiosis cases are caused by C. hominis, not C. parvum
(2-4). C. parvum is used most often for in vitro studies because it can be produced in large
quantities by calves; C. hominis oocysts have limited availability and are only routinely produced
by one lab (Tzipori, Tufts University). C. hominis is most frequently cultured in neonatal piglets
(71) but can infect calves (71, 72) and immunosuppressed gerbils (74). The neonatal piglet
model is most often used to study drug efficacy against C. hominis (70, 77). The only cell culture
systems available for C. hominis are human cancer cell lines that only support a few days of
growth, which obviously limits in vitro studies. Just like for C. parvum, there is interest in
developing an in vitro culture system that can support C. hominis development and propagation.
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This system would facilitate drug studies and enable evaluation of drug efficacy in vitro before
moving drugs into the neonatal piglet model.
We have already attempted to grow C. hominis in the murine ALI monolayers but were
unsuccessful, which is unsurprising because C. hominis does not grow in mice. However, we
plan to establish ALI cultures with human ileal cells to see if these would support C. hominis
growth. It also may be worthwhile to try porcine or bovine ileal cells to see if there are any
differences in growth. For all these cell types, it will be necessary to confirm that the monolayers
support C. parvum growth first as a positive control. It may also be necessary to re-test a lot of
the variables that were fine-tuned to enhance C. parvum growth in the murine monolayers, such
as host cell seeding density, timing of infection post top medium removal, and infectious dose.
If C. parvum and C. hominis can both grow in human ALI monolayers, it would be
possible to perform crossing experiments to create recombinant strains. There is evidence of
recombinant strains occurring in nature (210) so it could be possible to force this to happen in
vitro. These kinds of studies could lead to the identification of genes that control host specificity.
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Concluding remarks
Due to its ability to support long-term growth and complete life cycle development, the
ALI system will be a great platform for future investigation into C. parvum biology. Essentially,
this culture system is a key that unlocks many parasite processes that were previously unable to
be studied in vitro. This system will greatly aid research into basic scientific questions about C.
parvum, which will further our understanding of this previously intractable pathogen and
importantly, support innovative drug development and identification of new therapeutic targets.
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